| 16S rRNA and metagenomic shotgun sequencing data revealed consistent patterns of gut microbiome signature in pediatric ulcerative colitis |
|
|
|
| 16S rRNA and metagenomic shotgun sequencing data revealed consistent patterns of gut microbiome signature in pediatric ulcerative colitis/Experiment 1/Signature 1 |
|
|
|
| 16S rRNA and metagenomic shotgun sequencing data revealed consistent patterns of gut microbiome signature in pediatric ulcerative colitis/Experiment 1/Signature 2 |
|
|
|
| 16S rRNA gene pyrosequencing reveals shift in patient faecal microbiota during high-dose chemotherapy as conditioning regimen for bone marrow transplantation |
|
|
|
| 16S rRNA gene pyrosequencing reveals shift in patient faecal microbiota during high-dose chemotherapy as conditioning regimen for bone marrow transplantation/Experiment 1 |
|
|
|
| 16S rRNA gene pyrosequencing reveals shift in patient faecal microbiota during high-dose chemotherapy as conditioning regimen for bone marrow transplantation/Experiment 1/Signature 1 |
|
|
|
| 16S rRNA gene pyrosequencing reveals shift in patient faecal microbiota during high-dose chemotherapy as conditioning regimen for bone marrow transplantation/Experiment 1/Signature 2 |
|
|
|
| 16S rRNA gene sequencing reveals altered composition of gut microbiota in individuals with kidney stones |
|
|
|
| 16S rRNA gene sequencing reveals altered composition of gut microbiota in individuals with kidney stones/Experiment 1 |
|
|
|
| 16S rRNA gene sequencing reveals altered composition of gut microbiota in individuals with kidney stones/Experiment 1/Signature 1 |
|
|
|
| 16S rRNA gene sequencing reveals altered composition of gut microbiota in individuals with kidney stones/Experiment 1/Signature 2 |
|
|
|
| 16S rRNA gene sequencing reveals altered composition of gut microbiota in individuals with kidney stones/Experiment 2 |
|
|
|
| 16S rRNA gene sequencing reveals altered composition of gut microbiota in individuals with kidney stones/Experiment 2/Signature 1 |
|
|
|
| 16S rRNA gene sequencing reveals altered composition of gut microbiota in individuals with kidney stones/Experiment 2/Signature 2 |
|
|
|
| A comprehensive analysis of the microbiota composition and gene expression in colorectal cancer |
|
|
|
| A comprehensive analysis of the microbiota composition and gene expression in colorectal cancer/Experiment 1 |
|
|
|
| A comprehensive analysis of the microbiota composition and gene expression in colorectal cancer/Experiment 1/Signature 1 |
|
|
|
| A comprehensive analysis of the microbiota composition and gene expression in colorectal cancer/Experiment 1/Signature 2 |
|
|
|
| A comprehensive analysis of the microbiota composition and host driver gene mutations in colorectal cancer/Experiment 2/Signature 2 |
|
|
|
| A comprehensive analysis of the microbiota composition and host driver gene mutations in colorectal cancer/Experiment 3 |
|
|
|
| A comprehensive analysis of the microbiota composition and host driver gene mutations in colorectal cancer/Experiment 3/Signature 1 |
|
|
|
| A comprehensive analysis of the microbiota composition and host driver gene mutations in colorectal cancer/Experiment 3/Signature 2 |
|
|
|
| A comprehensive analysis of the microbiota composition and host driver gene mutations in colorectal cancer/Experiment 4 |
|
|
|
| A comprehensive analysis of the microbiota composition and host driver gene mutations in colorectal cancer/Experiment 4/Signature 1 |
|
|
|
| A comprehensive analysis of the microbiota composition and host driver gene mutations in colorectal cancer/Experiment 5 |
|
|
|
| A comprehensive analysis of the microbiota composition and host driver gene mutations in colorectal cancer/Experiment 5/Signature 1 |
|
|
|
| A comprehensive analysis of the microbiota composition and host driver gene mutations in colorectal cancer/Experiment 5/Signature 2 |
|
|
|
| A prospective microbiome-wide association study of food sensitization and food allergy in early childhood |
|
|
|
| A prospective microbiome-wide association study of food sensitization and food allergy in early childhood/Experiment 1 |
|
|
|
| A prospective microbiome-wide association study of food sensitization and food allergy in early childhood/Experiment 1/Signature 1 |
|
|
|
| A prospective microbiome-wide association study of food sensitization and food allergy in early childhood/Experiment 2 |
|
|
|
| A prospective microbiome-wide association study of food sensitization and food allergy in early childhood/Experiment 2/Signature 1 |
|
|
|
| A prospective study to examine the association of the urinary and fecal microbiota with prostate cancer diagnosis after transrectal biopsy of the prostate using 16sRNA gene analysis |
|
|
|
| A prospective study to examine the association of the urinary and fecal microbiota with prostate cancer diagnosis after transrectal biopsy of the prostate using 16sRNA gene analysis/Experiment 1 |
|
|
|
| A prospective study to examine the association of the urinary and fecal microbiota with prostate cancer diagnosis after transrectal biopsy of the prostate using 16sRNA gene analysis/Experiment 1/Signature 1 |
|
|
|
| A prospective study to examine the association of the urinary and fecal microbiota with prostate cancer diagnosis after transrectal biopsy of the prostate using 16sRNA gene analysis/Experiment 2 |
|
|
|
| A prospective study to examine the association of the urinary and fecal microbiota with prostate cancer diagnosis after transrectal biopsy of the prostate using 16sRNA gene analysis/Experiment 2/Signature 1 |
|
|
|
| A Walnut-Enriched Diet Affects Gut Microbiome in Healthy Caucasian Subjects: A Randomized, Controlled Trial |
|
|
|
| A Walnut-Enriched Diet Affects Gut Microbiome in Healthy Caucasian Subjects: A Randomized, Controlled Trial/Experiment 1 |
|
|
|
| A Walnut-Enriched Diet Affects Gut Microbiome in Healthy Caucasian Subjects: A Randomized, Controlled Trial/Experiment 1/Signature 1 |
|
|
|
| A Walnut-Enriched Diet Affects Gut Microbiome in Healthy Caucasian Subjects: A Randomized, Controlled Trial/Experiment 1/Signature 2 |
|
|
|
| A Walnut-Enriched Diet Affects Gut Microbiome in Healthy Caucasian Subjects: A Randomized, Controlled Trial/Experiment 2 |
|
|
|
| A Walnut-Enriched Diet Affects Gut Microbiome in Healthy Caucasian Subjects: A Randomized, Controlled Trial/Experiment 2/Signature 1 |
|
|
|
| A Walnut-Enriched Diet Affects Gut Microbiome in Healthy Caucasian Subjects: A Randomized, Controlled Trial/Experiment 3 |
|
|
|
| A Walnut-Enriched Diet Affects Gut Microbiome in Healthy Caucasian Subjects: A Randomized, Controlled Trial/Experiment 3/Signature 1 |
|
|
|
| Acute SARS-CoV-2 infection is associated with an expansion of bacteria pathogens in the nose including Pseudomonas Aeruginosa |
|
|
|
| Acute SARS-CoV-2 infection is associated with an expansion of bacteria pathogens in the nose including Pseudomonas Aeruginosa/Experiment 1 |
|
|
|
| Acute SARS-CoV-2 infection is associated with an expansion of bacteria pathogens in the nose including Pseudomonas Aeruginosa/Experiment 1/Signature 1 |
|
|
|
| Acute SARS-CoV-2 infection is associated with an expansion of bacteria pathogens in the nose including Pseudomonas Aeruginosa/Experiment 2 |
|
|
|
| Acute SARS-CoV-2 infection is associated with an expansion of bacteria pathogens in the nose including Pseudomonas Aeruginosa/Experiment 2/Signature 1 |
|
|
|
| Acute SARS-CoV-2 infection is associated with an expansion of bacteria pathogens in the nose including Pseudomonas Aeruginosa/Experiment 3 |
|
|
|
| Acute SARS-CoV-2 infection is associated with an expansion of bacteria pathogens in the nose including Pseudomonas Aeruginosa/Experiment 3/Signature 1 |
|
|
|
| Acute SARS-CoV-2 infection is associated with an expansion of bacteria pathogens in the nose including Pseudomonas Aeruginosa/Experiment 3/Signature 2 |
|
|
|
| Age-specific differential changes on gut microbiota composition in patients with major depressive disorder/Experiment 1 |
|
|
|
| Almond Snacking for 8 wk Increases Alpha-Diversity of the Gastrointestinal Microbiome and Decreases Bacteroides fragilis Abundance Compared with an Isocaloric Snack in College Freshmen |
|
|
|
| Almond Snacking for 8 wk Increases Alpha-Diversity of the Gastrointestinal Microbiome and Decreases Bacteroides fragilis Abundance Compared with an Isocaloric Snack in College Freshmen/Experiment 1 |
|
|
|
| Almond Snacking for 8 wk Increases Alpha-Diversity of the Gastrointestinal Microbiome and Decreases Bacteroides fragilis Abundance Compared with an Isocaloric Snack in College Freshmen/Experiment 1/Signature 1 |
|
|
|
| Almond Snacking for 8 wk Increases Alpha-Diversity of the Gastrointestinal Microbiome and Decreases Bacteroides fragilis Abundance Compared with an Isocaloric Snack in College Freshmen/Experiment 2 |
|
|
|
| Almond Snacking for 8 wk Increases Alpha-Diversity of the Gastrointestinal Microbiome and Decreases Bacteroides fragilis Abundance Compared with an Isocaloric Snack in College Freshmen/Experiment 2/Signature 1 |
|
|
|
| Almond Snacking for 8 wk Increases Alpha-Diversity of the Gastrointestinal Microbiome and Decreases Bacteroides fragilis Abundance Compared with an Isocaloric Snack in College Freshmen/Experiment 2/Signature 2 |
|
|
|
| Almond Snacking for 8 wk Increases Alpha-Diversity of the Gastrointestinal Microbiome and Decreases Bacteroides fragilis Abundance Compared with an Isocaloric Snack in College Freshmen/Experiment 3 |
|
|
|
| Almond Snacking for 8 wk Increases Alpha-Diversity of the Gastrointestinal Microbiome and Decreases Bacteroides fragilis Abundance Compared with an Isocaloric Snack in College Freshmen/Experiment 3/Signature 1 |
|
|
|
| Alteration of the gut microbiome in first-episode drug-naïve and chronic medicated schizophrenia correlate with regional brain volumes/Experiment 1 |
|
|
|
| Alteration of the gut microbiome in first-episode drug-naïve and chronic medicated schizophrenia correlate with regional brain volumes/Experiment 1/Signature 1 |
|
|
|
| Alteration of the gut microbiome in first-episode drug-naïve and chronic medicated schizophrenia correlate with regional brain volumes/Experiment 1/Signature 2 |
|
|
|
| Alteration of the gut microbiome in first-episode drug-naïve and chronic medicated schizophrenia correlate with regional brain volumes/Experiment 2 |
|
|
|
| Alteration of the gut microbiome in first-episode drug-naïve and chronic medicated schizophrenia correlate with regional brain volumes/Experiment 2/Signature 1 |
|
|
|
| Alteration of the gut microbiome in first-episode drug-naïve and chronic medicated schizophrenia correlate with regional brain volumes/Experiment 2/Signature 2 |
|
|
|
| Alteration of the gut microbiome in first-episode drug-naïve and chronic medicated schizophrenia correlate with regional brain volumes/Experiment 3 |
|
|
|
| Alteration of the gut microbiome in first-episode drug-naïve and chronic medicated schizophrenia correlate with regional brain volumes/Experiment 3/Signature 1 |
|
|
|
| Alteration of the gut microbiome in first-episode drug-naïve and chronic medicated schizophrenia correlate with regional brain volumes/Experiment 3/Signature 2 |
|
|
|
| Alterations in composition and diversity of the intestinal microbiota in patients with diarrhea-predominant irritable bowel syndrome |
|
|
|
| Alterations in composition and diversity of the intestinal microbiota in patients with diarrhea-predominant irritable bowel syndrome/Experiment 1 |
|
|
|
| Alterations in composition and diversity of the intestinal microbiota in patients with diarrhea-predominant irritable bowel syndrome/Experiment 1/Signature 1 |
|
|
|
| Alterations in composition and diversity of the intestinal microbiota in patients with diarrhea-predominant irritable bowel syndrome/Experiment 1/Signature 2 |
|
|
|
| Alterations in composition and diversity of the intestinal microbiota in patients with diarrhea-predominant irritable bowel syndrome/Experiment 2 |
|
|
|
| Alterations in composition and diversity of the intestinal microbiota in patients with diarrhea-predominant irritable bowel syndrome/Experiment 2/Signature 1 |
|
|
|
| Alterations in intestinal microbiota of elderly Irish subjects post-antibiotic therapy/Experiment 1/Signature 2 |
|
|
|
| Alterations in intestinal microbiota of elderly Irish subjects post-antibiotic therapy/Experiment 2/Signature 2 |
|
|
|
| Alterations in intestinal microbiota of elderly Irish subjects post-antibiotic therapy/Experiment 3/Signature 1 |
|
|
|
| Alterations in intestinal microbiota of elderly Irish subjects post-antibiotic therapy/Experiment 4/Signature 1 |
|
|
|
| Alterations in the gut bacterial microbiome in people with type 2 diabetes mellitus and diabetic retinopathy/Experiment 3/Signature 1 |
|
|
|
| Alterations in the gut microbiotas of children with food sensitization in early life |
|
|
|
| Alterations in the gut microbiotas of children with food sensitization in early life/Experiment 1 |
|
|
|
| Alterations in the gut microbiotas of children with food sensitization in early life/Experiment 1/Signature 1 |
|
|
|
| Alterations in the gut microbiotas of children with food sensitization in early life/Experiment 1/Signature 2 |
|
|
|
| Alterations in the gut microbiotas of children with food sensitization in early life/Experiment 2 |
|
|
|
| Alterations in the gut microbiotas of children with food sensitization in early life/Experiment 2/Signature 1 |
|
|
|
| Alterations in the gut microbiotas of children with food sensitization in early life/Experiment 2/Signature 2 |
|
|
|
| Alterations in the human oral and gut microbiomes and lipidomics in COVID-19/Experiment 3 |
|
|
|
| Alterations in the skin microbiome are associated with disease severity and treatment in the perioral zone of the skin of infants with atopic dermatitis |
|
|
|
| Alterations in the skin microbiome are associated with disease severity and treatment in the perioral zone of the skin of infants with atopic dermatitis/Experiment 1 |
|
|
|
| Alterations in the skin microbiome are associated with disease severity and treatment in the perioral zone of the skin of infants with atopic dermatitis/Experiment 1/Signature 1 |
|
|
|
| Alterations in the skin microbiome are associated with disease severity and treatment in the perioral zone of the skin of infants with atopic dermatitis/Experiment 1/Signature 2 |
|
|
|
| Alterations of gastric mucosal microbiota across different stomach microhabitats in a cohort of 276 patients with gastric cancer/Experiment 3/Signature 1 |
|
|
|
| Alterations of gastric mucosal microbiota across different stomach microhabitats in a cohort of 276 patients with gastric cancer/Experiment 4/Signature 2 |
|
|
|
| Alterations of gastric mucosal microbiota across different stomach microhabitats in a cohort of 276 patients with gastric cancer/Experiment 5/Signature 1 |
|
|
|
| Alterations of gastric mucosal microbiota across different stomach microhabitats in a cohort of 276 patients with gastric cancer/Experiment 7/Signature 1 |
|
|
|
| Alterations of gastric mucosal microbiota across different stomach microhabitats in a cohort of 276 patients with gastric cancer/Experiment 9/Signature 2 |
|
|
|
| Alterations of gastric mucosal microbiota across different stomach microhabitats in a cohort of 276 patients with gastric cancer/Experiment 10/Signature 1 |
|
|
|
| Alterations of gut microbiome in autoimmune hepatitis |
|
|
|
| Alterations of gut microbiome in autoimmune hepatitis/Experiment 1 |
|
|
|
| Alterations of gut microbiome in autoimmune hepatitis/Experiment 1/Signature 1 |
|
|
|
| Alterations of gut microbiome in autoimmune hepatitis/Experiment 1/Signature 2 |
|
|
|
| Alterations of gut microbiome in autoimmune hepatitis/Experiment 2 |
|
|
|
| Alterations of the Gut Microbiota in Hashimoto's Thyroiditis Patients |
|
|
|
| Alterations of the Gut Microbiota in Hashimoto's Thyroiditis Patients/Experiment 1 |
|
|
|
| Alterations of the Gut Microbiota in Hashimoto's Thyroiditis Patients/Experiment 1/Signature 1 |
|
|
|
| Alterations of the Gut Microbiota in Hashimoto's Thyroiditis Patients/Experiment 1/Signature 2 |
|
|
|
| Alterations of the Gut Microbiota in Patients With Coronavirus Disease 2019 or H1N1 Influenza/Experiment 2/Signature 1 |
|
|
|
| Alterations of the Gut Microbiota in Patients With Coronavirus Disease 2019 or H1N1 Influenza/Experiment 2/Signature 2 |
|
|
|
| Alterations of the Gut Microbiota in Patients With Coronavirus Disease 2019 or H1N1 Influenza/Experiment 4 |
|
|
|
| Alterations of the Gut Microbiota in Patients With Coronavirus Disease 2019 or H1N1 Influenza/Experiment 4/Signature 1 |
|
|
|
| Alterations to the Gastrointestinal Microbiome Associated with Methamphetamine Use among Young Men who have Sex with Men/Experiment 5 |
|
|
|
| Altered fecal microbiota composition associated with food allergy in infants |
|
|
|
| Altered fecal microbiota composition associated with food allergy in infants/Experiment 1 |
|
|
|
| Altered fecal microbiota composition associated with food allergy in infants/Experiment 1/Signature 1 |
|
|
|
| Altered fecal microbiota composition associated with food allergy in infants/Experiment 1/Signature 2 |
|
|
|
| Altered fecal microbiota composition associated with food allergy in infants/Experiment 1/Signature 3 |
|
|
|
| Altered fecal microbiota composition associated with food allergy in infants/Experiment 1/Signature 4 |
|
|
|
| Altered fecal microbiota composition associated with food allergy in infants/Experiment 1/Signature 5 |
|
|
|
| Altered fecal microbiota composition associated with food allergy in infants/Experiment 1/Signature 6 |
|
|
|
| Altered fecal microbiota composition associated with food allergy in infants/Experiment 2 |
|
|
|
| Altered fecal microbiota composition associated with food allergy in infants/Experiment 2/Signature 1 |
|
|
|
| Altered fecal microbiota composition associated with food allergy in infants/Experiment 2/Signature 2 |
|
|
|
| Altered fecal microbiota composition associated with food allergy in infants/Experiment 3 |
|
|
|
| Altered fecal microbiota composition associated with food allergy in infants/Experiment 3/Signature 1 |
|
|
|
| Altered fecal microbiota composition associated with food allergy in infants/Experiment 3/Signature 2 |
|
|
|
| Altered fecal microbiota composition associated with food allergy in infants/Experiment 4 |
|
|
|
| Altered fecal microbiota composition associated with food allergy in infants/Experiment 4/Signature 1 |
|
|
|
| Altered fecal microbiota composition associated with food allergy in infants/Experiment 4/Signature 2 |
|
|
|
| Altered Fecal Small RNA Profiles in Colorectal Cancer Reflect Gut Microbiome Composition in Stool Samples/Experiment 1/Signature 1 |
|
|
|
| Altered Fecal Small RNA Profiles in Colorectal Cancer Reflect Gut Microbiome Composition in Stool Samples/Experiment 1/Signature 2 |
|
|
|
| Altered Fecal Small RNA Profiles in Colorectal Cancer Reflect Gut Microbiome Composition in Stool Samples/Experiment 2 |
|
|
|
| Altered Fecal Small RNA Profiles in Colorectal Cancer Reflect Gut Microbiome Composition in Stool Samples/Experiment 2/Signature 1 |
|
|
|
| Altered Fecal Small RNA Profiles in Colorectal Cancer Reflect Gut Microbiome Composition in Stool Samples/Experiment 2/Signature 2 |
|
|
|
| Altered Fecal Small RNA Profiles in Colorectal Cancer Reflect Gut Microbiome Composition in Stool Samples/Experiment 3 |
|
|
|
| Altered Fecal Small RNA Profiles in Colorectal Cancer Reflect Gut Microbiome Composition in Stool Samples/Experiment 3/Signature 1 |
|
|
|
| Altered Fecal Small RNA Profiles in Colorectal Cancer Reflect Gut Microbiome Composition in Stool Samples/Experiment 3/Signature 2 |
|
|
|
| Altered Gut Microbiota in Irritable Bowel Syndrome and Its Association with Food Components |
|
|
|
| Altered Gut Microbiota in Irritable Bowel Syndrome and Its Association with Food Components/Experiment 1/Signature 1 |
|
|
|
| Altered Gut Microbiota in Irritable Bowel Syndrome and Its Association with Food Components/Experiment 1/Signature 2 |
|
|
|
| Altered intestinal microbiota associated with colorectal cancer |
|
|
|
| Altered intestinal microbiota associated with colorectal cancer/Experiment 1 |
|
|
|
| Altered intestinal microbiota associated with colorectal cancer/Experiment 1/Signature 1 |
|
|
|
| Altered intestinal microbiota associated with colorectal cancer/Experiment 1/Signature 2 |
|
|
|
| Altered profiles of intestinal microbiota and organic acids may be the origin of symptoms in irritable bowel syndrome |
|
|
|
| Altered profiles of intestinal microbiota and organic acids may be the origin of symptoms in irritable bowel syndrome/Experiment 1 |
|
|
|
| Altered profiles of intestinal microbiota and organic acids may be the origin of symptoms in irritable bowel syndrome/Experiment 1/Signature 1 |
|
|
|
| An Exploratory Study for the Association of Gut Microbiome with Efficacy of Immune Checkpoint Inhibitor in Patients with Hepatocellular Carcinoma |
|
|
|
| An Exploratory Study for the Association of Gut Microbiome with Efficacy of Immune Checkpoint Inhibitor in Patients with Hepatocellular Carcinoma/Experiment 1 |
|
|
|
| An Exploratory Study for the Association of Gut Microbiome with Efficacy of Immune Checkpoint Inhibitor in Patients with Hepatocellular Carcinoma/Experiment 1/Signature 1 |
|
|
|
| An Exploratory Study for the Association of Gut Microbiome with Efficacy of Immune Checkpoint Inhibitor in Patients with Hepatocellular Carcinoma/Experiment 1/Signature 2 |
|
|
|
| An Exploratory Study for the Association of Gut Microbiome with Efficacy of Immune Checkpoint Inhibitor in Patients with Hepatocellular Carcinoma/Experiment 2 |
|
|
|
| An Exploratory Study for the Association of Gut Microbiome with Efficacy of Immune Checkpoint Inhibitor in Patients with Hepatocellular Carcinoma/Experiment 2/Signature 1 |
|
|
|
| An Exploratory Study for the Association of Gut Microbiome with Efficacy of Immune Checkpoint Inhibitor in Patients with Hepatocellular Carcinoma/Experiment 2/Signature 2 |
|
|
|
| An Exploratory Study for the Association of Gut Microbiome with Efficacy of Immune Checkpoint Inhibitor in Patients with Hepatocellular Carcinoma/Experiment 3 |
|
|
|
| An Exploratory Study for the Association of Gut Microbiome with Efficacy of Immune Checkpoint Inhibitor in Patients with Hepatocellular Carcinoma/Experiment 3/Signature 1 |
|
|
|
| Analysis of endoscopic brush samples identified mucosa-associated dysbiosis in inflammatory bowel disease |
|
|
|
| Analysis of microbiota in first episode psychosis identifies preliminary associations with symptom severity and treatment response/Experiment 2 |
|
|
|
| Analysis of microbiota in first episode psychosis identifies preliminary associations with symptom severity and treatment response/Experiment 2/Signature 1 |
|
|
|
| Analysis of microbiota in first episode psychosis identifies preliminary associations with symptom severity and treatment response/Experiment 2/Signature 2 |
|
|
|
| Analysis of subgingival microbiome of periodontal disease and rheumatoid arthritis in Chinese: A case-control study |
|
|
|
| Analysis of the diversity of intestinal microbiome and its potential value as a biomarker in patients with schizophrenia: A cohort study |
|
|
|
| Analysis of the diversity of intestinal microbiome and its potential value as a biomarker in patients with schizophrenia: A cohort study/Experiment 1 |
|
|
|
| Analysis of the diversity of intestinal microbiome and its potential value as a biomarker in patients with schizophrenia: A cohort study/Experiment 1/Signature 1 |
|
|
|
| Analysis of the diversity of intestinal microbiome and its potential value as a biomarker in patients with schizophrenia: A cohort study/Experiment 1/Signature 2 |
|
|
|
| Analysis of the diversity of intestinal microbiome and its potential value as a biomarker in patients with schizophrenia: A cohort study/Experiment 2 |
|
|
|
| Analysis of the diversity of intestinal microbiome and its potential value as a biomarker in patients with schizophrenia: A cohort study/Experiment 2/Signature 1 |
|
|
|
| Analysis of the diversity of intestinal microbiome and its potential value as a biomarker in patients with schizophrenia: A cohort study/Experiment 2/Signature 2 |
|
|
|
| Analysis of the diversity of intestinal microbiome and its potential value as a biomarker in patients with schizophrenia: A cohort study/Experiment 3 |
|
|
|
| Analysis of the diversity of intestinal microbiome and its potential value as a biomarker in patients with schizophrenia: A cohort study/Experiment 3/Signature 1 |
|
|
|
| Analysis of the Gut Mycobiome in Adult Patients with Type 1 and Type 2 Diabetes Using Next-Generation Sequencing (NGS) with Increased Sensitivity-Pilot Study |
|
|
|
| Analysis of the Gut Mycobiome in Adult Patients with Type 1 and Type 2 Diabetes Using Next-Generation Sequencing (NGS) with Increased Sensitivity-Pilot Study/Experiment 1 |
|
|
|
| Analysis of the Gut Mycobiome in Adult Patients with Type 1 and Type 2 Diabetes Using Next-Generation Sequencing (NGS) with Increased Sensitivity-Pilot Study/Experiment 1/Signature 1 |
|
|
|
| Analysis of the Gut Mycobiome in Adult Patients with Type 1 and Type 2 Diabetes Using Next-Generation Sequencing (NGS) with Increased Sensitivity-Pilot Study/Experiment 1/Signature 2 |
|
|
|
| Analysis of the Gut Mycobiome in Adult Patients with Type 1 and Type 2 Diabetes Using Next-Generation Sequencing (NGS) with Increased Sensitivity-Pilot Study/Experiment 2 |
|
|
|
| Analysis of the Gut Mycobiome in Adult Patients with Type 1 and Type 2 Diabetes Using Next-Generation Sequencing (NGS) with Increased Sensitivity-Pilot Study/Experiment 2/Signature 1 |
|
|
|
| Analysis of the Gut Mycobiome in Adult Patients with Type 1 and Type 2 Diabetes Using Next-Generation Sequencing (NGS) with Increased Sensitivity-Pilot Study/Experiment 2/Signature 2 |
|
|
|
| Analysis of the Gut Mycobiome in Adult Patients with Type 1 and Type 2 Diabetes Using Next-Generation Sequencing (NGS) with Increased Sensitivity-Pilot Study/Experiment 3 |
|
|
|
| Analysis of the Gut Mycobiome in Adult Patients with Type 1 and Type 2 Diabetes Using Next-Generation Sequencing (NGS) with Increased Sensitivity-Pilot Study/Experiment 3/Signature 1 |
|
|
|
| Analysis of the Gut Mycobiome in Adult Patients with Type 1 and Type 2 Diabetes Using Next-Generation Sequencing (NGS) with Increased Sensitivity-Pilot Study/Experiment 3/Signature 2 |
|
|
|
| Antibiotics at birth and later antibiotic courses: effects on gut microbiota/Experiment 1 |
|
|
|
| Association of Bitter Taste Receptor T2R38 Polymorphisms, Oral Microbiota, and Rheumatoid Arthritis |
|
|
|
| Association of dietary fibre intake and gut microbiota in adults |
|
|
|
| Association of dietary fibre intake and gut microbiota in adults |
|
|
|
| Association of dietary fibre intake and gut microbiota in adults/Experiment 1 |
|
|
|
| Association of dietary fibre intake and gut microbiota in adults/Experiment 1 |
|
|
|
| Association of dietary fibre intake and gut microbiota in adults/Experiment 1/Signature 1 |
|
|
|
| Association of dietary fibre intake and gut microbiota in adults/Experiment 1/Signature 1 |
|
|
|
| Association of dietary fibre intake and gut microbiota in adults/Experiment 1/Signature 2 |
|
|
|
| Association of dietary fibre intake and gut microbiota in adults/Experiment 1/Signature 2 |
|
|
|
| Association of dietary fibre intake and gut microbiota in adults/Experiment 2 |
|
|
|
| Association of dietary fibre intake and gut microbiota in adults/Experiment 2/Signature 1 |
|
|
|
| Association of dietary fibre intake and gut microbiota in adults/Experiment 3 |
|
|
|
| Association of dietary fibre intake and gut microbiota in adults/Experiment 3/Signature 1 |
|
|
|
| Association of dietary fibre intake and gut microbiota in adults/Experiment 3/Signature 2 |
|
|
|
| Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab/Experiment 1/Signature 1 |
|
|
|
| Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab/Experiment 1/Signature 2 |
|
|
|
| Berberine may rescue Fusobacterium nucleatum-induced colorectal tumorigenesis by modulating the tumor microenvironment |
|
|
|
| Berberine may rescue Fusobacterium nucleatum-induced colorectal tumorigenesis by modulating the tumor microenvironment/Experiment 1 |
|
|
|
| Berberine may rescue Fusobacterium nucleatum-induced colorectal tumorigenesis by modulating the tumor microenvironment/Experiment 1/Signature 1 |
|
|
|
| Berberine may rescue Fusobacterium nucleatum-induced colorectal tumorigenesis by modulating the tumor microenvironment/Experiment 1/Signature 2 |
|
|
|
| Berberine may rescue Fusobacterium nucleatum-induced colorectal tumorigenesis by modulating the tumor microenvironment/Experiment 2 |
|
|
|
| Berberine may rescue Fusobacterium nucleatum-induced colorectal tumorigenesis by modulating the tumor microenvironment/Experiment 2/Signature 1 |
|
|
|
| Berberine may rescue Fusobacterium nucleatum-induced colorectal tumorigenesis by modulating the tumor microenvironment/Experiment 3 |
|
|
|
| Berberine may rescue Fusobacterium nucleatum-induced colorectal tumorigenesis by modulating the tumor microenvironment/Experiment 3/Signature 1 |
|
|
|
| Body site-typical microbiome signatures/Experiment 1 |
|
|
|
| Body site-typical microbiome signatures/Experiment 2 |
|
|
|
| Body site-typical microbiome signatures/Experiment 2/Signature 1 |
|
|
|
| Body site-typical microbiome signatures/Experiment 2/Signature 2 |
|
|
|
| Cervical microbiota in women with cervical intra-epithelial neoplasia, prior to and after local excisional treatment, a Norwegian cohort study/Experiment 2/Signature 1 |
|
|
|
| Cervical microbiota in women with cervical intra-epithelial neoplasia, prior to and after local excisional treatment, a Norwegian cohort study/Experiment 3/Signature 1 |
|
|
|
| Cervical microbiota in women with cervical intra-epithelial neoplasia, prior to and after local excisional treatment, a Norwegian cohort study/Experiment 4/Signature 1 |
|
|
|
| Cervical microbiota in women with cervical intra-epithelial neoplasia, prior to and after local excisional treatment, a Norwegian cohort study/Experiment 5/Signature 1 |
|
|
|
| Cervical microbiota in women with cervical intra-epithelial neoplasia, prior to and after local excisional treatment, a Norwegian cohort study/Experiment 6/Signature 1 |
|
|
|
| Cervicovaginal microbiota dysbiosis correlates with HPV persistent infection |
|
|
|
| Cervicovaginal microbiota dysbiosis correlates with HPV persistent infection/Experiment 1 |
|
|
|
| Cervicovaginal microbiota dysbiosis correlates with HPV persistent infection/Experiment 1/Signature 1 |
|
|
|
| Cervicovaginal microbiota dysbiosis correlates with HPV persistent infection/Experiment 1/Signature 2 |
|
|
|
| Cervicovaginal microbiota dysbiosis correlates with HPV persistent infection/Experiment 2 |
|
|
|
| Cervicovaginal microbiota dysbiosis correlates with HPV persistent infection/Experiment 2/Signature 1 |
|
|
|
| Cervicovaginal microbiota dysbiosis correlates with HPV persistent infection/Experiment 2/Signature 2 |
|
|
|
| Changes in metabolism and microbiota after 24-week risperidone treatment in drug naïve, normal weight patients with first episode schizophrenia |
|
|
|
| Changes in metabolism and microbiota after 24-week risperidone treatment in drug naïve, normal weight patients with first episode schizophrenia/Experiment 1 |
|
|
|
| Changes in metabolism and microbiota after 24-week risperidone treatment in drug naïve, normal weight patients with first episode schizophrenia/Experiment 1/Signature 1 |
|
|
|
| Characteristics of the Salivary Microbiota in Patients With Various Digestive Tract Cancers/Experiment 2/Signature 2 |
|
|
|
| Characteristics of the Salivary Microbiota in Patients With Various Digestive Tract Cancers/Experiment 3/Signature 1 |
|
|
|
| Characteristics of the Salivary Microbiota in Patients With Various Digestive Tract Cancers/Experiment 3/Signature 2 |
|
|
|
| Characteristics of the Salivary Microbiota in Patients With Various Digestive Tract Cancers/Experiment 4/Signature 2 |
|
|
|
| Characteristics of the Salivary Microbiota in Patients With Various Digestive Tract Cancers/Experiment 5/Signature 1 |
|
|
|
| Characteristics of the Salivary Microbiota in Patients With Various Digestive Tract Cancers/Experiment 5/Signature 2 |
|
|
|
| Characterization and Analysis of the Skin Microbiota in Rosacea: A Case-Control Study/Experiment 1/Signature 2 |
|
|
|
| Characterization of gut microbiota in patients with primary hepatocellular carcinoma received immune checkpoint inhibitors: A Chinese population-based study/Experiment 1/Signature 1 |
|
|
|
| Characterization of oral and gut microbiome temporal variability in hospitalized cancer patients/Experiment 1/Signature 1 |
|
|
|
| Characterization of oral and gut microbiome temporal variability in hospitalized cancer patients/Experiment 1/Signature 2 |
|
|
|
| Chemotherapy-driven dysbiosis in the intestinal microbiome/Experiment 1/Signature 2 |
|
|
|
| Cigarette smoking and the oral microbiome in a large study of American adults/Experiment 1/Signature 2 |
|
|
|
| Clinical impact of pre-transplant gut microbial diversity on outcomes of allogeneic hematopoietic stem cell transplantation |
|
|
|
| Clinical impact of pre-transplant gut microbial diversity on outcomes of allogeneic hematopoietic stem cell transplantation/Experiment 1 |
|
|
|
| Clinical impact of pre-transplant gut microbial diversity on outcomes of allogeneic hematopoietic stem cell transplantation/Experiment 1/Signature 1 |
|
|
|
| Clinical impact of pre-transplant gut microbial diversity on outcomes of allogeneic hematopoietic stem cell transplantation/Experiment 2 |
|
|
|
| Clinical impact of pre-transplant gut microbial diversity on outcomes of allogeneic hematopoietic stem cell transplantation/Experiment 2/Signature 1 |
|
|
|
| Collateral damage from oral ciprofloxacin versus nitrofurantoin in outpatients with urinary tract infections: a culture-free analysis of gut microbiota/Experiment 1/Signature 1 |
|
|
|
| Colorectal Cancer Stage-Specific Fecal Bacterial Community Fingerprinting of the Taiwanese Population and Underpinning of Potential Taxonomic Biomarkers |
|
|
|
| Colorectal Cancer Stage-Specific Fecal Bacterial Community Fingerprinting of the Taiwanese Population and Underpinning of Potential Taxonomic Biomarkers/Experiment 1 |
|
|
|
| Comparative analysis of the oral microbiota between iron-deficiency anaemia (IDA) patients and healthy individuals by high-throughput sequencing |
|
|
|
| Comparative analysis of the oral microbiota between iron-deficiency anaemia (IDA) patients and healthy individuals by high-throughput sequencing/Experiment 1 |
|
|
|
| Comparative analysis of the oral microbiota between iron-deficiency anaemia (IDA) patients and healthy individuals by high-throughput sequencing/Experiment 1/Signature 2 |
|
|
|
| Comparative analysis of the oral microbiota between iron-deficiency anaemia (IDA) patients and healthy individuals by high-throughput sequencing/Experiment 2 |
|
|
|
| Composition and metabolism of fecal microbiota from normal and overweight children are differentially affected by melibiose, raffinose and raffinose-derived fructans |
|
|
|
| Composition and metabolism of fecal microbiota from normal and overweight children are differentially affected by melibiose, raffinose and raffinose-derived fructans/Experiment 1 |
|
|
|
| Composition and metabolism of fecal microbiota from normal and overweight children are differentially affected by melibiose, raffinose and raffinose-derived fructans/Experiment 1/Signature 1 |
|
|
|
| Composition and metabolism of fecal microbiota from normal and overweight children are differentially affected by melibiose, raffinose and raffinose-derived fructans/Experiment 1/Signature 2 |
|
|
|
| Composition and metabolism of fecal microbiota from normal and overweight children are differentially affected by melibiose, raffinose and raffinose-derived fructans/Experiment 2 |
|
|
|
| Composition and metabolism of fecal microbiota from normal and overweight children are differentially affected by melibiose, raffinose and raffinose-derived fructans/Experiment 2/Signature 1 |
|
|
|
| Composition and metabolism of fecal microbiota from normal and overweight children are differentially affected by melibiose, raffinose and raffinose-derived fructans/Experiment 2/Signature 2 |
|
|
|
| Compositional and Functional Differences between Microbiota and Cervical Carcinogenesis as Identified by Shotgun Metagenomic Sequencing/Experiment 2/Signature 2 |
|
|
|
| Correlation between body mass index and gut concentrations of Lactobacillus reuteri, Bifidobacterium animalis, Methanobrevibacter smithii and Escherichia coli/Experiment 2/Signature 1 |
|
|
|
| Correlation between body mass index and gut concentrations of Lactobacillus reuteri, Bifidobacterium animalis, Methanobrevibacter smithii and Escherichia coli/Experiment 3/Signature 2 |
|
|
|
| Correlation between body mass index and gut concentrations of Lactobacillus reuteri, Bifidobacterium animalis, Methanobrevibacter smithii and Escherichia coli/Experiment 4 |
|
|
|
| Correlation between body mass index and gut concentrations of Lactobacillus reuteri, Bifidobacterium animalis, Methanobrevibacter smithii and Escherichia coli/Experiment 4/Signature 1 |
|
|
|
| Correlation between body mass index and gut concentrations of Lactobacillus reuteri, Bifidobacterium animalis, Methanobrevibacter smithii and Escherichia coli/Experiment 5 |
|
|
|
| Correlation between body mass index and gut concentrations of Lactobacillus reuteri, Bifidobacterium animalis, Methanobrevibacter smithii and Escherichia coli/Experiment 5/Signature 1 |
|
|
|
| Correlation of fecal metabolomics and gut microbiota in mice with endometriosis/Experiment 1/Signature 1 |
|
|
|
| Cotrimoxazole reduces systemic inflammation in HIV infection by altering the gut microbiome and immune activation |
|
|
|
| Cotrimoxazole reduces systemic inflammation in HIV infection by altering the gut microbiome and immune activation/Experiment 1 |
|
|
|
| Cotrimoxazole reduces systemic inflammation in HIV infection by altering the gut microbiome and immune activation/Experiment 1/Signature 1 |
|
|
|
| Cotrimoxazole reduces systemic inflammation in HIV infection by altering the gut microbiome and immune activation/Experiment 1/Signature 2 |
|
|
|
| Cotrimoxazole reduces systemic inflammation in HIV infection by altering the gut microbiome and immune activation/Experiment 1/Signature 3 |
|
|
|
| Cotrimoxazole reduces systemic inflammation in HIV infection by altering the gut microbiome and immune activation/Experiment 1/Signature 4 |
|
|
|
| Cutaneous microbiome effects of fluticasone propionate cream and adjunctive bleach baths in childhood atopic dermatitis/Experiment 1/Signature 1 |
|
|
|
| Cutaneous microbiome effects of fluticasone propionate cream and adjunctive bleach baths in childhood atopic dermatitis/Experiment 2/Signature 1 |
|
|
|
| Cutaneous microbiome effects of fluticasone propionate cream and adjunctive bleach baths in childhood atopic dermatitis/Experiment 3/Signature 1 |
|
|
|
| Daidzein Intake Is Associated with Equol Producing Status through an Increase in the Intestinal Bacteria Responsible for Equol Production |
|
|
|
| Daidzein Intake Is Associated with Equol Producing Status through an Increase in the Intestinal Bacteria Responsible for Equol Production/Experiment 1 |
|
|
|
| Daidzein Intake Is Associated with Equol Producing Status through an Increase in the Intestinal Bacteria Responsible for Equol Production/Experiment 1/Signature 1 |
|
|
|
| Decreased bacterial diversity characterizes the altered gut microbiota in patients with psoriatic arthritis, resembling dysbiosis in inflammatory bowel disease/Experiment 2/Signature 1 |
|
|
|
| Decreased bacterial diversity characterizes the altered gut microbiota in patients with psoriatic arthritis, resembling dysbiosis in inflammatory bowel disease/Experiment 3/Signature 2 |
|
|
|
| Decreased dietary fiber intake and structural alteration of gut microbiota in patients with advanced colorectal adenoma/Experiment 1 |
|
|
|
| Delivery Mode and the Transition of Pioneering Gut-Microbiota Structure, Composition and Predicted Metabolic Function/Experiment 2 |
|
|
|
| Delivery mode shapes the acquisition and structure of the initial microbiota across multiple body habitats in newborns/Experiment 1 |
|
|
|
| Difference of lower airway microbiome in bilateral protected specimen brush between lung cancer patients with unilateral lobar masses and control subjects/Experiment 1 |
|
|
|
| Difference of lower airway microbiome in bilateral protected specimen brush between lung cancer patients with unilateral lobar masses and control subjects/Experiment 3/Signature 1 |
|
|
|
| Difference of lower airway microbiome in bilateral protected specimen brush between lung cancer patients with unilateral lobar masses and control subjects/Experiment 4 |
|
|
|
| Difference of lower airway microbiome in bilateral protected specimen brush between lung cancer patients with unilateral lobar masses and control subjects/Experiment 4/Signature 1 |
|
|
|
| Difference of lower airway microbiome in bilateral protected specimen brush between lung cancer patients with unilateral lobar masses and control subjects/Experiment 4/Signature 2 |
|
|
|
| Differences in foot skin microbiomes between patients with type 2 diabetes and healthy individuals |
|
|
|
| Differences in foot skin microbiomes between patients with type 2 diabetes and healthy individuals/Experiment 1 |
|
|
|
| Differences in foot skin microbiomes between patients with type 2 diabetes and healthy individuals/Experiment 1/Signature 1 |
|
|
|
| Differences in foot skin microbiomes between patients with type 2 diabetes and healthy individuals/Experiment 1/Signature 2 |
|
|
|
| Differences in foot skin microbiomes between patients with type 2 diabetes and healthy individuals/Experiment 2 |
|
|
|
| Differences in gastric mucosal microbiota profiling in patients with chronic gastritis, intestinal metaplasia, and gastric cancer using pyrosequencing methods |
|
|
|
| Differences in gastric mucosal microbiota profiling in patients with chronic gastritis, intestinal metaplasia, and gastric cancer using pyrosequencing methods/Experiment 1 |
|
|
|
| Differences in gastric mucosal microbiota profiling in patients with chronic gastritis, intestinal metaplasia, and gastric cancer using pyrosequencing methods/Experiment 1/Signature 1 |
|
|
|
| Differences in gastric mucosal microbiota profiling in patients with chronic gastritis, intestinal metaplasia, and gastric cancer using pyrosequencing methods/Experiment 1/Signature 2 |
|
|
|
| Differences in gastric mucosal microbiota profiling in patients with chronic gastritis, intestinal metaplasia, and gastric cancer using pyrosequencing methods/Experiment 2 |
|
|
|
| Differences in gastric mucosal microbiota profiling in patients with chronic gastritis, intestinal metaplasia, and gastric cancer using pyrosequencing methods/Experiment 2/Signature 1 |
|
|
|
| Differences in gut microbiome composition between persons with chronic schizophrenia and healthy comparison subjects |
|
|
|
| Differences in gut microbiome composition between persons with chronic schizophrenia and healthy comparison subjects/Experiment 1 |
|
|
|
| Differences in gut microbiome composition between persons with chronic schizophrenia and healthy comparison subjects/Experiment 1/Signature 1 |
|
|
|
| Differences in gut microbiome composition between persons with chronic schizophrenia and healthy comparison subjects/Experiment 1/Signature 2 |
|
|
|
| Differences in the Oral Microbiome in Patients With Early Rheumatoid Arthritis and Individuals at Risk of Rheumatoid Arthritis Compared to Healthy Individuals/Experiment 1/Signature 1 |
|
|
|
| Differences in the Oral Microbiome in Patients With Early Rheumatoid Arthritis and Individuals at Risk of Rheumatoid Arthritis Compared to Healthy Individuals/Experiment 1/Signature 2 |
|
|
|
| Different functional genes of upper airway microbiome associated with natural course of childhood asthma |
|
|
|
| Different functional genes of upper airway microbiome associated with natural course of childhood asthma/Experiment 1 |
|
|
|
| Different functional genes of upper airway microbiome associated with natural course of childhood asthma/Experiment 1/Signature 1 |
|
|
|
| Different functional genes of upper airway microbiome associated with natural course of childhood asthma/Experiment 1/Signature 2 |
|
|
|
| Different functional genes of upper airway microbiome associated with natural course of childhood asthma/Experiment 2 |
|
|
|
| Different functional genes of upper airway microbiome associated with natural course of childhood asthma/Experiment 2/Signature 1 |
|
|
|
| Different functional genes of upper airway microbiome associated with natural course of childhood asthma/Experiment 2/Signature 2 |
|
|
|
| Different gastric microbiota compositions in two human populations with high and low gastric cancer risk in Colombia/Experiment 1/Signature 2 |
|
|
|
| Differential effects of depot medroxyprogesterone acetate administration on vaginal microbiome in Hispanic White and Black women |
|
|
|
| Differential effects of depot medroxyprogesterone acetate administration on vaginal microbiome in Hispanic White and Black women/Experiment 1 |
|
|
|
| Differential effects of depot medroxyprogesterone acetate administration on vaginal microbiome in Hispanic White and Black women/Experiment 1/Signature 1 |
|
|
|
| Differential effects of depot medroxyprogesterone acetate administration on vaginal microbiome in Hispanic White and Black women/Experiment 2 |
|
|
|
| Differential effects of depot medroxyprogesterone acetate administration on vaginal microbiome in Hispanic White and Black women/Experiment 2/Signature 1 |
|
|
|
| Differential intestinal and oral microbiota features associated with gestational diabetes and maternal inflammation/Experiment 1/Signature 2 |
|
|
|
| Differential intestinal and oral microbiota features associated with gestational diabetes and maternal inflammation/Experiment 2/Signature 1 |
|
|
|
| Differential intestinal and oral microbiota features associated with gestational diabetes and maternal inflammation/Experiment 2/Signature 2 |
|
|
|
| Distinct mucosal microbial communities in infants with surgical necrotizing enterocolitis correlate with age and antibiotic exposure/Experiment 1/Signature 2 |
|
|
|
| Distinct mucosal microbial communities in infants with surgical necrotizing enterocolitis correlate with age and antibiotic exposure/Experiment 2/Signature 1 |
|
|
|
| Distinct nasal airway bacterial microbiotas differentially relate to exacerbation in pediatric patients with asthma/Experiment 1/Signature 1 |
|
|
|
| Distinct nasal airway bacterial microbiotas differentially relate to exacerbation in pediatric patients with asthma/Experiment 2/Signature 2 |
|
|
|
| Distinct nasal airway bacterial microbiotas differentially relate to exacerbation in pediatric patients with asthma/Experiment 3/Signature 1 |
|
|
|
| Distinct nasal airway bacterial microbiotas differentially relate to exacerbation in pediatric patients with asthma/Experiment 4/Signature 1 |
|
|
|
| Distinct nasal airway bacterial microbiotas differentially relate to exacerbation in pediatric patients with asthma/Experiment 5/Signature 2 |
|
|
|
| Distinct nasal airway bacterial microbiotas differentially relate to exacerbation in pediatric patients with asthma/Experiment 7 |
|
|
|
| Distinct nasal airway bacterial microbiotas differentially relate to exacerbation in pediatric patients with asthma/Experiment 8/Signature 1 |
|
|
|
| Distinct nasal airway bacterial microbiotas differentially relate to exacerbation in pediatric patients with asthma/Experiment 8/Signature 2 |
|
|
|
| Distinct nasal airway bacterial microbiotas differentially relate to exacerbation in pediatric patients with asthma/Experiment 9/Signature 1 |
|
|
|
| Distinct nasal airway bacterial microbiotas differentially relate to exacerbation in pediatric patients with asthma/Experiment 9/Signature 2 |
|
|
|
| Distinct nasal airway bacterial microbiotas differentially relate to exacerbation in pediatric patients with asthma/Experiment 10/Signature 1 |
|
|
|
| Distinct nasal airway bacterial microbiotas differentially relate to exacerbation in pediatric patients with asthma/Experiment 10/Signature 2 |
|
|
|
| Duodenal and rectal mucosal microbiota related to small intestinal bacterial overgrowth in diarrhea-predominant irritable bowel syndrome |
|
|
|
| Duodenal and rectal mucosal microbiota related to small intestinal bacterial overgrowth in diarrhea-predominant irritable bowel syndrome/Experiment 1 |
|
|
|
| Duodenal and rectal mucosal microbiota related to small intestinal bacterial overgrowth in diarrhea-predominant irritable bowel syndrome/Experiment 1/Signature 1 |
|
|
|
| Duodenal and rectal mucosal microbiota related to small intestinal bacterial overgrowth in diarrhea-predominant irritable bowel syndrome/Experiment 1/Signature 2 |
|
|
|
| Duodenal and rectal mucosal microbiota related to small intestinal bacterial overgrowth in diarrhea-predominant irritable bowel syndrome/Experiment 2 |
|
|
|
| Duodenal and rectal mucosal microbiota related to small intestinal bacterial overgrowth in diarrhea-predominant irritable bowel syndrome/Experiment 3 |
|
|
|
| Duodenal and rectal mucosal microbiota related to small intestinal bacterial overgrowth in diarrhea-predominant irritable bowel syndrome/Experiment 4 |
|
|
|
| Duodenal and rectal mucosal microbiota related to small intestinal bacterial overgrowth in diarrhea-predominant irritable bowel syndrome/Experiment 4/Signature 1 |
|
|
|
| Duodenal and rectal mucosal microbiota related to small intestinal bacterial overgrowth in diarrhea-predominant irritable bowel syndrome/Experiment 5 |
|
|
|
| Duodenal and rectal mucosal microbiota related to small intestinal bacterial overgrowth in diarrhea-predominant irritable bowel syndrome/Experiment 5/Signature 1 |
|
|
|
| Dynamics of the bacterial gut microbiota in preterm and term infants after intravenous amoxicillin/ceftazidime treatment |
|
|
|
| Dynamics of the bacterial gut microbiota in preterm and term infants after intravenous amoxicillin/ceftazidime treatment/Experiment 1 |
|
|
|
| Dynamics of the bacterial gut microbiota in preterm and term infants after intravenous amoxicillin/ceftazidime treatment/Experiment 1/Signature 1 |
|
|
|
| Dynamics of the bacterial gut microbiota in preterm and term infants after intravenous amoxicillin/ceftazidime treatment/Experiment 1/Signature 2 |
|
|
|
| Dynamics of the bacterial gut microbiota in preterm and term infants after intravenous amoxicillin/ceftazidime treatment/Experiment 2 |
|
|
|
| Dynamics of the bacterial gut microbiota in preterm and term infants after intravenous amoxicillin/ceftazidime treatment/Experiment 2/Signature 1 |
|
|
|
| Dynamics of the bacterial gut microbiota in preterm and term infants after intravenous amoxicillin/ceftazidime treatment/Experiment 2/Signature 2 |
|
|
|
| Dysbiosis of gut microbiota in patients with neuromyelitis optica spectrum disorders: A cross sectional study |
|
|
|
| Dysbiosis of gut microbiota in patients with neuromyelitis optica spectrum disorders: A cross sectional study/Experiment 1 |
|
|
|
| Dysbiosis of gut microbiota in patients with neuromyelitis optica spectrum disorders: A cross sectional study/Experiment 1/Signature 1 |
|
|
|
| Dysbiosis of gut microbiota in patients with neuromyelitis optica spectrum disorders: A cross sectional study/Experiment 1/Signature 2 |
|
|
|
| Dysbiosis of human gut microbiome in young-onset colorectal cancer/Experiment 2/Signature 1 |
|
|
|
| Dysbiosis of the Gut Microbiome in Lung Cancer/Experiment 1/Signature 1 |
|
|
|
| Dysbiosis of the Gut Microbiome is associated with Tumor Biomarkers in Lung Cancer/Experiment 2/Signature 1 |
|
|
|
| Dysbiosis of the Gut Microbiome is associated with Tumor Biomarkers in Lung Cancer/Experiment 4/Signature 1 |
|
|
|
| Dysbiosis of upper respiratory tract microbiota in elderly pneumonia patients/Experiment 2/Signature 2 |
|
|
|
| Dysbiosis patterns during re-induction/salvage versus induction chemotherapy for acute leukemia |
|
|
|
| Dysbiosis patterns during re-induction/salvage versus induction chemotherapy for acute leukemia/Experiment 1 |
|
|
|
| Dysbiosis patterns during re-induction/salvage versus induction chemotherapy for acute leukemia/Experiment 1/Signature 1 |
|
|
|
| Dysbiosis patterns during re-induction/salvage versus induction chemotherapy for acute leukemia/Experiment 1/Signature 2 |
|
|
|
| Dysbiotic Subgingival Microbial Communities in Periodontally Healthy Patients With Rheumatoid Arthritis |
|
|
|
| Dysbiotic Subgingival Microbial Communities in Periodontally Healthy Patients With Rheumatoid Arthritis/Experiment 1 |
|
|
|
| Dysbiotic Subgingival Microbial Communities in Periodontally Healthy Patients With Rheumatoid Arthritis/Experiment 1/Signature 1 |
|
|
|
| Dysbiotic Subgingival Microbial Communities in Periodontally Healthy Patients With Rheumatoid Arthritis/Experiment 1/Signature 2 |
|
|
|
| Early-life gut microbiome and egg allergy |
|
|
|
| Early-life gut microbiome and egg allergy/Experiment 1 |
|
|
|
| Early-life gut microbiome and egg allergy/Experiment 1/Signature 1 |
|
|
|
| Early-life gut microbiome and egg allergy/Experiment 1/Signature 2 |
|
|
|
| Early-life gut microbiome and egg allergy/Experiment 2 |
|
|
|
| Early-life gut microbiome and egg allergy/Experiment 2/Signature 1 |
|
|
|
| Early-life gut microbiome composition and milk allergy resolution/Experiment 1/Signature 1 |
|
|
|
| Ecological succession in the vaginal microbiota during pregnancy and birth/Experiment 1/Signature 2 |
|
|
|
| Effect of a Nutritional Intervention on the Intestinal Microbiota of Vertically HIV-Infected Children: The Pediabiota Study/Experiment 1/Signature 2 |
|
|
|
| Effect of a Nutritional Intervention on the Intestinal Microbiota of Vertically HIV-Infected Children: The Pediabiota Study/Experiment 2/Signature 1 |
|
|
|
| Effect of ethnicity and socioeconomic variation to the gut microbiota composition among pre-adolescent in Malaysia/Experiment 2 |
|
|
|
| Effect of ethnicity and socioeconomic variation to the gut microbiota composition among pre-adolescent in Malaysia/Experiment 2/Signature 2 |
|
|
|
| Effect of ethnicity and socioeconomic variation to the gut microbiota composition among pre-adolescent in Malaysia/Experiment 3 |
|
|
|
| Effect of ethnicity and socioeconomic variation to the gut microbiota composition among pre-adolescent in Malaysia/Experiment 3/Signature 1 |
|
|
|
| Effect of ethnicity and socioeconomic variation to the gut microbiota composition among pre-adolescent in Malaysia/Experiment 3/Signature 2 |
|
|
|
| Effect of Lactobacillus rhamnosus GG Supplementation on Intestinal Inflammation Assessed by PET/MRI Scans and Gut Microbiota Composition in HIV-Infected Individuals/Experiment 2/Signature 1 |
|
|
|
| Effect of Lactobacillus rhamnosus GG Supplementation on Intestinal Inflammation Assessed by PET/MRI Scans and Gut Microbiota Composition in HIV-Infected Individuals/Experiment 2/Signature 2 |
|
|
|
| Effects of amoxicillin treatment on the salivary microbiota in children with acute otitis media/Experiment 1 |
|
|
|
| Effects of amoxicillin treatment on the salivary microbiota in children with acute otitis media/Experiment 2/Signature 1 |
|
|
|
| Effects of Commercial Apple Varieties on Human Gut Microbiota Composition and Metabolic Output Using an In Vitro Colonic Model |
|
|
|
| Effects of Commercial Apple Varieties on Human Gut Microbiota Composition and Metabolic Output Using an In Vitro Colonic Model/Experiment 1 |
|
|
|
| Effects of Commercial Apple Varieties on Human Gut Microbiota Composition and Metabolic Output Using an In Vitro Colonic Model/Experiment 1/Signature 1 |
|
|
|
| Effects of Commercial Apple Varieties on Human Gut Microbiota Composition and Metabolic Output Using an In Vitro Colonic Model/Experiment 2 |
|
|
|
| Effects of Commercial Apple Varieties on Human Gut Microbiota Composition and Metabolic Output Using an In Vitro Colonic Model/Experiment 2/Signature 1 |
|
|
|
| Effects of Commercial Apple Varieties on Human Gut Microbiota Composition and Metabolic Output Using an In Vitro Colonic Model/Experiment 3 |
|
|
|
| Effects of Commercial Apple Varieties on Human Gut Microbiota Composition and Metabolic Output Using an In Vitro Colonic Model/Experiment 3/Signature 1 |
|
|
|
| Effects of inhaled air pollution on markers of integrity, inflammation, and microbiota profiles of the intestines in Apolipoprotein E knockout mice |
|
|
|
| Effects of inhaled air pollution on markers of integrity, inflammation, and microbiota profiles of the intestines in Apolipoprotein E knockout mice/Experiment 1 |
|
|
|
| Effects of inhaled air pollution on markers of integrity, inflammation, and microbiota profiles of the intestines in Apolipoprotein E knockout mice/Experiment 1/Signature 1 |
|
|
|
| Effects of inhaled air pollution on markers of integrity, inflammation, and microbiota profiles of the intestines in Apolipoprotein E knockout mice/Experiment 1/Signature 2 |
|
|
|
| Effects of inhaled air pollution on markers of integrity, inflammation, and microbiota profiles of the intestines in Apolipoprotein E knockout mice/Experiment 2 |
|
|
|
| Effects of inhaled air pollution on markers of integrity, inflammation, and microbiota profiles of the intestines in Apolipoprotein E knockout mice/Experiment 2/Signature 1 |
|
|
|
| Effects of inhaled air pollution on markers of integrity, inflammation, and microbiota profiles of the intestines in Apolipoprotein E knockout mice/Experiment 2/Signature 2 |
|
|
|
| Effects of PM2.5 exposure during gestation on maternal gut microbiota and pregnancy outcomes |
|
|
|
| Effects of PM2.5 exposure during gestation on maternal gut microbiota and pregnancy outcomes/Experiment 1 |
|
|
|
| Effects of PM2.5 exposure during gestation on maternal gut microbiota and pregnancy outcomes/Experiment 1/Signature 1 |
|
|
|
| Effects of PM2.5 exposure during gestation on maternal gut microbiota and pregnancy outcomes/Experiment 1/Signature 2 |
|
|
|
| Effects of prebiotics on immunologic indicators and intestinal microbiota structure in perioperative colorectal cancer patients/Experiment 1/Signature 2 |
|
|
|
| Effects of prebiotics on immunologic indicators and intestinal microbiota structure in perioperative colorectal cancer patients/Experiment 3/Signature 1 |
|
|
|
| Effects of prebiotics on immunologic indicators and intestinal microbiota structure in perioperative colorectal cancer patients/Experiment 4/Signature 1 |
|
|
|
| Effects of prebiotics on immunologic indicators and intestinal microbiota structure in perioperative colorectal cancer patients/Experiment 4/Signature 2 |
|
|
|
| Effects of sex and chronic cigarette smoke exposure on the mouse cecal microbiome/Experiment 4/Signature 1 |
|
|
|
| Electronic Cigarette Aerosol Modulates the Oral Microbiome and Increases Risk of Infection/Experiment 2/Signature 1 |
|
|
|
| Electronic Cigarette Aerosol Modulates the Oral Microbiome and Increases Risk of Infection/Experiment 3/Signature 2 |
|
|
|
| Enriched Opportunistic Pathogens Revealed by Metagenomic Sequencing Hint Potential Linkages between Pharyngeal Microbiota and COVID-19/Experiment 4 |
|
|
|
| Enterotype-based Analysis of Gut Microbiota along the Conventional Adenoma-Carcinoma Colorectal Cancer Pathway/Experiment 1/Signature 2 |
|
|
|
| Environmental and intrinsic factors shaping gut microbiota composition and diversity and its relation to metabolic health in children and early adolescents: A population-based study |
|
|
|
| Environmental and intrinsic factors shaping gut microbiota composition and diversity and its relation to metabolic health in children and early adolescents: A population-based study/Experiment 1 |
|
|
|
| Environmental and intrinsic factors shaping gut microbiota composition and diversity and its relation to metabolic health in children and early adolescents: A population-based study/Experiment 1/Signature 1 |
|
|
|
| Environmental and intrinsic factors shaping gut microbiota composition and diversity and its relation to metabolic health in children and early adolescents: A population-based study/Experiment 1/Signature 2 |
|
|
|
| Environmental exposures and child and maternal gut microbiota in rural Malawi/Experiment 1/Signature 2 |
|
|
|
| Environmental particulate matter induces murine intestinal inflammatory responses and alters the gut microbiome |
|
|
|
| Environmental particulate matter induces murine intestinal inflammatory responses and alters the gut microbiome/Experiment 1 |
|
|
|
| Environmental particulate matter induces murine intestinal inflammatory responses and alters the gut microbiome/Experiment 1/Signature 1 |
|
|
|
| Environmental particulate matter induces murine intestinal inflammatory responses and alters the gut microbiome/Experiment 2 |
|
|
|
| Environmental particulate matter induces murine intestinal inflammatory responses and alters the gut microbiome/Experiment 2/Signature 1 |
|
|
|
| Environmental particulate matter induces murine intestinal inflammatory responses and alters the gut microbiome/Experiment 2/Signature 2 |
|
|
|
| Environmental toxicants in breast milk of Norwegian mothers and gut bacteria composition and metabolites in their infants at 1 month |
|
|
|
| Environmental toxicants in breast milk of Norwegian mothers and gut bacteria composition and metabolites in their infants at 1 month/Experiment 1 |
|
|
|
| Environmental toxicants in breast milk of Norwegian mothers and gut bacteria composition and metabolites in their infants at 1 month/Experiment 1/Signature 1 |
|
|
|
| Environmental toxicants in breast milk of Norwegian mothers and gut bacteria composition and metabolites in their infants at 1 month/Experiment 1/Signature 2 |
|
|
|
| Establishment of vaginal microbiota composition in early pregnancy and its association with subsequent preterm prelabor rupture of the fetal membranes |
|
|
|
| Establishment of vaginal microbiota composition in early pregnancy and its association with subsequent preterm prelabor rupture of the fetal membranes/Experiment 1 |
|
|
|
| Establishment of vaginal microbiota composition in early pregnancy and its association with subsequent preterm prelabor rupture of the fetal membranes/Experiment 1/Signature 1 |
|
|
|
| Establishment of vaginal microbiota composition in early pregnancy and its association with subsequent preterm prelabor rupture of the fetal membranes/Experiment 1/Signature 2 |
|
|
|
| Ethnic variability associating gut and oral microbiome with obesity in children |
|
|
|
| Ethnic variability associating gut and oral microbiome with obesity in children/Experiment 1 |
|
|
|
| Ethnic variability associating gut and oral microbiome with obesity in children/Experiment 1/Signature 1 |
|
|
|
| Ethnic variability associating gut and oral microbiome with obesity in children/Experiment 1/Signature 2 |
|
|
|
| Ethnic variability associating gut and oral microbiome with obesity in children/Experiment 2 |
|
|
|
| Ethnic variability associating gut and oral microbiome with obesity in children/Experiment 2/Signature 1 |
|
|
|
| Ethnic variability associating gut and oral microbiome with obesity in children/Experiment 2/Signature 2 |
|
|
|
| Ethnic variability associating gut and oral microbiome with obesity in children/Experiment 3 |
|
|
|
| Ethnic variability associating gut and oral microbiome with obesity in children/Experiment 3/Signature 1 |
|
|
|
| Ethnic variability associating gut and oral microbiome with obesity in children/Experiment 3/Signature 2 |
|
|
|
| Ethnic variability associating gut and oral microbiome with obesity in children/Experiment 4 |
|
|
|
| Ethnic variability associating gut and oral microbiome with obesity in children/Experiment 4/Signature 1 |
|
|
|
| Ethnicity influences the gut microbiota of individuals sharing a geographical location: a cross-sectional study from a middle-income country/Experiment 1/Signature 2 |
|
|
|
| Ethnicity influences the gut microbiota of individuals sharing a geographical location: a cross-sectional study from a middle-income country/Experiment 2/Signature 2 |
|
|
|
| Ethnicity influences the gut microbiota of individuals sharing a geographical location: a cross-sectional study from a middle-income country/Experiment 3/Signature 2 |
|
|
|
| Ethnicity influences the gut microbiota of individuals sharing a geographical location: a cross-sectional study from a middle-income country/Experiment 4/Signature 1 |
|
|
|
| Evaluation of the effects of intrapartum antibiotic prophylaxis on newborn intestinal microbiota using a sequencing approach targeted to multi hypervariable 16S rDNA regions |
|
|
|
| Evaluation of the effects of intrapartum antibiotic prophylaxis on newborn intestinal microbiota using a sequencing approach targeted to multi hypervariable 16S rDNA regions/Experiment 1 |
|
|
|
| Evaluation of the effects of intrapartum antibiotic prophylaxis on newborn intestinal microbiota using a sequencing approach targeted to multi hypervariable 16S rDNA regions/Experiment 1/Signature 1 |
|
|
|
| Evaluation of the effects of intrapartum antibiotic prophylaxis on newborn intestinal microbiota using a sequencing approach targeted to multi hypervariable 16S rDNA regions/Experiment 2 |
|
|
|
| Evaluation of the effects of intrapartum antibiotic prophylaxis on newborn intestinal microbiota using a sequencing approach targeted to multi hypervariable 16S rDNA regions/Experiment 2/Signature 1 |
|
|
|
| Evidence for a distinct gut microbiome in kidney stone formers compared to non-stone formers |
|
|
|
| Evidence for a distinct gut microbiome in kidney stone formers compared to non-stone formers/Experiment 1 |
|
|
|
| Evidence for a distinct gut microbiome in kidney stone formers compared to non-stone formers/Experiment 1/Signature 1 |
|
|
|
| Evidence for a distinct gut microbiome in kidney stone formers compared to non-stone formers/Experiment 1/Signature 2 |
|
|
|
| Evolution of the gut microbiome following acute HIV-1 infection/Experiment 1/Signature 1 |
|
|
|
| Exercise Alters Gut Microbiota Composition and Function in Lean and Obese Humans |
|
|
|
| Exercise Alters Gut Microbiota Composition and Function in Lean and Obese Humans/Experiment 1/Signature 2 |
|
|
|
| Exercise Alters Gut Microbiota Composition and Function in Lean and Obese Humans/Experiment 2/Signature 1 |
|
|
|
| Exposure to concentrated ambient PM2.5 alters the composition of gut microbiota in a murine model/Experiment 1/Signature 2 |
|
|
|
| Family SES Is Associated with the Gut Microbiome in Infants and Children/Experiment 1 |
|
|
|
| Family SES Is Associated with the Gut Microbiome in Infants and Children/Experiment 1/Signature 1 |
|
|
|
| Family SES Is Associated with the Gut Microbiome in Infants and Children/Experiment 1/Signature 2 |
|
|
|
| Features of the bronchial bacterial microbiome associated with atopy, asthma, and responsiveness to inhaled corticosteroid treatment/Experiment 1/Signature 2 |
|
|
|
| Features of the bronchial bacterial microbiome associated with atopy, asthma, and responsiveness to inhaled corticosteroid treatment/Experiment 2/Signature 2 |
|
|
|
| Features of the bronchial bacterial microbiome associated with atopy, asthma, and responsiveness to inhaled corticosteroid treatment/Experiment 3/Signature 2 |
|
|
|
| Features of the bronchial bacterial microbiome associated with atopy, asthma, and responsiveness to inhaled corticosteroid treatment/Experiment 4/Signature 2 |
|
|
|
| Fecal microbial dysbiosis in Chinese patients with inflammatory bowel disease |
|
|
|
| Fecal microbial dysbiosis in Chinese patients with inflammatory bowel disease/Experiment 1 |
|
|
|
| Fecal microbial dysbiosis in Chinese patients with inflammatory bowel disease/Experiment 1/Signature 1 |
|
|
|
| Fecal microbial dysbiosis in Chinese patients with inflammatory bowel disease/Experiment 1/Signature 2 |
|
|
|
| Fecal microbial dysbiosis in Chinese patients with inflammatory bowel disease/Experiment 2 |
|
|
|
| Fecal microbial dysbiosis in Chinese patients with inflammatory bowel disease/Experiment 2/Signature 1 |
|
|
|
| Fecal microbial dysbiosis in Chinese patients with inflammatory bowel disease/Experiment 2/Signature 2 |
|
|
|
| Fecal microbial dysbiosis in Chinese patients with inflammatory bowel disease/Experiment 3 |
|
|
|
| Fecal microbial dysbiosis in Chinese patients with inflammatory bowel disease/Experiment 3/Signature 1 |
|
|
|
| Fecal microbial dysbiosis in Chinese patients with inflammatory bowel disease/Experiment 3/Signature 2 |
|
|
|
| Fecal microbiome and volatile organic compound metabolome in obese humans with nonalcoholic fatty liver disease |
|
|
|
| Fecal microbiome and volatile organic compound metabolome in obese humans with nonalcoholic fatty liver disease/Experiment 1 |
|
|
|
| Fecal microbiome and volatile organic compound metabolome in obese humans with nonalcoholic fatty liver disease/Experiment 1/Signature 1 |
|
|
|
| Fecal microbiome and volatile organic compound metabolome in obese humans with nonalcoholic fatty liver disease/Experiment 1/Signature 2 |
|
|
|
| Fecal microbiome signatures are different in food-allergic children compared to siblings and healthy children |
|
|
|
| Fecal microbiome signatures are different in food-allergic children compared to siblings and healthy children/Experiment 1 |
|
|
|
| Fecal microbiome signatures are different in food-allergic children compared to siblings and healthy children/Experiment 1/Signature 1 |
|
|
|
| Fecal microbiome signatures are different in food-allergic children compared to siblings and healthy children/Experiment 1/Signature 2 |
|
|
|
| Fecal microbiome signatures are different in food-allergic children compared to siblings and healthy children/Experiment 2 |
|
|
|
| Fecal microbiome signatures are different in food-allergic children compared to siblings and healthy children/Experiment 2/Signature 1 |
|
|
|
| Fecal microbiome signatures are different in food-allergic children compared to siblings and healthy children/Experiment 2/Signature 2 |
|
|
|
| Fecal microbiome signatures are different in food-allergic children compared to siblings and healthy children/Experiment 3 |
|
|
|
| Fecal microbiome signatures are different in food-allergic children compared to siblings and healthy children/Experiment 3/Signature 1 |
|
|
|
| Fecal microbiome signatures are different in food-allergic children compared to siblings and healthy children/Experiment 3/Signature 2 |
|
|
|
| Fecal microbiome signatures are different in food-allergic children compared to siblings and healthy children/Experiment 4 |
|
|
|
| Fecal microbiome signatures are different in food-allergic children compared to siblings and healthy children/Experiment 4/Signature 1 |
|
|
|
| Fecal microbiome signatures are different in food-allergic children compared to siblings and healthy children/Experiment 4/Signature 2 |
|
|
|
| Fecal microbiome signatures of pancreatic cancer patients/Experiment 3/Signature 2 |
|
|
|
| Fecal microbiome signatures of pancreatic cancer patients/Experiment 4/Signature 1 |
|
|
|
| Fecal Microbiota in Patients with Irritable Bowel Syndrome Compared with Healthy Controls Using Real-Time Polymerase Chain Reaction: An Evidence of Dysbiosis/Experiment 1 |
|
|
|
| Fecal Microbiota in Patients with Irritable Bowel Syndrome Compared with Healthy Controls Using Real-Time Polymerase Chain Reaction: An Evidence of Dysbiosis/Experiment 1/Signature 1 |
|
|
|
| Fecal Microbiota in Patients with Irritable Bowel Syndrome Compared with Healthy Controls Using Real-Time Polymerase Chain Reaction: An Evidence of Dysbiosis/Experiment 1/Signature 2 |
|
|
|
| Fecal Microbiota in Patients with Irritable Bowel Syndrome Compared with Healthy Controls Using Real-Time Polymerase Chain Reaction: An Evidence of Dysbiosis/Experiment 2 |
|
|
|
| Fecal Microbiota in Patients with Irritable Bowel Syndrome Compared with Healthy Controls Using Real-Time Polymerase Chain Reaction: An Evidence of Dysbiosis/Experiment 2/Signature 1 |
|
|
|
| Fecal Microbiota in Patients with Irritable Bowel Syndrome Compared with Healthy Controls Using Real-Time Polymerase Chain Reaction: An Evidence of Dysbiosis/Experiment 2/Signature 2 |
|
|
|
| Fecal Microbiota in Patients with Irritable Bowel Syndrome Compared with Healthy Controls Using Real-Time Polymerase Chain Reaction: An Evidence of Dysbiosis/Experiment 3 |
|
|
|
| Fecal Microbiota in Patients with Irritable Bowel Syndrome Compared with Healthy Controls Using Real-Time Polymerase Chain Reaction: An Evidence of Dysbiosis/Experiment 3/Signature 1 |
|
|
|
| Fecal Microbiota in Patients with Irritable Bowel Syndrome Compared with Healthy Controls Using Real-Time Polymerase Chain Reaction: An Evidence of Dysbiosis/Experiment 3/Signature 2 |
|
|
|
| Fecal Microbiota in Patients with Irritable Bowel Syndrome Compared with Healthy Controls Using Real-Time Polymerase Chain Reaction: An Evidence of Dysbiosis/Experiment 4 |
|
|
|
| Fecal Microbiota in Patients with Irritable Bowel Syndrome Compared with Healthy Controls Using Real-Time Polymerase Chain Reaction: An Evidence of Dysbiosis/Experiment 4/Signature 1 |
|
|
|
| Fecal Microbiota in Patients with Irritable Bowel Syndrome Compared with Healthy Controls Using Real-Time Polymerase Chain Reaction: An Evidence of Dysbiosis/Experiment 4/Signature 2 |
|
|
|
| Fecal Microbiota Taxonomic Shifts in Chinese Multiple Myeloma Patients Analyzed by Quantitative Polimerase Chain Reaction (QPCR) and 16S rRNA High-Throughput Sequencing |
|
|
|
| Fecal Microbiota Taxonomic Shifts in Chinese Multiple Myeloma Patients Analyzed by Quantitative Polimerase Chain Reaction (QPCR) and 16S rRNA High-Throughput Sequencing/Experiment 1 |
|
|
|
| Fecal Microbiota Taxonomic Shifts in Chinese Multiple Myeloma Patients Analyzed by Quantitative Polimerase Chain Reaction (QPCR) and 16S rRNA High-Throughput Sequencing/Experiment 1/Signature 1 |
|
|
|
| Fecal Microbiota Taxonomic Shifts in Chinese Multiple Myeloma Patients Analyzed by Quantitative Polimerase Chain Reaction (QPCR) and 16S rRNA High-Throughput Sequencing/Experiment 1/Signature 2 |
|
|
|
| Fecal Microbiota Taxonomic Shifts in Chinese Multiple Myeloma Patients Analyzed by Quantitative Polimerase Chain Reaction (QPCR) and 16S rRNA High-Throughput Sequencing/Experiment 2 |
|
|
|
| Fecal Microbiota Taxonomic Shifts in Chinese Multiple Myeloma Patients Analyzed by Quantitative Polimerase Chain Reaction (QPCR) and 16S rRNA High-Throughput Sequencing/Experiment 2/Signature 1 |
|
|
|
| Fecal Microbiota Taxonomic Shifts in Chinese Multiple Myeloma Patients Analyzed by Quantitative Polimerase Chain Reaction (QPCR) and 16S rRNA High-Throughput Sequencing/Experiment 2/Signature 2 |
|
|
|
| Fecal Microbiota Taxonomic Shifts in Chinese Multiple Myeloma Patients Analyzed by Quantitative Polimerase Chain Reaction (QPCR) and 16S rRNA High-Throughput Sequencing/Experiment 3 |
|
|
|
| Fecal Microbiota Taxonomic Shifts in Chinese Multiple Myeloma Patients Analyzed by Quantitative Polimerase Chain Reaction (QPCR) and 16S rRNA High-Throughput Sequencing/Experiment 3/Signature 1 |
|
|
|
| Fecal Microbiota Taxonomic Shifts in Chinese Multiple Myeloma Patients Analyzed by Quantitative Polimerase Chain Reaction (QPCR) and 16S rRNA High-Throughput Sequencing/Experiment 4 |
|
|
|
| Fecal Microbiota Taxonomic Shifts in Chinese Multiple Myeloma Patients Analyzed by Quantitative Polimerase Chain Reaction (QPCR) and 16S rRNA High-Throughput Sequencing/Experiment 4/Signature 1 |
|
|
|
| Functional implications of microbial and viral gut metagenome changes in early stage L-DOPA-naïve Parkinson's disease patients |
|
|
|
| Functional implications of microbial and viral gut metagenome changes in early stage L-DOPA-naïve Parkinson's disease patients/Experiment 1/Signature 1 |
|
|
|
| Functional implications of microbial and viral gut metagenome changes in early stage L-DOPA-naïve Parkinson's disease patients/Experiment 1/Signature 2 |
|
|
|
| Functional implications of microbial and viral gut metagenome changes in early stage L-DOPA-naïve Parkinson's disease patients/Experiment 2/Signature 1 |
|
|
|
| Functional implications of microbial and viral gut metagenome changes in early stage L-DOPA-naïve Parkinson's disease patients/Experiment 3 |
|
|
|
| Functional implications of microbial and viral gut metagenome changes in early stage L-DOPA-naïve Parkinson's disease patients/Experiment 3/Signature 1 |
|
|
|
| Fusobacterium nucleatum and T Cells in Colorectal Carcinoma/Experiment 1/Signature 1 |
|
|
|
| Gastric microbial community profiling reveals a dysbiotic cancer-associated microbiota/Experiment 1/Signature 2 |
|
|
|
| Gastro-intestinal and oral microbiome signatures associated with healthy aging |
|
|
|
| Gastro-intestinal and oral microbiome signatures associated with healthy aging/Experiment 1 |
|
|
|
| Gastro-intestinal and oral microbiome signatures associated with healthy aging/Experiment 1/Signature 1 |
|
|
|
| Gastro-intestinal and oral microbiome signatures associated with healthy aging/Experiment 1/Signature 2 |
|
|
|
| Gastro-intestinal and oral microbiome signatures associated with healthy aging/Experiment 2 |
|
|
|
| Gastro-intestinal and oral microbiome signatures associated with healthy aging/Experiment 2/Signature 1 |
|
|
|
| Gastro-intestinal and oral microbiome signatures associated with healthy aging/Experiment 2/Signature 2 |
|
|
|
| Gastrointestinal microbial populations can distinguish pediatric and adolescent Acute Lymphoblastic Leukemia (ALL) at the time of disease diagnosis/Experiment 1/Signature 2 |
|
|
|
| Gastrointestinal microbiome signatures of pediatric patients with irritable bowel syndrome/Experiment 1 |
|
|
|
| Gastrointestinal microbiome signatures of pediatric patients with irritable bowel syndrome/Experiment 1/Signature 1 |
|
|
|
| Gastrointestinal microbiome signatures of pediatric patients with irritable bowel syndrome/Experiment 1/Signature 2 |
|
|
|
| Gegen Qinlian decoction enhances the effect of PD-1 blockade in colorectal cancer with microsatellite stability by remodelling the gut microbiota and the tumour microenvironment/Experiment 1/Signature 2 |
|
|
|
| Gegen Qinlian decoction enhances the effect of PD-1 blockade in colorectal cancer with microsatellite stability by remodelling the gut microbiota and the tumour microenvironment/Experiment 6/Signature 1 |
|
|
|
| Gut bacteria identified in colorectal cancer patients promote tumourigenesis via butyrate secretion/Experiment 3 |
|
|
|
| Gut bacteria identified in colorectal cancer patients promote tumourigenesis via butyrate secretion/Experiment 3/Signature 1 |
|
|
|
| Gut Bacterial Families Are Associated with Body Composition and Metabolic Risk Markers in School-Aged Children in Rural Mexico |
|
|
|
| Gut Bacterial Families Are Associated with Body Composition and Metabolic Risk Markers in School-Aged Children in Rural Mexico/Experiment 1 |
|
|
|
| Gut Bacterial Families Are Associated with Body Composition and Metabolic Risk Markers in School-Aged Children in Rural Mexico/Experiment 1/Signature 1 |
|
|
|
| Gut Bacterial Families Are Associated with Body Composition and Metabolic Risk Markers in School-Aged Children in Rural Mexico/Experiment 1/Signature 2 |
|
|
|
| Gut Dysbiosis and IL-21 Response in Patients with Severe COVID-19/Experiment 3/Signature 2 |
|
|
|
| Gut metagenomics-derived genes as potential biomarkers of Parkinson's disease |
|
|
|
| Gut Microbial Composition and Function Are Altered in Patients with Early Rheumatoid Arthritis/Experiment 1/Signature 2 |
|
|
|
| Gut Microbial Dysbiosis Is Associated with Altered Hepatic Functions and Serum Metabolites in Chronic Hepatitis B Patients/Experiment 1/Signature 2 |
|
|
|
| Gut microbial profile analysis by MiSeq sequencing of pancreatic carcinoma patients in China/Experiment 1/Signature 1 |
|
|
|
| Gut microbial species and metabolic pathways associated with response to treatment with immune checkpoint inhibitors in metastatic melanoma/Experiment 1/Signature 2 |
|
|
|
| Gut microbial-derived butyrate is inversely associated with IgE responses to allergens in childhood asthma |
|
|
|
| Gut microbial-derived butyrate is inversely associated with IgE responses to allergens in childhood asthma/Experiment 1 |
|
|
|
| Gut microbial-derived butyrate is inversely associated with IgE responses to allergens in childhood asthma/Experiment 1/Signature 1 |
|
|
|
| Gut microbial-derived butyrate is inversely associated with IgE responses to allergens in childhood asthma/Experiment 1/Signature 2 |
|
|
|
| Gut microbial-derived butyrate is inversely associated with IgE responses to allergens in childhood asthma/Experiment 2 |
|
|
|
| Gut microbial-derived butyrate is inversely associated with IgE responses to allergens in childhood asthma/Experiment 2/Signature 1 |
|
|
|
| Gut microbial-derived butyrate is inversely associated with IgE responses to allergens in childhood asthma/Experiment 2/Signature 2 |
|
|
|
| Gut microbiome and innate immune response patterns in IgE-associated eczema |
|
|
|
| Gut microbiome and innate immune response patterns in IgE-associated eczema/Experiment 1 |
|
|
|
| Gut microbiome and innate immune response patterns in IgE-associated eczema/Experiment 1/Signature 1 |
|
|
|
| Gut microbiome and innate immune response patterns in IgE-associated eczema/Experiment 2 |
|
|
|
| Gut microbiome and innate immune response patterns in IgE-associated eczema/Experiment 2/Signature 1 |
|
|
|
| Gut microbiome and innate immune response patterns in IgE-associated eczema/Experiment 3 |
|
|
|
| Gut microbiome and innate immune response patterns in IgE-associated eczema/Experiment 3/Signature 1 |
|
|
|
| Gut microbiome and innate immune response patterns in IgE-associated eczema/Experiment 3/Signature 2 |
|
|
|
| Gut microbiome and serum metabolome alterations in obesity and after weight-loss intervention |
|
|
|
| Gut microbiome and serum metabolome alterations in obesity and after weight-loss intervention/Experiment 1 |
|
|
|
| Gut microbiome and serum metabolome alterations in obesity and after weight-loss intervention/Experiment 1/Signature 2 |
|
|
|
| Gut microbiome associations with breast cancer risk factors and tumor characteristics: a pilot study/Experiment 1/Signature 1 |
|
|
|
| Gut microbiome associations with breast cancer risk factors and tumor characteristics: a pilot study/Experiment 2/Signature 1 |
|
|
|
| Gut microbiome composition is linked to whole grain-induced immunological improvements/Experiment 2/Signature 1 |
|
|
|
| Gut microbiome composition is linked to whole grain-induced immunological improvements/Experiment 3/Signature 2 |
|
|
|
| Gut Microbiome Composition Predicts Infection Risk During Chemotherapy in Children With Acute Lymphoblastic Leukemia |
|
|
|
| Gut Microbiome Composition Predicts Infection Risk During Chemotherapy in Children With Acute Lymphoblastic Leukemia/Experiment 1 |
|
|
|
| Gut Microbiome Composition Predicts Infection Risk During Chemotherapy in Children With Acute Lymphoblastic Leukemia/Experiment 1/Signature 1 |
|
|
|
| Gut Microbiome Composition Predicts Infection Risk During Chemotherapy in Children With Acute Lymphoblastic Leukemia/Experiment 1/Signature 2 |
|
|
|
| Gut Microbiome Composition Predicts Infection Risk During Chemotherapy in Children With Acute Lymphoblastic Leukemia/Experiment 2 |
|
|
|
| Gut Microbiome Composition Predicts Infection Risk During Chemotherapy in Children With Acute Lymphoblastic Leukemia/Experiment 2/Signature 1 |
|
|
|
| Gut Microbiome Composition Predicts Infection Risk During Chemotherapy in Children With Acute Lymphoblastic Leukemia/Experiment 2/Signature 2 |
|
|
|
| Gut Microbiome Composition Predicts Infection Risk During Chemotherapy in Children With Acute Lymphoblastic Leukemia/Experiment 3 |
|
|
|
| Gut Microbiome Composition Predicts Infection Risk During Chemotherapy in Children With Acute Lymphoblastic Leukemia/Experiment 3/Signature 1 |
|
|
|
| Gut Microbiome Composition Predicts Infection Risk During Chemotherapy in Children With Acute Lymphoblastic Leukemia/Experiment 3/Signature 2 |
|
|
|
| Gut Microbiome Composition Predicts Infection Risk During Chemotherapy in Children With Acute Lymphoblastic Leukemia/Experiment 4 |
|
|
|
| Gut Microbiome Composition Predicts Infection Risk During Chemotherapy in Children With Acute Lymphoblastic Leukemia/Experiment 4/Signature 1 |
|
|
|
| Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors |
|
|
|
| Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors/Experiment 1 |
|
|
|
| Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors/Experiment 1/Signature 1 |
|
|
|
| Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors/Experiment 1/Signature 2 |
|
|
|
| Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors/Experiment 2 |
|
|
|
| Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors/Experiment 2/Signature 1 |
|
|
|
| Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors/Experiment 2/Signature 2 |
|
|
|
| Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors/Experiment 3 |
|
|
|
| Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors/Experiment 3/Signature 1 |
|
|
|
| Gut Microbiome Influences the Efficacy of PD-1 Antibody Immunotherapy on MSS-Type Colorectal Cancer via Metabolic Pathway/Experiment 1 |
|
|
|
| Gut Microbiome Influences the Efficacy of PD-1 Antibody Immunotherapy on MSS-Type Colorectal Cancer via Metabolic Pathway/Experiment 1/Signature 1 |
|
|
|
| Gut Microbiome Influences the Efficacy of PD-1 Antibody Immunotherapy on MSS-Type Colorectal Cancer via Metabolic Pathway/Experiment 1/Signature 2 |
|
|
|
| Gut Microbiome Influences the Efficacy of PD-1 Antibody Immunotherapy on MSS-Type Colorectal Cancer via Metabolic Pathway/Experiment 2 |
|
|
|
| Gut Microbiome Influences the Efficacy of PD-1 Antibody Immunotherapy on MSS-Type Colorectal Cancer via Metabolic Pathway/Experiment 2/Signature 1 |
|
|
|
| Gut Microbiome Influences the Efficacy of PD-1 Antibody Immunotherapy on MSS-Type Colorectal Cancer via Metabolic Pathway/Experiment 2/Signature 2 |
|
|
|
| Gut Microbiome Influences the Efficacy of PD-1 Antibody Immunotherapy on MSS-Type Colorectal Cancer via Metabolic Pathway/Experiment 3 |
|
|
|
| Gut Microbiome Influences the Efficacy of PD-1 Antibody Immunotherapy on MSS-Type Colorectal Cancer via Metabolic Pathway/Experiment 3/Signature 1 |
|
|
|
| Gut Microbiome Influences the Efficacy of PD-1 Antibody Immunotherapy on MSS-Type Colorectal Cancer via Metabolic Pathway/Experiment 3/Signature 2 |
|
|
|
| Gut Microbiome Influences the Efficacy of PD-1 Antibody Immunotherapy on MSS-Type Colorectal Cancer via Metabolic Pathway/Experiment 4 |
|
|
|
| Gut Microbiome Influences the Efficacy of PD-1 Antibody Immunotherapy on MSS-Type Colorectal Cancer via Metabolic Pathway/Experiment 4/Signature 1 |
|
|
|
| Gut Microbiome Influences the Efficacy of PD-1 Antibody Immunotherapy on MSS-Type Colorectal Cancer via Metabolic Pathway/Experiment 4/Signature 2 |
|
|
|
| Gut Microbiome Influences the Efficacy of PD-1 Antibody Immunotherapy on MSS-Type Colorectal Cancer via Metabolic Pathway/Experiment 5 |
|
|
|
| Gut Microbiome Influences the Efficacy of PD-1 Antibody Immunotherapy on MSS-Type Colorectal Cancer via Metabolic Pathway/Experiment 5/Signature 1 |
|
|
|
| Gut Microbiome Influences the Efficacy of PD-1 Antibody Immunotherapy on MSS-Type Colorectal Cancer via Metabolic Pathway/Experiment 5/Signature 2 |
|
|
|
| Gut Microbiome Influences the Efficacy of PD-1 Antibody Immunotherapy on MSS-Type Colorectal Cancer via Metabolic Pathway/Experiment 6 |
|
|
|
| Gut Microbiome Influences the Efficacy of PD-1 Antibody Immunotherapy on MSS-Type Colorectal Cancer via Metabolic Pathway/Experiment 6/Signature 1 |
|
|
|
| Gut Microbiome Influences the Efficacy of PD-1 Antibody Immunotherapy on MSS-Type Colorectal Cancer via Metabolic Pathway/Experiment 6/Signature 2 |
|
|
|
| Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients/Experiment 1/Signature 1 |
|
|
|
| Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients/Experiment 1/Signature 2 |
|
|
|
| Gut Microbiome of Healthy and Arthritic Dogs/Experiment 1/Signature 2 |
|
|
|
| Gut microbiome of Moroccan colorectal cancer patients/Experiment 1 |
|
|
|
| Gut microbiome of Moroccan colorectal cancer patients/Experiment 1/Signature 1 |
|
|
|
| Gut Microbiome Profiles Are Associated With Type 2 Diabetes in Urban Africans/Experiment 1/Signature 1 |
|
|
|
| Gut microbiota analysis and its significance in vasovagal syncope in children/Experiment 1/Signature 1 |
|
|
|
| Gut Microbiota and Metabolic Endotoxemia in Young Obese Mexican Subjects/Experiment 1/Signature 2 |
|
|
|
| Gut microbiota and overweight in 3-year old children |
|
|
|
| Gut microbiota and overweight in 3-year old children/Experiment 1 |
|
|
|
| Gut microbiota and overweight in 3-year old children/Experiment 1/Signature 1 |
|
|
|
| Gut microbiota and overweight in 3-year old children/Experiment 1/Signature 2 |
|
|
|
| Gut microbiota and overweight in 3-year old children/Experiment 2 |
|
|
|
| Gut microbiota and overweight in 3-year old children/Experiment 2/Signature 1 |
|
|
|
| Gut microbiota and overweight in 3-year old children/Experiment 2/Signature 2 |
|
|
|
| Gut microbiota and overweight in 3-year old children/Experiment 3 |
|
|
|
| Gut microbiota and overweight in 3-year old children/Experiment 3/Signature 1 |
|
|
|
| Gut microbiota and overweight in 3-year old children/Experiment 3/Signature 2 |
|
|
|
| Gut microbiota composition and butyrate production in children affected by non-IgE-mediated cow's milk allergy/Experiment 3/Signature 1 |
|
|
|
| Gut microbiota composition and butyrate production in children affected by non-IgE-mediated cow's milk allergy/Experiment 4/Signature 2 |
|
|
|
| Gut microbiota composition and functional prediction in diarrhea-predominant irritable bowel syndrome/Experiment 1/Signature 2 |
|
|
|
| Gut microbiota composition in patients with newly diagnosed bipolar disorder and their unaffected first-degree relatives |
|
|
|
| Gut microbiota composition in patients with newly diagnosed bipolar disorder and their unaffected first-degree relatives/Experiment 1 |
|
|
|
| Gut microbiota composition in patients with newly diagnosed bipolar disorder and their unaffected first-degree relatives/Experiment 1/Signature 1 |
|
|
|
| Gut Microbiota Differences in Children From Distinct Socioeconomic Levels Living in the Same Urban Area in Brazil/Experiment 1/Signature 1 |
|
|
|
| Gut Microbiota Differs Between Parkinson's Disease Patients and Healthy Controls in Northeast China |
|
|
|
| Gut Microbiota Differs Between Parkinson's Disease Patients and Healthy Controls in Northeast China/Experiment 1 |
|
|
|
| Gut Microbiota Differs Between Parkinson's Disease Patients and Healthy Controls in Northeast China/Experiment 1/Signature 1 |
|
|
|
| Gut Microbiota Differs Between Parkinson's Disease Patients and Healthy Controls in Northeast China/Experiment 1/Signature 2 |
|
|
|
| Gut Microbiota Differs Between Parkinson's Disease Patients and Healthy Controls in Northeast China/Experiment 1/Signature 3 |
|
|
|
| Gut Microbiota Differs Between Parkinson's Disease Patients and Healthy Controls in Northeast China/Experiment 1/Signature 4 |
|
|
|
| Gut Microbiota Differs Between Parkinson's Disease Patients and Healthy Controls in Northeast China/Experiment 1/Signature 5 |
|
|
|
| Gut Microbiota Differs Between Parkinson's Disease Patients and Healthy Controls in Northeast China/Experiment 1/Signature 6 |
|
|
|
| Gut Microbiota Differs Between Parkinson's Disease Patients and Healthy Controls in Northeast China/Experiment 1/Signature 7 |
|
|
|
| Gut Microbiota Differs Between Parkinson's Disease Patients and Healthy Controls in Northeast China/Experiment 1/Signature 8 |
|
|
|
| Gut Microbiota Differs Between Parkinson's Disease Patients and Healthy Controls in Northeast China/Experiment 2 |
|
|
|
| Gut Microbiota Differs Between Parkinson's Disease Patients and Healthy Controls in Northeast China/Experiment 3 |
|
|
|
| Gut Microbiota Differs Between Parkinson's Disease Patients and Healthy Controls in Northeast China/Experiment 3/Signature 2 |
|
|
|
| Gut microbiota diversity across ethnicities in the United States |
|
|
|
| Gut microbiota diversity across ethnicities in the United States/Experiment 1 |
|
|
|
| Gut microbiota diversity across ethnicities in the United States/Experiment 1/Signature 1 |
|
|
|
| Gut microbiota diversity across ethnicities in the United States/Experiment 1/Signature 2 |
|
|
|
| Gut microbiota diversity across ethnicities in the United States/Experiment 2 |
|
|
|
| Gut microbiota diversity across ethnicities in the United States/Experiment 2/Signature 1 |
|
|
|
| Gut microbiota diversity across ethnicities in the United States/Experiment 2/Signature 2 |
|
|
|
| Gut microbiota diversity across ethnicities in the United States/Experiment 3 |
|
|
|
| Gut microbiota diversity across ethnicities in the United States/Experiment 3/Signature 1 |
|
|
|
| Gut microbiota diversity across ethnicities in the United States/Experiment 3/Signature 2 |
|
|
|
| Gut microbiota diversity across ethnicities in the United States/Experiment 4 |
|
|
|
| Gut microbiota diversity across ethnicities in the United States/Experiment 4/Signature 1 |
|
|
|
| Gut microbiota diversity across ethnicities in the United States/Experiment 4/Signature 2 |
|
|
|
| Gut microbiota diversity across ethnicities in the United States/Experiment 5 |
|
|
|
| Gut microbiota diversity across ethnicities in the United States/Experiment 5/Signature 1 |
|
|
|
| Gut microbiota diversity across ethnicities in the United States/Experiment 5/Signature 2 |
|
|
|
| Gut microbiota diversity across ethnicities in the United States/Experiment 6 |
|
|
|
| Gut microbiota diversity across ethnicities in the United States/Experiment 6/Signature 1 |
|
|
|
| Gut microbiota diversity across ethnicities in the United States/Experiment 6/Signature 2 |
|
|
|
| Gut microbiota imbalance and its correlations with hormone and inflammatory factors in patients with stage 3/4 endometriosis |
|
|
|
| Gut microbiota imbalance and its correlations with hormone and inflammatory factors in patients with stage 3/4 endometriosis/Experiment 1 |
|
|
|
| Gut microbiota imbalance and its correlations with hormone and inflammatory factors in patients with stage 3/4 endometriosis/Experiment 1/Signature 1 |
|
|
|
| Gut microbiota imbalance and its correlations with hormone and inflammatory factors in patients with stage 3/4 endometriosis/Experiment 1/Signature 2 |
|
|
|
| Gut microbiota in early pediatric multiple sclerosis: a case-control study |
|
|
|
| Gut microbiota in early pediatric multiple sclerosis: a case-control study/Experiment 1 |
|
|
|
| Gut microbiota in early pediatric multiple sclerosis: a case-control study/Experiment 1/Signature 1 |
|
|
|
| Gut microbiota in early pediatric multiple sclerosis: a case-control study/Experiment 1/Signature 2 |
|
|
|
| Gut microbiota in early pediatric multiple sclerosis: a case-control study/Experiment 2 |
|
|
|
| Gut microbiota in early pediatric multiple sclerosis: a case-control study/Experiment 2/Signature 1 |
|
|
|
| Gut microbiota in early pediatric multiple sclerosis: a case-control study/Experiment 2/Signature 2 |
|
|
|
| Gut microbiota in early pediatric multiple sclerosis: a case-control study/Experiment 3 |
|
|
|
| Gut microbiota in early pediatric multiple sclerosis: a case-control study/Experiment 3/Signature 1 |
|
|
|
| Gut microbiota in early pediatric multiple sclerosis: a case-control study/Experiment 3/Signature 2 |
|
|
|
| Gut microbiota is critical for the induction of chemotherapy-induced pain |
|
|
|
| Gut microbiota is critical for the induction of chemotherapy-induced pain/Experiment 1 |
|
|
|
| Gut microbiota is critical for the induction of chemotherapy-induced pain/Experiment 1/Signature 1 |
|
|
|
| Gut microbiota is critical for the induction of chemotherapy-induced pain/Experiment 1/Signature 2 |
|
|
|
| Gut microbiota profiles in treatment-naïve children with attention deficit hyperactivity disorder |
|
|
|
| Gut microbiota profiles in treatment-naïve children with attention deficit hyperactivity disorder/Experiment 1 |
|
|
|
| Gut microbiota profiles in treatment-naïve children with attention deficit hyperactivity disorder/Experiment 1/Signature 1 |
|
|
|
| Gut microbiota profiles in treatment-naïve children with attention deficit hyperactivity disorder/Experiment 1/Signature 2 |
|
|
|
| Gut microbiota trajectory in pediatric patients undergoing hematopoietic SCT |
|
|
|
| Gut microbiota trajectory in pediatric patients undergoing hematopoietic SCT/Experiment 1 |
|
|
|
| Gut microbiota trajectory in pediatric patients undergoing hematopoietic SCT/Experiment 1/Signature 1 |
|
|
|
| Gut microbiota trajectory in pediatric patients undergoing hematopoietic SCT/Experiment 2 |
|
|
|
| Gut microbiota trajectory in pediatric patients undergoing hematopoietic SCT/Experiment 2/Signature 1 |
|
|
|
| Gut mucosal microbiome across stages of colorectal carcinogenesis |
|
|
|
| Gut mucosal microbiome across stages of colorectal carcinogenesis/Experiment 1 |
|
|
|
| Gut mucosal microbiome across stages of colorectal carcinogenesis/Experiment 1/Signature 1 |
|
|
|
| Gut mucosal microbiome across stages of colorectal carcinogenesis/Experiment 1/Signature 2 |
|
|
|
| Gut mucosal microbiome across stages of colorectal carcinogenesis/Experiment 2 |
|
|
|
| Gut mucosal microbiome across stages of colorectal carcinogenesis/Experiment 2/Signature 1 |
|
|
|
| Gut mucosal microbiome across stages of colorectal carcinogenesis/Experiment 2/Signature 2 |
|
|
|
| Gut mucosal microbiome across stages of colorectal carcinogenesis/Experiment 3 |
|
|
|
| Gut mucosal microbiome across stages of colorectal carcinogenesis/Experiment 3/Signature 1 |
|
|
|
| Gut mucosal microbiome across stages of colorectal carcinogenesis/Experiment 3/Signature 2 |
|
|
|
| Gut mucosal microbiome across stages of colorectal carcinogenesis/Experiment 4 |
|
|
|
| Gut mucosal microbiome across stages of colorectal carcinogenesis/Experiment 4/Signature 1 |
|
|
|
| Gut mucosal microbiome across stages of colorectal carcinogenesis/Experiment 4/Signature 2 |
|
|
|
| Gut mucosal microbiome across stages of colorectal carcinogenesis/Experiment 5 |
|
|
|
| Gut mucosal microbiome across stages of colorectal carcinogenesis/Experiment 5/Signature 1 |
|
|
|
| Gut mucosal microbiome across stages of colorectal carcinogenesis/Experiment 5/Signature 2 |
|
|
|
| Gut mucosal microbiome across stages of colorectal carcinogenesis/Experiment 6 |
|
|
|
| Gut mucosal microbiome across stages of colorectal carcinogenesis/Experiment 7 |
|
|
|
| Gut mucosal microbiome across stages of colorectal carcinogenesis/Experiment 7/Signature 1 |
|
|
|
| Gut mucosal microbiome across stages of colorectal carcinogenesis/Experiment 7/Signature 2 |
|
|
|
| Gut mucosal microbiome across stages of colorectal carcinogenesis/Experiment 8 |
|
|
|
| Gut mucosal microbiome across stages of colorectal carcinogenesis/Experiment 8/Signature 1 |
|
|
|
| Gut mucosal microbiome across stages of colorectal carcinogenesis/Experiment 9 |
|
|
|
| Gut mucosal microbiome across stages of colorectal carcinogenesis/Experiment 9/Signature 1 |
|
|
|
| Gut mucosal microbiome across stages of colorectal carcinogenesis/Experiment 9/Signature 2 |
|
|
|
| Habitual dietary fibre intake influences gut microbiota response to an inulin-type fructan prebiotic: a randomised, double-blind, placebo-controlled, cross-over, human intervention study |
|
|
|
| Habitual dietary fibre intake influences gut microbiota response to an inulin-type fructan prebiotic: a randomised, double-blind, placebo-controlled, cross-over, human intervention study/Experiment 1 |
|
|
|
| Habitual dietary fibre intake influences gut microbiota response to an inulin-type fructan prebiotic: a randomised, double-blind, placebo-controlled, cross-over, human intervention study/Experiment 1/Signature 1 |
|
|
|
| Habitual dietary fibre intake influences gut microbiota response to an inulin-type fructan prebiotic: a randomised, double-blind, placebo-controlled, cross-over, human intervention study/Experiment 1/Signature 2 |
|
|
|
| Habitual dietary fibre intake influences gut microbiota response to an inulin-type fructan prebiotic: a randomised, double-blind, placebo-controlled, cross-over, human intervention study/Experiment 2 |
|
|
|
| Habitual dietary fibre intake influences gut microbiota response to an inulin-type fructan prebiotic: a randomised, double-blind, placebo-controlled, cross-over, human intervention study/Experiment 2/Signature 1 |
|
|
|
| Habitual dietary fibre intake influences gut microbiota response to an inulin-type fructan prebiotic: a randomised, double-blind, placebo-controlled, cross-over, human intervention study/Experiment 3 |
|
|
|
| Habitual dietary fibre intake influences gut microbiota response to an inulin-type fructan prebiotic: a randomised, double-blind, placebo-controlled, cross-over, human intervention study/Experiment 3/Signature 1 |
|
|
|
| Habitual dietary fibre intake influences gut microbiota response to an inulin-type fructan prebiotic: a randomised, double-blind, placebo-controlled, cross-over, human intervention study/Experiment 3/Signature 2 |
|
|
|
| Habitual dietary fibre intake influences gut microbiota response to an inulin-type fructan prebiotic: a randomised, double-blind, placebo-controlled, cross-over, human intervention study/Experiment 4 |
|
|
|
| Habitual dietary fibre intake influences gut microbiota response to an inulin-type fructan prebiotic: a randomised, double-blind, placebo-controlled, cross-over, human intervention study/Experiment 4/Signature 1 |
|
|
|
| Healthy infants harbor intestinal bacteria that protect against food allergy |
|
|
|
| Healthy infants harbor intestinal bacteria that protect against food allergy/Experiment 1 |
|
|
|
| Healthy infants harbor intestinal bacteria that protect against food allergy/Experiment 1/Signature 1 |
|
|
|
| Healthy infants harbor intestinal bacteria that protect against food allergy/Experiment 1/Signature 2 |
|
|
|
| High Abundance of genus Prevotella in the gut of perinatally HIV-infected children is associated with IP-10 levels despite therapy |
|
|
|
| High Abundance of genus Prevotella in the gut of perinatally HIV-infected children is associated with IP-10 levels despite therapy/Experiment 1 |
|
|
|
| High Abundance of genus Prevotella in the gut of perinatally HIV-infected children is associated with IP-10 levels despite therapy/Experiment 1/Signature 1 |
|
|
|
| High Abundance of genus Prevotella in the gut of perinatally HIV-infected children is associated with IP-10 levels despite therapy/Experiment 1/Signature 2 |
|
|
|
| High-level adherence to a Mediterranean diet beneficially impacts the gut microbiota and associated metabolome |
|
|
|
| High-level adherence to a Mediterranean diet beneficially impacts the gut microbiota and associated metabolome/Experiment 1 |
|
|
|
| High-level adherence to a Mediterranean diet beneficially impacts the gut microbiota and associated metabolome/Experiment 1/Signature 2 |
|
|
|
| High-level adherence to a Mediterranean diet beneficially impacts the gut microbiota and associated metabolome/Experiment 2 |
|
|
|
| High-level adherence to a Mediterranean diet beneficially impacts the gut microbiota and associated metabolome/Experiment 2/Signature 1 |
|
|
|
| High-level adherence to a Mediterranean diet beneficially impacts the gut microbiota and associated metabolome/Experiment 2/Signature 2 |
|
|
|
| High-Level PM2.5/PM10 Exposure Is Associated With Alterations in the Human Pharyngeal Microbiota Composition/Experiment 1/Signature 2 |
|
|
|
| High-throughput sequencing reveals the incomplete, short-term recovery of infant gut microbiota following parenteral antibiotic treatment with ampicillin and gentamicin/Experiment 6/Signature 1 |
|
|
|
| HIV Infection is associated with compositional and functional shifts in the rectal mucosal microbiota/Experiment 1/Signature 1 |
|
|
|
| HIV Infection is associated with compositional and functional shifts in the rectal mucosal microbiota/Experiment 1/Signature 2 |
|
|
|
| HIV-associated gut dysbiosis is independent of sexual practice and correlates with noncommunicable diseases |
|
|
|
| HPV infection and bacterial microbiota in breast milk and infant oral mucosa/Experiment 2/Signature 1 |
|
|
|
| HPV infection and bacterial microbiota in breast milk and infant oral mucosa/Experiment 2/Signature 2 |
|
|
|
| Human gut microbiome and risk for colorectal cancer/Experiment 1/Signature 1 |
|
|
|
| Human intestinal lumen and mucosa-associated microbiota in patients with colorectal cancer |
|
|
|
| Human intestinal lumen and mucosa-associated microbiota in patients with colorectal cancer/Experiment 1 |
|
|
|
| Human intestinal lumen and mucosa-associated microbiota in patients with colorectal cancer/Experiment 1/Signature 1 |
|
|
|
| Human intestinal lumen and mucosa-associated microbiota in patients with colorectal cancer/Experiment 1/Signature 2 |
|
|
|
| Human intestinal lumen and mucosa-associated microbiota in patients with colorectal cancer/Experiment 2 |
|
|
|
| Human intestinal lumen and mucosa-associated microbiota in patients with colorectal cancer/Experiment 2/Signature 1 |
|
|
|
| Human intestinal lumen and mucosa-associated microbiota in patients with colorectal cancer/Experiment 2/Signature 2 |
|
|
|
| Human intestinal lumen and mucosa-associated microbiota in patients with colorectal cancer/Experiment 3 |
|
|
|
| Human intestinal lumen and mucosa-associated microbiota in patients with colorectal cancer/Experiment 3/Signature 1 |
|
|
|
| Human intestinal lumen and mucosa-associated microbiota in patients with colorectal cancer/Experiment 4 |
|
|
|
| Human intestinal lumen and mucosa-associated microbiota in patients with colorectal cancer/Experiment 4/Signature 1 |
|
|
|
| Human Oral Buccal Microbiomes Are Associated with Farmworker Status and Azinphos-Methyl Agricultural Pesticide Exposure |
|
|
|
| Human Oral Buccal Microbiomes Are Associated with Farmworker Status and Azinphos-Methyl Agricultural Pesticide Exposure/Experiment 1 |
|
|
|
| Human Oral Buccal Microbiomes Are Associated with Farmworker Status and Azinphos-Methyl Agricultural Pesticide Exposure/Experiment 1/Signature 1 |
|
|
|
| Human oral microbiome and prospective risk for pancreatic cancer: a population-based nested case-control study/Experiment 3/Signature 1 |
|
|
|
| Human papillomavirus infection and cervical intraepithelial neoplasia progression are associated with increased vaginal microbiome diversity in a Chinese cohort |
|
|
|
| Human papillomavirus infection and cervical intraepithelial neoplasia progression are associated with increased vaginal microbiome diversity in a Chinese cohort/Experiment 1 |
|
|
|
| Human papillomavirus infection and cervical intraepithelial neoplasia progression are associated with increased vaginal microbiome diversity in a Chinese cohort/Experiment 1/Signature 1 |
|
|
|
| Human papillomavirus infection and cervical intraepithelial neoplasia progression are associated with increased vaginal microbiome diversity in a Chinese cohort/Experiment 1/Signature 2 |
|
|
|
| Human papillomavirus infection and cervical intraepithelial neoplasia progression are associated with increased vaginal microbiome diversity in a Chinese cohort/Experiment 2 |
|
|
|
| Human papillomavirus infection and cervical intraepithelial neoplasia progression are associated with increased vaginal microbiome diversity in a Chinese cohort/Experiment 2/Signature 1 |
|
|
|
| Human papillomavirus infection and cervical intraepithelial neoplasia progression are associated with increased vaginal microbiome diversity in a Chinese cohort/Experiment 2/Signature 2 |
|
|
|
| Human papillomavirus infection and cervical intraepithelial neoplasia progression are associated with increased vaginal microbiome diversity in a Chinese cohort/Experiment 3 |
|
|
|
| Human papillomavirus infection and cervical intraepithelial neoplasia progression are associated with increased vaginal microbiome diversity in a Chinese cohort/Experiment 3/Signature 1 |
|
|
|
| Human papillomavirus infection and cervical intraepithelial neoplasia progression are associated with increased vaginal microbiome diversity in a Chinese cohort/Experiment 3/Signature 2 |
|
|
|
| Human papillomavirus infection and cervical intraepithelial neoplasia progression are associated with increased vaginal microbiome diversity in a Chinese cohort/Experiment 4 |
|
|
|
| Human papillomavirus infection and cervical intraepithelial neoplasia progression are associated with increased vaginal microbiome diversity in a Chinese cohort/Experiment 4/Signature 1 |
|
|
|
| Human papillomavirus infection and cervical intraepithelial neoplasia progression are associated with increased vaginal microbiome diversity in a Chinese cohort/Experiment 4/Signature 2 |
|
|
|
| IBS-associated phylogenetic unbalances of the intestinal microbiota are not reverted by probiotic supplementation |
|
|
|
| IBS-associated phylogenetic unbalances of the intestinal microbiota are not reverted by probiotic supplementation/Experiment 1 |
|
|
|
| IBS-associated phylogenetic unbalances of the intestinal microbiota are not reverted by probiotic supplementation/Experiment 1/Signature 1 |
|
|
|
| IBS-associated phylogenetic unbalances of the intestinal microbiota are not reverted by probiotic supplementation/Experiment 1/Signature 2 |
|
|
|
| IBS-associated phylogenetic unbalances of the intestinal microbiota are not reverted by probiotic supplementation/Experiment 2 |
|
|
|
| IBS-associated phylogenetic unbalances of the intestinal microbiota are not reverted by probiotic supplementation/Experiment 2/Signature 1 |
|
|
|
| IBS-associated phylogenetic unbalances of the intestinal microbiota are not reverted by probiotic supplementation/Experiment 2/Signature 2 |
|
|
|
| IBS-associated phylogenetic unbalances of the intestinal microbiota are not reverted by probiotic supplementation/Experiment 3 |
|
|
|
| IBS-associated phylogenetic unbalances of the intestinal microbiota are not reverted by probiotic supplementation/Experiment 3/Signature 1 |
|
|
|
| IBS-associated phylogenetic unbalances of the intestinal microbiota are not reverted by probiotic supplementation/Experiment 3/Signature 2 |
|
|
|
| IBS-associated phylogenetic unbalances of the intestinal microbiota are not reverted by probiotic supplementation/Experiment 4 |
|
|
|
| IBS-associated phylogenetic unbalances of the intestinal microbiota are not reverted by probiotic supplementation/Experiment 4/Signature 1 |
|
|
|
| Imbalance of Gut Streptococcus, Clostridium, and Akkermansia Determines the Natural Course of Atopic Dermatitis in Infant |
|
|
|
| Imbalance of Gut Streptococcus, Clostridium, and Akkermansia Determines the Natural Course of Atopic Dermatitis in Infant/Experiment 1 |
|
|
|
| Imbalance of Gut Streptococcus, Clostridium, and Akkermansia Determines the Natural Course of Atopic Dermatitis in Infant/Experiment 1/Signature 1 |
|
|
|
| Imbalance of Gut Streptococcus, Clostridium, and Akkermansia Determines the Natural Course of Atopic Dermatitis in Infant/Experiment 1/Signature 2 |
|
|
|
| Imbalance of Gut Streptococcus, Clostridium, and Akkermansia Determines the Natural Course of Atopic Dermatitis in Infant/Experiment 2 |
|
|
|
| Imbalance of Gut Streptococcus, Clostridium, and Akkermansia Determines the Natural Course of Atopic Dermatitis in Infant/Experiment 2/Signature 1 |
|
|
|
| Imbalance of Gut Streptococcus, Clostridium, and Akkermansia Determines the Natural Course of Atopic Dermatitis in Infant/Experiment 2/Signature 2 |
|
|
|
| Imbalance of Gut Streptococcus, Clostridium, and Akkermansia Determines the Natural Course of Atopic Dermatitis in Infant/Experiment 3 |
|
|
|
| Imbalance of Gut Streptococcus, Clostridium, and Akkermansia Determines the Natural Course of Atopic Dermatitis in Infant/Experiment 3/Signature 1 |
|
|
|
| Imbalance of Gut Streptococcus, Clostridium, and Akkermansia Determines the Natural Course of Atopic Dermatitis in Infant/Experiment 3/Signature 2 |
|
|
|
| Imbalance of Gut Streptococcus, Clostridium, and Akkermansia Determines the Natural Course of Atopic Dermatitis in Infant/Experiment 4 |
|
|
|
| Imbalance of Gut Streptococcus, Clostridium, and Akkermansia Determines the Natural Course of Atopic Dermatitis in Infant/Experiment 4/Signature 1 |
|
|
|
| Imbalance of Gut Streptococcus, Clostridium, and Akkermansia Determines the Natural Course of Atopic Dermatitis in Infant/Experiment 4/Signature 2 |
|
|
|
| Imbalance of Gut Streptococcus, Clostridium, and Akkermansia Determines the Natural Course of Atopic Dermatitis in Infant/Experiment 5 |
|
|
|
| Imbalance of Gut Streptococcus, Clostridium, and Akkermansia Determines the Natural Course of Atopic Dermatitis in Infant/Experiment 5/Signature 1 |
|
|
|
| Imbalance of Gut Streptococcus, Clostridium, and Akkermansia Determines the Natural Course of Atopic Dermatitis in Infant/Experiment 5/Signature 2 |
|
|
|
| Imbalance of Gut Streptococcus, Clostridium, and Akkermansia Determines the Natural Course of Atopic Dermatitis in Infant/Experiment 6 |
|
|
|
| Imbalance of Gut Streptococcus, Clostridium, and Akkermansia Determines the Natural Course of Atopic Dermatitis in Infant/Experiment 6/Signature 1 |
|
|
|
| Imbalance of Gut Streptococcus, Clostridium, and Akkermansia Determines the Natural Course of Atopic Dermatitis in Infant/Experiment 6/Signature 2 |
|
|
|
| Impact of diet in shaping gut microbiota revealed by a comparative study in children from Europe and rural Africa |
|
|
|
| Impact of diet in shaping gut microbiota revealed by a comparative study in children from Europe and rural Africa/Experiment 1 |
|
|
|
| Impact of diet in shaping gut microbiota revealed by a comparative study in children from Europe and rural Africa/Experiment 1/Signature 1 |
|
|
|
| Impact of diet in shaping gut microbiota revealed by a comparative study in children from Europe and rural Africa/Experiment 1/Signature 2 |
|
|
|
| Impact of intrapartum and postnatal antibiotics on the gut microbiome and emergence of antimicrobial resistance in infants |
|
|
|
| Impact of intrapartum and postnatal antibiotics on the gut microbiome and emergence of antimicrobial resistance in infants/Experiment 1 |
|
|
|
| Impact of intrapartum and postnatal antibiotics on the gut microbiome and emergence of antimicrobial resistance in infants/Experiment 1/Signature 1 |
|
|
|
| Impact of intrapartum and postnatal antibiotics on the gut microbiome and emergence of antimicrobial resistance in infants/Experiment 1/Signature 2 |
|
|
|
| Impact of intrapartum and postnatal antibiotics on the gut microbiome and emergence of antimicrobial resistance in infants/Experiment 2 |
|
|
|
| Impact of intrapartum and postnatal antibiotics on the gut microbiome and emergence of antimicrobial resistance in infants/Experiment 2/Signature 1 |
|
|
|
| Impact of intrapartum and postnatal antibiotics on the gut microbiome and emergence of antimicrobial resistance in infants/Experiment 3 |
|
|
|
| Impact of intrapartum and postnatal antibiotics on the gut microbiome and emergence of antimicrobial resistance in infants/Experiment 3/Signature 1 |
|
|
|
| Impact of intrapartum and postnatal antibiotics on the gut microbiome and emergence of antimicrobial resistance in infants/Experiment 4 |
|
|
|
| Impact of intrapartum and postnatal antibiotics on the gut microbiome and emergence of antimicrobial resistance in infants/Experiment 4/Signature 1 |
|
|
|
| Impact of intrapartum and postnatal antibiotics on the gut microbiome and emergence of antimicrobial resistance in infants/Experiment 4/Signature 2 |
|
|
|
| Impact of intrapartum and postnatal antibiotics on the gut microbiome and emergence of antimicrobial resistance in infants/Experiment 5 |
|
|
|
| Impact of intrapartum and postnatal antibiotics on the gut microbiome and emergence of antimicrobial resistance in infants/Experiment 5/Signature 1 |
|
|
|
| Impact of intrapartum and postnatal antibiotics on the gut microbiome and emergence of antimicrobial resistance in infants/Experiment 6 |
|
|
|
| Impact of intrapartum and postnatal antibiotics on the gut microbiome and emergence of antimicrobial resistance in infants/Experiment 6/Signature 1 |
|
|
|
| Impact of intrapartum antimicrobial prophylaxis upon the intestinal microbiota and the prevalence of antibiotic resistance genes in vaginally delivered full-term neonates |
|
|
|
| Impact of intrapartum antimicrobial prophylaxis upon the intestinal microbiota and the prevalence of antibiotic resistance genes in vaginally delivered full-term neonates/Experiment 1 |
|
|
|
| Impact of intrapartum antimicrobial prophylaxis upon the intestinal microbiota and the prevalence of antibiotic resistance genes in vaginally delivered full-term neonates/Experiment 1/Signature 1 |
|
|
|
| Impact of intrapartum antimicrobial prophylaxis upon the intestinal microbiota and the prevalence of antibiotic resistance genes in vaginally delivered full-term neonates/Experiment 1/Signature 2 |
|
|
|
| Impact of intrapartum antimicrobial prophylaxis upon the intestinal microbiota and the prevalence of antibiotic resistance genes in vaginally delivered full-term neonates/Experiment 2 |
|
|
|
| Impact of intrapartum antimicrobial prophylaxis upon the intestinal microbiota and the prevalence of antibiotic resistance genes in vaginally delivered full-term neonates/Experiment 2/Signature 1 |
|
|
|
| Impact of intrapartum antimicrobial prophylaxis upon the intestinal microbiota and the prevalence of antibiotic resistance genes in vaginally delivered full-term neonates/Experiment 2/Signature 2 |
|
|
|
| Impact of intrapartum antimicrobial prophylaxis upon the intestinal microbiota and the prevalence of antibiotic resistance genes in vaginally delivered full-term neonates/Experiment 3 |
|
|
|
| Impact of intrapartum antimicrobial prophylaxis upon the intestinal microbiota and the prevalence of antibiotic resistance genes in vaginally delivered full-term neonates/Experiment 3/Signature 1 |
|
|
|
| Impact of intrapartum antimicrobial prophylaxis upon the intestinal microbiota and the prevalence of antibiotic resistance genes in vaginally delivered full-term neonates/Experiment 3/Signature 2 |
|
|
|
| Impact of probiotic Saccharomyces boulardii on the gut microbiome composition in HIV-treated patients: A double-blind, randomised, placebo-controlled trial |
|
|
|
| Impact of probiotic Saccharomyces boulardii on the gut microbiome composition in HIV-treated patients: A double-blind, randomised, placebo-controlled trial/Experiment 1 |
|
|
|
| Impact of probiotic Saccharomyces boulardii on the gut microbiome composition in HIV-treated patients: A double-blind, randomised, placebo-controlled trial/Experiment 1/Signature 1 |
|
|
|
| Impact of probiotic Saccharomyces boulardii on the gut microbiome composition in HIV-treated patients: A double-blind, randomised, placebo-controlled trial/Experiment 1/Signature 2 |
|
|
|
| Impact of probiotic Saccharomyces boulardii on the gut microbiome composition in HIV-treated patients: A double-blind, randomised, placebo-controlled trial/Experiment 2 |
|
|
|
| Impact of probiotic Saccharomyces boulardii on the gut microbiome composition in HIV-treated patients: A double-blind, randomised, placebo-controlled trial/Experiment 2/Signature 1 |
|
|
|
| Impact of probiotic Saccharomyces boulardii on the gut microbiome composition in HIV-treated patients: A double-blind, randomised, placebo-controlled trial/Experiment 2/Signature 2 |
|
|
|
| Implication of the gut microbiome composition of type 2 diabetic patients from northern China |
|
|
|
| Implication of the gut microbiome composition of type 2 diabetic patients from northern China/Experiment 1 |
|
|
|
| Implication of the gut microbiome composition of type 2 diabetic patients from northern China/Experiment 1/Signature 1 |
|
|
|
| Implication of the gut microbiome composition of type 2 diabetic patients from northern China/Experiment 1/Signature 2 |
|
|
|
| Improved feeding tolerance and growth are linked to increased gut microbial community diversity in very-low-birth-weight infants fed mother's own milk compared with donor breast milk/Experiment 1 |
|
|
|
| Improved feeding tolerance and growth are linked to increased gut microbial community diversity in very-low-birth-weight infants fed mother's own milk compared with donor breast milk/Experiment 1/Signature 1 |
|
|
|
| Improved feeding tolerance and growth are linked to increased gut microbial community diversity in very-low-birth-weight infants fed mother's own milk compared with donor breast milk/Experiment 1/Signature 2 |
|
|
|
| Increase in fecal primary bile acids and dysbiosis in patients with diarrhea-predominant irritable bowel syndrome |
|
|
|
| Increase in fecal primary bile acids and dysbiosis in patients with diarrhea-predominant irritable bowel syndrome/Experiment 1 |
|
|
|
| Increase in fecal primary bile acids and dysbiosis in patients with diarrhea-predominant irritable bowel syndrome/Experiment 1/Signature 1 |
|
|
|
| Infant airway microbiota and topical immune perturbations in the origins of childhood asthma/Experiment 1/Signature 1 |
|
|
|
| Infant gut microbiota and food sensitization: associations in the first year of life |
|
|
|
| Infant gut microbiota and food sensitization: associations in the first year of life/Experiment 1 |
|
|
|
| Infant gut microbiota and food sensitization: associations in the first year of life/Experiment 1/Signature 1 |
|
|
|
| Infant gut microbiota and food sensitization: associations in the first year of life/Experiment 2 |
|
|
|
| Infant gut microbiota and food sensitization: associations in the first year of life/Experiment 2/Signature 1 |
|
|
|
| Infant gut microbiota and food sensitization: associations in the first year of life/Experiment 2/Signature 2 |
|
|
|
| Inflammatory cytokines IL-6, IL-10, IL-13, TNF-α and peritoneal fluid flora were associated with infertility in patients with endometriosis/Experiment 1 |
|
|
|
| Influence of cigarette smoking on the human duodenal mucosa-associated microbiota |
|
|
|
| Influence of cigarette smoking on the human duodenal mucosa-associated microbiota/Experiment 1 |
|
|
|
| Influence of cigarette smoking on the human duodenal mucosa-associated microbiota/Experiment 1/Signature 1 |
|
|
|
| Influence of cigarette smoking on the human duodenal mucosa-associated microbiota/Experiment 2 |
|
|
|
| Influence of cigarette smoking on the human duodenal mucosa-associated microbiota/Experiment 2/Signature 1 |
|
|
|
| Influence of Intrapartum Antibiotic Prophylaxis for Group B Streptococcus on Gut Microbiota in the First Month of Life |
|
|
|
| Influence of Intrapartum Antibiotic Prophylaxis for Group B Streptococcus on Gut Microbiota in the First Month of Life/Experiment 1 |
|
|
|
| Influence of Intrapartum Antibiotic Prophylaxis for Group B Streptococcus on Gut Microbiota in the First Month of Life/Experiment 1/Signature 1 |
|
|
|
| Inhalational exposure to particulate matter air pollution alters the composition of the gut microbiome |
|
|
|
| Inhalational exposure to particulate matter air pollution alters the composition of the gut microbiome/Experiment 1 |
|
|
|
| Inhalational exposure to particulate matter air pollution alters the composition of the gut microbiome/Experiment 1/Signature 1 |
|
|
|
| Inhalational exposure to particulate matter air pollution alters the composition of the gut microbiome/Experiment 1/Signature 2 |
|
|
|
| Inhalational exposure to particulate matter air pollution alters the composition of the gut microbiome/Experiment 2 |
|
|
|
| Inhalational exposure to particulate matter air pollution alters the composition of the gut microbiome/Experiment 2/Signature 1 |
|
|
|
| Inhalational exposure to particulate matter air pollution alters the composition of the gut microbiome/Experiment 2/Signature 2 |
|
|
|
| Inhalational exposure to particulate matter air pollution alters the composition of the gut microbiome/Experiment 3 |
|
|
|
| Inhalational exposure to particulate matter air pollution alters the composition of the gut microbiome/Experiment 3/Signature 1 |
|
|
|
| Inhalational exposure to particulate matter air pollution alters the composition of the gut microbiome/Experiment 3/Signature 2 |
|
|
|
| Inhalational exposure to particulate matter air pollution alters the composition of the gut microbiome/Experiment 4 |
|
|
|
| Inhalational exposure to particulate matter air pollution alters the composition of the gut microbiome/Experiment 4/Signature 1 |
|
|
|
| Inhalational exposure to particulate matter air pollution alters the composition of the gut microbiome/Experiment 4/Signature 2 |
|
|
|
| Inhalational exposure to particulate matter air pollution alters the composition of the gut microbiome/Experiment 5 |
|
|
|
| Inhalational exposure to particulate matter air pollution alters the composition of the gut microbiome/Experiment 5/Signature 1 |
|
|
|
| Inhalational exposure to particulate matter air pollution alters the composition of the gut microbiome/Experiment 5/Signature 2 |
|
|
|
| Inhalational exposure to particulate matter air pollution alters the composition of the gut microbiome/Experiment 6 |
|
|
|
| Inhalational exposure to particulate matter air pollution alters the composition of the gut microbiome/Experiment 6/Signature 1 |
|
|
|
| Inhalational exposure to particulate matter air pollution alters the composition of the gut microbiome/Experiment 6/Signature 2 |
|
|
|
| Integrated gut virome and bacteriome dynamics in COVID-19 patients |
|
|
|
| Integrated gut virome and bacteriome dynamics in COVID-19 patients/Experiment 1 |
|
|
|
| Integrated gut virome and bacteriome dynamics in COVID-19 patients/Experiment 1/Signature 1 |
|
|
|
| Integrated gut virome and bacteriome dynamics in COVID-19 patients/Experiment 1/Signature 2 |
|
|
|
| Integrated gut virome and bacteriome dynamics in COVID-19 patients/Experiment 2 |
|
|
|
| Integrated gut virome and bacteriome dynamics in COVID-19 patients/Experiment 2/Signature 1 |
|
|
|
| Integrated gut virome and bacteriome dynamics in COVID-19 patients/Experiment 2/Signature 2 |
|
|
|
| Integrated gut virome and bacteriome dynamics in COVID-19 patients/Experiment 3 |
|
|
|
| Integrated gut virome and bacteriome dynamics in COVID-19 patients/Experiment 3/Signature 1 |
|
|
|
| Integrated gut virome and bacteriome dynamics in COVID-19 patients/Experiment 3/Signature 2 |
|
|
|
| Integrated microbiome and metabolome analysis reveals a novel interplay between commensal bacteria and metabolites in colorectal cancer |
|
|
|
| Integrated microbiome and metabolome analysis reveals a novel interplay between commensal bacteria and metabolites in colorectal cancer/Experiment 1/Signature 1 |
|
|
|
| Integrated microbiome and metabolome analysis reveals a novel interplay between commensal bacteria and metabolites in colorectal cancer/Experiment 1/Signature 2 |
|
|
|
| Integrative Analysis of Fecal Metagenomics and Metabolomics in Colorectal Cancer |
|
|
|
| Inter-relationship between diet, lifestyle habits, gut microflora, and the equol-producer phenotype: baseline findings from a placebo-controlled intervention trial |
|
|
|
| Inter-relationship between diet, lifestyle habits, gut microflora, and the equol-producer phenotype: baseline findings from a placebo-controlled intervention trial/Experiment 1 |
|
|
|
| Inter-relationship between diet, lifestyle habits, gut microflora, and the equol-producer phenotype: baseline findings from a placebo-controlled intervention trial/Experiment 1/Signature 1 |
|
|
|
| Inter-relationship between diet, lifestyle habits, gut microflora, and the equol-producer phenotype: baseline findings from a placebo-controlled intervention trial/Experiment 2 |
|
|
|
| Inter-relationship between diet, lifestyle habits, gut microflora, and the equol-producer phenotype: baseline findings from a placebo-controlled intervention trial/Experiment 2/Signature 1 |
|
|
|
| Intestinal microbiome analysis demonstrates azithromycin post-treatment effects improve when combined with lactulose |
|
|
|
| Intestinal microbiome analysis demonstrates azithromycin post-treatment effects improve when combined with lactulose/Experiment 1 |
|
|
|
| Intestinal microbiome analysis demonstrates azithromycin post-treatment effects improve when combined with lactulose/Experiment 1/Signature 1 |
|
|
|
| Intestinal microbiome analysis demonstrates azithromycin post-treatment effects improve when combined with lactulose/Experiment 1/Signature 2 |
|
|
|
| Intestinal microbiome analysis demonstrates azithromycin post-treatment effects improve when combined with lactulose/Experiment 2 |
|
|
|
| Intestinal microbiome analysis demonstrates azithromycin post-treatment effects improve when combined with lactulose/Experiment 2/Signature 1 |
|
|
|
| Intestinal microbiome analysis demonstrates azithromycin post-treatment effects improve when combined with lactulose/Experiment 2/Signature 2 |
|
|
|
| Intestinal microbiome analysis demonstrates azithromycin post-treatment effects improve when combined with lactulose/Experiment 3 |
|
|
|
| Intestinal microbiome analysis demonstrates azithromycin post-treatment effects improve when combined with lactulose/Experiment 3/Signature 1 |
|
|
|
| Intestinal microbiome analysis demonstrates azithromycin post-treatment effects improve when combined with lactulose/Experiment 3/Signature 2 |
|
|
|
| Intestinal microbiome analysis demonstrates azithromycin post-treatment effects improve when combined with lactulose/Experiment 4 |
|
|
|
| Intestinal microbiome analysis demonstrates azithromycin post-treatment effects improve when combined with lactulose/Experiment 4/Signature 1 |
|
|
|
| Intestinal microbiome analysis demonstrates azithromycin post-treatment effects improve when combined with lactulose/Experiment 4/Signature 2 |
|
|
|
| Intestinal microbiome as a risk factor for urinary tract infections in children |
|
|
|
| Intestinal microbiome as a risk factor for urinary tract infections in children/Experiment 1 |
|
|
|
| Intestinal microbiome as a risk factor for urinary tract infections in children/Experiment 1/Signature 1 |
|
|
|
| Intestinal microbiome as a risk factor for urinary tract infections in children/Experiment 1/Signature 2 |
|
|
|
| Intestinal Microbiota at Engraftment Influence Acute Graft-Versus-Host Disease via the Treg/Th17 Balance in Allo-HSCT Recipients |
|
|
|
| Intestinal Microbiota at Engraftment Influence Acute Graft-Versus-Host Disease via the Treg/Th17 Balance in Allo-HSCT Recipients/Experiment 1 |
|
|
|
| Intestinal Microbiota at Engraftment Influence Acute Graft-Versus-Host Disease via the Treg/Th17 Balance in Allo-HSCT Recipients/Experiment 1/Signature 1 |
|
|
|
| Intestinal Microbiota at Engraftment Influence Acute Graft-Versus-Host Disease via the Treg/Th17 Balance in Allo-HSCT Recipients/Experiment 1/Signature 2 |
|
|
|
| Intestinal Microbiota at Engraftment Influence Acute Graft-Versus-Host Disease via the Treg/Th17 Balance in Allo-HSCT Recipients/Experiment 2 |
|
|
|
| Intestinal Microbiota at Engraftment Influence Acute Graft-Versus-Host Disease via the Treg/Th17 Balance in Allo-HSCT Recipients/Experiment 2/Signature 1 |
|
|
|
| Intestinal Microbiota at Engraftment Influence Acute Graft-Versus-Host Disease via the Treg/Th17 Balance in Allo-HSCT Recipients/Experiment 3 |
|
|
|
| Intestinal Microbiota at Engraftment Influence Acute Graft-Versus-Host Disease via the Treg/Th17 Balance in Allo-HSCT Recipients/Experiment 3/Signature 1 |
|
|
|
| Intestinal Microbiota at Engraftment Influence Acute Graft-Versus-Host Disease via the Treg/Th17 Balance in Allo-HSCT Recipients/Experiment 4 |
|
|
|
| Intestinal Microbiota at Engraftment Influence Acute Graft-Versus-Host Disease via the Treg/Th17 Balance in Allo-HSCT Recipients/Experiment 4/Signature 1 |
|
|
|
| Intestinal microbiota development in preterm neonates and effect of perinatal antibiotics |
|
|
|
| Intestinal microbiota development in preterm neonates and effect of perinatal antibiotics/Experiment 1 |
|
|
|
| Intestinal microbiota development in preterm neonates and effect of perinatal antibiotics/Experiment 1/Signature 1 |
|
|
|
| Intestinal microbiota development in preterm neonates and effect of perinatal antibiotics/Experiment 1/Signature 2 |
|
|
|
| Intestinal microbiota development in preterm neonates and effect of perinatal antibiotics/Experiment 2 |
|
|
|
| Intestinal microbiota development in preterm neonates and effect of perinatal antibiotics/Experiment 2/Signature 1 |
|
|
|
| Intestinal microbiota development in preterm neonates and effect of perinatal antibiotics/Experiment 2/Signature 2 |
|
|
|
| Intestinal microbiota development in preterm neonates and effect of perinatal antibiotics/Experiment 3 |
|
|
|
| Intestinal microbiota development in preterm neonates and effect of perinatal antibiotics/Experiment 3/Signature 1 |
|
|
|
| Intestinal microbiota development in preterm neonates and effect of perinatal antibiotics/Experiment 3/Signature 2 |
|
|
|
| Intestinal microbiota development in preterm neonates and effect of perinatal antibiotics/Experiment 4 |
|
|
|
| Intestinal microbiota development in preterm neonates and effect of perinatal antibiotics/Experiment 4/Signature 1 |
|
|
|
| Intestinal microbiota development in preterm neonates and effect of perinatal antibiotics/Experiment 4/Signature 2 |
|
|
|
| Intestinal microbiota development in preterm neonates and effect of perinatal antibiotics/Experiment 5 |
|
|
|
| Intestinal microbiota development in preterm neonates and effect of perinatal antibiotics/Experiment 5/Signature 1 |
|
|
|
| Intestinal microbiota development in preterm neonates and effect of perinatal antibiotics/Experiment 6 |
|
|
|
| Intestinal microbiota development in preterm neonates and effect of perinatal antibiotics/Experiment 6/Signature 1 |
|
|
|
| Intestinal microbiota development in preterm neonates and effect of perinatal antibiotics/Experiment 7 |
|
|
|
| Intestinal microbiota development in preterm neonates and effect of perinatal antibiotics/Experiment 7/Signature 1 |
|
|
|
| Intestinal microbiota development in preterm neonates and effect of perinatal antibiotics/Experiment 8 |
|
|
|
| Intestinal microbiota development in preterm neonates and effect of perinatal antibiotics/Experiment 8/Signature 1 |
|
|
|
| Intestinal microbiota development in preterm neonates and effect of perinatal antibiotics/Experiment 9 |
|
|
|
| Intestinal microbiota development in preterm neonates and effect of perinatal antibiotics/Experiment 9/Signature 1 |
|
|
|
| Intestinal microbiota development in preterm neonates and effect of perinatal antibiotics/Experiment 9/Signature 2 |
|
|
|
| Intestinal microbiota development in preterm neonates and effect of perinatal antibiotics/Experiment 10 |
|
|
|
| Intestinal microbiota development in preterm neonates and effect of perinatal antibiotics/Experiment 10/Signature 1 |
|
|
|
| Intestinal microbiota development in preterm neonates and effect of perinatal antibiotics/Experiment 11 |
|
|
|
| Intestinal microbiota development in preterm neonates and effect of perinatal antibiotics/Experiment 11/Signature 1 |
|
|
|
| Intestinal microbiota in patients with chronic hepatitis C with and without cirrhosis compared with healthy controls |
|
|
|
| Intestinal microbiota in patients with chronic hepatitis C with and without cirrhosis compared with healthy controls/Experiment 1 |
|
|
|
| Intestinal microbiota in patients with chronic hepatitis C with and without cirrhosis compared with healthy controls/Experiment 1/Signature 1 |
|
|
|
| Intestinal microbiota in patients with chronic hepatitis C with and without cirrhosis compared with healthy controls/Experiment 1/Signature 2 |
|
|
|
| Intestinal microbiota in patients with chronic hepatitis C with and without cirrhosis compared with healthy controls/Experiment 2 |
|
|
|
| Intestinal microbiota in patients with chronic hepatitis C with and without cirrhosis compared with healthy controls/Experiment 2/Signature 1 |
|
|
|
| Intestinal microbiota in patients with chronic hepatitis C with and without cirrhosis compared with healthy controls/Experiment 3 |
|
|
|
| Intestinal microbiota in patients with chronic hepatitis C with and without cirrhosis compared with healthy controls/Experiment 3/Signature 1 |
|
|
|
| Intestinal microbiota in pediatric patients with end stage renal disease: a Midwest Pediatric Nephrology Consortium study |
|
|
|
| Intestinal microbiota in pediatric patients with end stage renal disease: a Midwest Pediatric Nephrology Consortium study/Experiment 1 |
|
|
|
| Intestinal microbiota in pediatric patients with end stage renal disease: a Midwest Pediatric Nephrology Consortium study/Experiment 1/Signature 1 |
|
|
|
| Intestinal microbiota in pediatric patients with end stage renal disease: a Midwest Pediatric Nephrology Consortium study/Experiment 2 |
|
|
|
| Intestinal microbiota in pediatric patients with end stage renal disease: a Midwest Pediatric Nephrology Consortium study/Experiment 2/Signature 1 |
|
|
|
| Intestinal microbiota in pediatric patients with end stage renal disease: a Midwest Pediatric Nephrology Consortium study/Experiment 3 |
|
|
|
| Intestinal microbiota in pediatric patients with end stage renal disease: a Midwest Pediatric Nephrology Consortium study/Experiment 3/Signature 1 |
|
|
|
| Intestinal microbiota is altered in patients with colon cancer and modified by probiotic intervention/Experiment 1/Signature 2 |
|
|
|
| Intestinal microbiota is altered in patients with colon cancer and modified by probiotic intervention/Experiment 2/Signature 1 |
|
|
|
| Intestinal microbiota is altered in patients with colon cancer and modified by probiotic intervention/Experiment 3 |
|
|
|
| Intestinal microbiota is altered in patients with colon cancer and modified by probiotic intervention/Experiment 3/Signature 2 |
|
|
|
| Investigation of Nasal/Oropharyngeal Microbial Community of COVID-19 Patients by 16S rDNA Sequencing |
|
|
|
| Investigation of Nasal/Oropharyngeal Microbial Community of COVID-19 Patients by 16S rDNA Sequencing/Experiment 1 |
|
|
|
| Investigation of Nasal/Oropharyngeal Microbial Community of COVID-19 Patients by 16S rDNA Sequencing/Experiment 1/Signature 1 |
|
|
|
| Investigation of Nasal/Oropharyngeal Microbial Community of COVID-19 Patients by 16S rDNA Sequencing/Experiment 1/Signature 2 |
|
|
|
| Investigation of Nasal/Oropharyngeal Microbial Community of COVID-19 Patients by 16S rDNA Sequencing/Experiment 2 |
|
|
|
| Investigation of Nasal/Oropharyngeal Microbial Community of COVID-19 Patients by 16S rDNA Sequencing/Experiment 2/Signature 1 |
|
|
|
| Investigation of Nasal/Oropharyngeal Microbial Community of COVID-19 Patients by 16S rDNA Sequencing/Experiment 2/Signature 2 |
|
|
|
| Investigation of Nasal/Oropharyngeal Microbial Community of COVID-19 Patients by 16S rDNA Sequencing/Experiment 3 |
|
|
|
| Investigation of Nasal/Oropharyngeal Microbial Community of COVID-19 Patients by 16S rDNA Sequencing/Experiment 3/Signature 1 |
|
|
|
| Investigation of Nasal/Oropharyngeal Microbial Community of COVID-19 Patients by 16S rDNA Sequencing/Experiment 3/Signature 2 |
|
|
|
| Investigation of Nasal/Oropharyngeal Microbial Community of COVID-19 Patients by 16S rDNA Sequencing/Experiment 4 |
|
|
|
| Investigation of Nasal/Oropharyngeal Microbial Community of COVID-19 Patients by 16S rDNA Sequencing/Experiment 4/Signature 1 |
|
|
|
| Investigation of Nasal/Oropharyngeal Microbial Community of COVID-19 Patients by 16S rDNA Sequencing/Experiment 4/Signature 2 |
|
|
|
| Iron deficiency anemia-related gut microbiota dysbiosis in infants and young children: A pilot study |
|
|
|
| Iron deficiency anemia-related gut microbiota dysbiosis in infants and young children: A pilot study/Experiment 1 |
|
|
|
| Iron deficiency anemia-related gut microbiota dysbiosis in infants and young children: A pilot study/Experiment 1/Signature 1 |
|
|
|
| Iron deficiency anemia-related gut microbiota dysbiosis in infants and young children: A pilot study/Experiment 1/Signature 2 |
|
|
|
| Joint effects of pregnancy, sociocultural, and environmental factors on early life gut microbiome structure and diversity |
|
|
|
| Joint effects of pregnancy, sociocultural, and environmental factors on early life gut microbiome structure and diversity/Experiment 1 |
|
|
|
| Joint effects of pregnancy, sociocultural, and environmental factors on early life gut microbiome structure and diversity/Experiment 1/Signature 1 |
|
|
|
| Joint effects of pregnancy, sociocultural, and environmental factors on early life gut microbiome structure and diversity/Experiment 1/Signature 2 |
|
|
|
| Joint effects of pregnancy, sociocultural, and environmental factors on early life gut microbiome structure and diversity/Experiment 2 |
|
|
|
| Joint effects of pregnancy, sociocultural, and environmental factors on early life gut microbiome structure and diversity/Experiment 2/Signature 1 |
|
|
|
| Joint effects of pregnancy, sociocultural, and environmental factors on early life gut microbiome structure and diversity/Experiment 2/Signature 2 |
|
|
|
| Lactobacillus rhamnosus GG-supplemented formula expands butyrate-producing bacterial strains in food allergic infants |
|
|
|
| Lactobacillus rhamnosus GG-supplemented formula expands butyrate-producing bacterial strains in food allergic infants/Experiment 1 |
|
|
|
| Lactobacillus rhamnosus GG-supplemented formula expands butyrate-producing bacterial strains in food allergic infants/Experiment 1/Signature 1 |
|
|
|
| Lactobacillus rhamnosus GG-supplemented formula expands butyrate-producing bacterial strains in food allergic infants/Experiment 1/Signature 2 |
|
|
|
| Linking gut microbiota, metabolic syndrome and economic status based on a population-level analysis |
|
|
|
| Linking gut microbiota, metabolic syndrome and economic status based on a population-level analysis/Experiment 1 |
|
|
|
| Linking gut microbiota, metabolic syndrome and economic status based on a population-level analysis/Experiment 1/Signature 1 |
|
|
|
| Linking gut microbiota, metabolic syndrome and economic status based on a population-level analysis/Experiment 1/Signature 2 |
|
|
|
| Linking long-term dietary patterns with gut microbial enterotypes |
|
|
|
| Linking long-term dietary patterns with gut microbial enterotypes/Experiment 1 |
|
|
|
| Linking long-term dietary patterns with gut microbial enterotypes/Experiment 1/Signature 1 |
|
|
|
| Linking long-term dietary patterns with gut microbial enterotypes/Experiment 1/Signature 2 |
|
|
|
| Linking long-term dietary patterns with gut microbial enterotypes/Experiment 2 |
|
|
|
| Linking long-term dietary patterns with gut microbial enterotypes/Experiment 2/Signature 1 |
|
|
|
| Linking long-term dietary patterns with gut microbial enterotypes/Experiment 2/Signature 2 |
|
|
|
| Linking the gut microbiota to persistent symptoms in survivors of COVID-19 after discharge |
|
|
|
| Linking the gut microbiota to persistent symptoms in survivors of COVID-19 after discharge/Experiment 1 |
|
|
|
| Linking the gut microbiota to persistent symptoms in survivors of COVID-19 after discharge/Experiment 1/Signature 1 |
|
|
|
| Linking the gut microbiota to persistent symptoms in survivors of COVID-19 after discharge/Experiment 1/Signature 2 |
|
|
|
| Low diversity of the gut microbiota in infants with atopic eczema |
|
|
|
| Low diversity of the gut microbiota in infants with atopic eczema/Experiment 1 |
|
|
|
| Low diversity of the gut microbiota in infants with atopic eczema/Experiment 1/Signature 1 |
|
|
|
| Low diversity of the gut microbiota in infants with atopic eczema/Experiment 1/Signature 2 |
|
|
|
| Lower airway microbiota and mycobiota in children with severe asthma/Experiment 1/Signature 1 |
|
|
|
| Lower gut microbiome diversity and higher abundance of proinflammatory genus Collinsella are associated with biopsy-proven nonalcoholic steatohepatitis |
|
|
|
| Lower gut microbiome diversity and higher abundance of proinflammatory genus Collinsella are associated with biopsy-proven nonalcoholic steatohepatitis/Experiment 1 |
|
|
|
| Lower gut microbiome diversity and higher abundance of proinflammatory genus Collinsella are associated with biopsy-proven nonalcoholic steatohepatitis/Experiment 1/Signature 1 |
|
|
|
| Lower gut microbiome diversity and higher abundance of proinflammatory genus Collinsella are associated with biopsy-proven nonalcoholic steatohepatitis/Experiment 1/Signature 2 |
|
|
|
| Lower gut microbiome diversity and higher abundance of proinflammatory genus Collinsella are associated with biopsy-proven nonalcoholic steatohepatitis/Experiment 2 |
|
|
|
| Lower gut microbiome diversity and higher abundance of proinflammatory genus Collinsella are associated with biopsy-proven nonalcoholic steatohepatitis/Experiment 2/Signature 1 |
|
|
|
| Lower gut microbiome diversity and higher abundance of proinflammatory genus Collinsella are associated with biopsy-proven nonalcoholic steatohepatitis/Experiment 2/Signature 2 |
|
|
|
| Lower Neighborhood Socioeconomic Status Associated with Reduced Diversity of the Colonic Microbiota in Healthy Adults |
|
|
|
| Lower Neighborhood Socioeconomic Status Associated with Reduced Diversity of the Colonic Microbiota in Healthy Adults/Experiment 1 |
|
|
|
| Lower Neighborhood Socioeconomic Status Associated with Reduced Diversity of the Colonic Microbiota in Healthy Adults/Experiment 1/Signature 1 |
|
|
|
| Lower Neighborhood Socioeconomic Status Associated with Reduced Diversity of the Colonic Microbiota in Healthy Adults/Experiment 1/Signature 2 |
|
|
|
| Maternal antimicrobial use at delivery has a stronger impact than mode of delivery on bifidobacterial colonization in infants: a pilot study |
|
|
|
| Maternal antimicrobial use at delivery has a stronger impact than mode of delivery on bifidobacterial colonization in infants: a pilot study/Experiment 1 |
|
|
|
| Maternal antimicrobial use at delivery has a stronger impact than mode of delivery on bifidobacterial colonization in infants: a pilot study/Experiment 1/Signature 1 |
|
|
|
| Maturation of the gut microbiome and risk of asthma in childhood |
|
|
|
| Maturation of the gut microbiome and risk of asthma in childhood/Experiment 1 |
|
|
|
| Maturation of the gut microbiome and risk of asthma in childhood/Experiment 1/Signature 1 |
|
|
|
| Maturation of the gut microbiome and risk of asthma in childhood/Experiment 1/Signature 2 |
|
|
|
| Maturation of the gut microbiome and risk of asthma in childhood/Experiment 2 |
|
|
|
| Maturation of the gut microbiome and risk of asthma in childhood/Experiment 2/Signature 1 |
|
|
|
| Maturation of the gut microbiome and risk of asthma in childhood/Experiment 2/Signature 2 |
|
|
|
| Maturation of the infant microbiome community structure and function across multiple body sites and in relation to mode of delivery |
|
|
|
| Maturation of the infant microbiome community structure and function across multiple body sites and in relation to mode of delivery/Experiment 1 |
|
|
|
| Meta-analysis of fecal metagenomes reveals global microbial signatures that are specific for colorectal cancer/Experiment 1/Signature 1 |
|
|
|
| Meta-analysis of fecal metagenomes reveals global microbial signatures that are specific for colorectal cancer/Experiment 1/Signature 2 |
|
|
|
| Meta-analysis of fecal metagenomes reveals global microbial signatures that are specific for colorectal cancer/Experiment 1/Signature 3 |
|
|
|
| Metagenome-wide association of gut microbiome features for schizophrenia |
|
|
|
| Metagenome-wide association of gut microbiome features for schizophrenia/Experiment 1 |
|
|
|
| Metagenome-wide association of gut microbiome features for schizophrenia/Experiment 1/Signature 2 |
|
|
|
| Metagenome-wide association of gut microbiome features for schizophrenia/Experiment 2 |
|
|
|
| Metagenome-wide association of gut microbiome features for schizophrenia/Experiment 2/Signature 1 |
|
|
|
| Metagenome-wide association of gut microbiome features for schizophrenia/Experiment 2/Signature 2 |
|
|
|
| Metagenome-wide association of gut microbiome features for schizophrenia/Experiment 2/Signature 3 |
|
|
|
| Metagenome-wide association of gut microbiome features for schizophrenia/Experiment 3 |
|
|
|
| Metagenome-wide association of gut microbiome features for schizophrenia/Experiment 3/Signature 1 |
|
|
|
| Metagenome-wide association of gut microbiome features for schizophrenia/Experiment 3/Signature 2 |
|
|
|
| Metagenome-wide association of gut microbiome features for schizophrenia/Experiment 4 |
|
|
|
| Metagenome-wide association of gut microbiome features for schizophrenia/Experiment 4/Signature 1 |
|
|
|
| Metagenome-wide association of gut microbiome features for schizophrenia/Experiment 5 |
|
|
|
| Metagenome-wide association of gut microbiome features for schizophrenia/Experiment 5/Signature 1 |
|
|
|
| Metagenomic analyses of the gut microbiota associated with colorectal adenoma |
|
|
|
| Metagenomic analyses of the gut microbiota associated with colorectal adenoma/Experiment 1 |
|
|
|
| Metagenomic analyses of the gut microbiota associated with colorectal adenoma/Experiment 1/Signature 1 |
|
|
|
| Metagenomic analyses of the gut microbiota associated with colorectal adenoma/Experiment 1/Signature 2 |
|
|
|
| Metagenomic analyses of the gut microbiota associated with colorectal adenoma/Experiment 1/Signature 3 |
|
|
|
| Metagenomic analyses of the gut microbiota associated with colorectal adenoma/Experiment 1/Signature 4 |
|
|
|
| Metagenomic analyses of the gut microbiota associated with colorectal adenoma/Experiment 2 |
|
|
|
| Metagenomic analyses of the gut microbiota associated with colorectal adenoma/Experiment 2/Signature 1 |
|
|
|
| Metagenomic analyses of the gut microbiota associated with colorectal adenoma/Experiment 2/Signature 2 |
|
|
|
| Metagenomic analyses of the gut microbiota associated with colorectal adenoma/Experiment 2/Signature 3 |
|
|
|
| Metagenomic analyses of the gut microbiota associated with colorectal adenoma/Experiment 2/Signature 4 |
|
|
|
| Metagenomic analyses of the gut microbiota associated with colorectal adenoma/Experiment 3 |
|
|
|
| Metagenomic analyses of the gut microbiota associated with colorectal adenoma/Experiment 3/Signature 1 |
|
|
|
| Metagenomic analyses of the gut microbiota associated with colorectal adenoma/Experiment 3/Signature 2 |
|
|
|
| Metagenomic analyses of the gut microbiota associated with colorectal adenoma/Experiment 3/Signature 3 |
|
|
|
| Metagenomic analyses of the gut microbiota associated with colorectal adenoma/Experiment 3/Signature 4 |
|
|
|
| Metagenomic analysis of colorectal cancer datasets identifies cross-cohort microbial diagnostic signatures and a link with choline degradation/Experiment 1 |
|
|
|
| Metagenomic Analysis of Common Intestinal Diseases Reveals Relationships among Microbial Signatures and Powers Multidisease Diagnostic Models |
|
|
|
| Metagenomic Analysis of Common Intestinal Diseases Reveals Relationships among Microbial Signatures and Powers Multidisease Diagnostic Models/Experiment 1 |
|
|
|
| Metagenomic Analysis of Common Intestinal Diseases Reveals Relationships among Microbial Signatures and Powers Multidisease Diagnostic Models/Experiment 1/Signature 1 |
|
|
|
| Metagenomic Analysis of Common Intestinal Diseases Reveals Relationships among Microbial Signatures and Powers Multidisease Diagnostic Models/Experiment 1/Signature 2 |
|
|
|
| Metagenomic analysis of the impact of nitrofurantoin treatment on the human faecal microbiota |
|
|
|
| Metagenomic analysis of the impact of nitrofurantoin treatment on the human faecal microbiota/Experiment 1 |
|
|
|
| Metagenomic analysis of the impact of nitrofurantoin treatment on the human faecal microbiota/Experiment 1/Signature 1 |
|
|
|
| Metagenomic analysis of the impact of nitrofurantoin treatment on the human faecal microbiota/Experiment 2 |
|
|
|
| Metagenomic analysis of the impact of nitrofurantoin treatment on the human faecal microbiota/Experiment 2/Signature 1 |
|
|
|
| Metagenomic analysis of the impact of nitrofurantoin treatment on the human faecal microbiota/Experiment 3 |
|
|
|
| Metagenomic analysis of the impact of nitrofurantoin treatment on the human faecal microbiota/Experiment 3/Signature 1 |
|
|
|
| Metagenomic analysis reveals oropharyngeal microbiota alterations in patients with COVID-19 |
|
|
|
| Metagenomic analysis reveals oropharyngeal microbiota alterations in patients with COVID-19/Experiment 1 |
|
|
|
| Metagenomic analysis reveals oropharyngeal microbiota alterations in patients with COVID-19/Experiment 1/Signature 1 |
|
|
|
| Metagenomic analysis reveals oropharyngeal microbiota alterations in patients with COVID-19/Experiment 1/Signature 2 |
|
|
|
| Metagenomic analysis reveals oropharyngeal microbiota alterations in patients with COVID-19/Experiment 2 |
|
|
|
| Metagenomic analysis reveals oropharyngeal microbiota alterations in patients with COVID-19/Experiment 2/Signature 1 |
|
|
|
| Metagenomic analysis reveals oropharyngeal microbiota alterations in patients with COVID-19/Experiment 3 |
|
|
|
| Metagenomic analysis reveals oropharyngeal microbiota alterations in patients with COVID-19/Experiment 3/Signature 1 |
|
|
|
| Metagenomic analysis reveals oropharyngeal microbiota alterations in patients with COVID-19/Experiment 3/Signature 2 |
|
|
|
| Metagenomic analysis reveals oropharyngeal microbiota alterations in patients with COVID-19/Experiment 4 |
|
|
|
| Metagenomic analysis reveals oropharyngeal microbiota alterations in patients with COVID-19/Experiment 4/Signature 1 |
|
|
|
| Metagenomic analysis reveals oropharyngeal microbiota alterations in patients with COVID-19/Experiment 4/Signature 2 |
|
|
|
| Metagenomic analysis reveals oropharyngeal microbiota alterations in patients with COVID-19/Experiment 5 |
|
|
|
| Metagenomic analysis reveals oropharyngeal microbiota alterations in patients with COVID-19/Experiment 5/Signature 1 |
|
|
|
| Metagenomic analysis reveals oropharyngeal microbiota alterations in patients with COVID-19/Experiment 5/Signature 2 |
|
|
|
| Metagenomic and metabolomic analyses reveal distinct stage-specific phenotypes of the gut microbiota in colorectal cancer |
|
|
|
| Metagenomic and metabolomic analyses reveal distinct stage-specific phenotypes of the gut microbiota in colorectal cancer/Experiment 1 |
|
|
|
| Metagenomic and metabolomic analyses reveal distinct stage-specific phenotypes of the gut microbiota in colorectal cancer/Experiment 1/Signature 1 |
|
|
|
| Metagenomic and metabolomic analyses reveal distinct stage-specific phenotypes of the gut microbiota in colorectal cancer/Experiment 1/Signature 2 |
|
|
|
| Metagenomic and metabolomic analyses reveal distinct stage-specific phenotypes of the gut microbiota in colorectal cancer/Experiment 2 |
|
|
|
| Metagenomic and metabolomic analyses reveal distinct stage-specific phenotypes of the gut microbiota in colorectal cancer/Experiment 2/Signature 1 |
|
|
|
| Metagenomic and metabolomic analyses reveal distinct stage-specific phenotypes of the gut microbiota in colorectal cancer/Experiment 2/Signature 2 |
|
|
|
| Metagenomic and metabolomic analyses reveal distinct stage-specific phenotypes of the gut microbiota in colorectal cancer/Experiment 3 |
|
|
|
| Metagenomic and metabolomic analyses reveal distinct stage-specific phenotypes of the gut microbiota in colorectal cancer/Experiment 3/Signature 1 |
|
|
|
| Metagenomic and metabolomic analyses reveal distinct stage-specific phenotypes of the gut microbiota in colorectal cancer/Experiment 3/Signature 2 |
|
|
|
| Metagenomic and metabolomic analyses reveal distinct stage-specific phenotypes of the gut microbiota in colorectal cancer/Experiment 4 |
|
|
|
| Metagenomic and metabolomic analyses reveal distinct stage-specific phenotypes of the gut microbiota in colorectal cancer/Experiment 4/Signature 1 |
|
|
|
| Metagenomic and metabolomic analyses reveal distinct stage-specific phenotypes of the gut microbiota in colorectal cancer/Experiment 4/Signature 2 |
|
|
|
| Metagenomic Next-Generation Sequencing of Nasopharyngeal Specimens Collected from Confirmed and Suspect COVID-19 Patients |
|
|
|
| Metagenomic Next-Generation Sequencing of Nasopharyngeal Specimens Collected from Confirmed and Suspect COVID-19 Patients/Experiment 1 |
|
|
|
| Metagenomic Next-Generation Sequencing of Nasopharyngeal Specimens Collected from Confirmed and Suspect COVID-19 Patients/Experiment 1/Signature 1 |
|
|
|
| Metagenomic Next-Generation Sequencing of Nasopharyngeal Specimens Collected from Confirmed and Suspect COVID-19 Patients/Experiment 1/Signature 2 |
|
|
|
| Metagenomic Shotgun Sequencing and Unbiased Metabolomic Profiling Identify Specific Human Gut Microbiota and Metabolites Associated with Immune Checkpoint Therapy Efficacy in Melanoma Patients |
|
|
|
| Metagenomic Shotgun Sequencing and Unbiased Metabolomic Profiling Identify Specific Human Gut Microbiota and Metabolites Associated with Immune Checkpoint Therapy Efficacy in Melanoma Patients/Experiment 1 |
|
|
|
| Metagenomic Shotgun Sequencing and Unbiased Metabolomic Profiling Identify Specific Human Gut Microbiota and Metabolites Associated with Immune Checkpoint Therapy Efficacy in Melanoma Patients/Experiment 1/Signature 1 |
|
|
|
| Metaproteomics characterizes human gut microbiome function in colorectal cancer |
|
|
|
| Metatranscriptomic analysis to define the Secrebiome, and 16S rRNA profiling of the gut microbiome in obesity and metabolic syndrome of Mexican children |
|
|
|
| Metatranscriptomic analysis to define the Secrebiome, and 16S rRNA profiling of the gut microbiome in obesity and metabolic syndrome of Mexican children/Experiment 1 |
|
|
|
| Metatranscriptomic analysis to define the Secrebiome, and 16S rRNA profiling of the gut microbiome in obesity and metabolic syndrome of Mexican children/Experiment 1/Signature 1 |
|
|
|
| Metatranscriptomic analysis to define the Secrebiome, and 16S rRNA profiling of the gut microbiome in obesity and metabolic syndrome of Mexican children/Experiment 1/Signature 2 |
|
|
|
| Metatranscriptomic analysis to define the Secrebiome, and 16S rRNA profiling of the gut microbiome in obesity and metabolic syndrome of Mexican children/Experiment 2 |
|
|
|
| Metatranscriptomic analysis to define the Secrebiome, and 16S rRNA profiling of the gut microbiome in obesity and metabolic syndrome of Mexican children/Experiment 2/Signature 1 |
|
|
|
| Metatranscriptomic analysis to define the Secrebiome, and 16S rRNA profiling of the gut microbiome in obesity and metabolic syndrome of Mexican children/Experiment 2/Signature 2 |
|
|
|
| Microarray analysis reveals marked intestinal microbiota aberrancy in infants having eczema compared to healthy children in at-risk for atopic disease |
|
|
|
| Microarray analysis reveals marked intestinal microbiota aberrancy in infants having eczema compared to healthy children in at-risk for atopic disease/Experiment 1 |
|
|
|
| Microarray analysis reveals marked intestinal microbiota aberrancy in infants having eczema compared to healthy children in at-risk for atopic disease/Experiment 1/Signature 1 |
|
|
|
| Microarray analysis reveals marked intestinal microbiota aberrancy in infants having eczema compared to healthy children in at-risk for atopic disease/Experiment 1/Signature 2 |
|
|
|
| Microarray analysis reveals marked intestinal microbiota aberrancy in infants having eczema compared to healthy children in at-risk for atopic disease/Experiment 2 |
|
|
|
| Microarray analysis reveals marked intestinal microbiota aberrancy in infants having eczema compared to healthy children in at-risk for atopic disease/Experiment 2/Signature 1 |
|
|
|
| Microarray analysis reveals marked intestinal microbiota aberrancy in infants having eczema compared to healthy children in at-risk for atopic disease/Experiment 2/Signature 2 |
|
|
|
| Microarray analysis reveals marked intestinal microbiota aberrancy in infants having eczema compared to healthy children in at-risk for atopic disease/Experiment 3 |
|
|
|
| Microarray analysis reveals marked intestinal microbiota aberrancy in infants having eczema compared to healthy children in at-risk for atopic disease/Experiment 3/Signature 1 |
|
|
|
| Microarray analysis reveals marked intestinal microbiota aberrancy in infants having eczema compared to healthy children in at-risk for atopic disease/Experiment 3/Signature 2 |
|
|
|
| Microbe-host interplay in atopic dermatitis and psoriasis |
|
|
|
| Microbe-host interplay in atopic dermatitis and psoriasis/Experiment 1 |
|
|
|
| Microbe-host interplay in atopic dermatitis and psoriasis/Experiment 1/Signature 1 |
|
|
|
| Microbe-host interplay in atopic dermatitis and psoriasis/Experiment 1/Signature 2 |
|
|
|
| Microbe-host interplay in atopic dermatitis and psoriasis/Experiment 2 |
|
|
|
| Microbe-host interplay in atopic dermatitis and psoriasis/Experiment 2/Signature 1 |
|
|
|
| Microbe-host interplay in atopic dermatitis and psoriasis/Experiment 2/Signature 2 |
|
|
|
| Microbial biomarkers of common tongue coatings in patients with gastric cancer |
|
|
|
| Microbial biomarkers of common tongue coatings in patients with gastric cancer/Experiment 1 |
|
|
|
| Microbial biomarkers of common tongue coatings in patients with gastric cancer/Experiment 1/Signature 1 |
|
|
|
| Microbial biomarkers of common tongue coatings in patients with gastric cancer/Experiment 1/Signature 2 |
|
|
|
| Microbial biomarkers of common tongue coatings in patients with gastric cancer/Experiment 2 |
|
|
|
| Microbial biomarkers of common tongue coatings in patients with gastric cancer/Experiment 2/Signature 1 |
|
|
|
| Microbial biomarkers of common tongue coatings in patients with gastric cancer/Experiment 2/Signature 2 |
|
|
|
| Microbial biomarkers of common tongue coatings in patients with gastric cancer/Experiment 3 |
|
|
|
| Microbial biomarkers of common tongue coatings in patients with gastric cancer/Experiment 3/Signature 1 |
|
|
|
| Microbial changes in relation to oral mucositis in autologous hematopoietic stem cell transplantation recipients |
|
|
|
| Microbial changes in relation to oral mucositis in autologous hematopoietic stem cell transplantation recipients/Experiment 1 |
|
|
|
| Microbial changes in relation to oral mucositis in autologous hematopoietic stem cell transplantation recipients/Experiment 1/Signature 1 |
|
|
|
| Microbial changes in relation to oral mucositis in autologous hematopoietic stem cell transplantation recipients/Experiment 1/Signature 2 |
|
|
|
| Microbial changes in relation to oral mucositis in autologous hematopoietic stem cell transplantation recipients/Experiment 2 |
|
|
|
| Microbial changes in relation to oral mucositis in autologous hematopoietic stem cell transplantation recipients/Experiment 2/Signature 1 |
|
|
|
| Microbial changes in relation to oral mucositis in autologous hematopoietic stem cell transplantation recipients/Experiment 2/Signature 2 |
|
|
|
| Microbial changes in relation to oral mucositis in autologous hematopoietic stem cell transplantation recipients/Experiment 3 |
|
|
|
| Microbial changes in relation to oral mucositis in autologous hematopoietic stem cell transplantation recipients/Experiment 3/Signature 1 |
|
|
|
| Microbial changes in relation to oral mucositis in autologous hematopoietic stem cell transplantation recipients/Experiment 3/Signature 2 |
|
|
|
| Microbial changes in relation to oral mucositis in autologous hematopoietic stem cell transplantation recipients/Experiment 4 |
|
|
|
| Microbial changes in relation to oral mucositis in autologous hematopoietic stem cell transplantation recipients/Experiment 4/Signature 1 |
|
|
|
| Microbial changes in relation to oral mucositis in autologous hematopoietic stem cell transplantation recipients/Experiment 4/Signature 2 |
|
|
|
| Microbial Community of Healthy Thai Vegetarians and Non-Vegetarians, Their Core Gut Microbiota, and Pathogen Risk |
|
|
|
| Microbial Community of Healthy Thai Vegetarians and Non-Vegetarians, Their Core Gut Microbiota, and Pathogen Risk/Experiment 1 |
|
|
|
| Microbial Community of Healthy Thai Vegetarians and Non-Vegetarians, Their Core Gut Microbiota, and Pathogen Risk/Experiment 1/Signature 1 |
|
|
|
| Microbial Community of Healthy Thai Vegetarians and Non-Vegetarians, Their Core Gut Microbiota, and Pathogen Risk/Experiment 1/Signature 2 |
|
|
|
| Microbial dysbiosis is associated with human breast cancer |
|
|
|
| Microbial dysbiosis is associated with human breast cancer/Experiment 1 |
|
|
|
| Microbial dysbiosis is associated with human breast cancer/Experiment 1/Signature 1 |
|
|
|
| Microbial dysbiosis is associated with human breast cancer/Experiment 1/Signature 2 |
|
|
|
| Microbiome and diversity indices during blood stem cells transplantation - new perspectives? |
|
|
|
| Microbiome and diversity indices during blood stem cells transplantation - new perspectives?/Experiment 1 |
|
|
|
| Microbiome and diversity indices during blood stem cells transplantation - new perspectives?/Experiment 1/Signature 1 |
|
|
|
| Microbiome and diversity indices during blood stem cells transplantation - new perspectives?/Experiment 1/Signature 2 |
|
|
|
| Microbiome changes in healthy volunteers treated with GSK1322322, a novel antibiotic targeting bacterial peptide deformylase |
|
|
|
| Microbiome changes in healthy volunteers treated with GSK1322322, a novel antibiotic targeting bacterial peptide deformylase/Experiment 1 |
|
|
|
| Microbiome changes in healthy volunteers treated with GSK1322322, a novel antibiotic targeting bacterial peptide deformylase/Experiment 1/Signature 1 |
|
|
|
| Microbiome changes in healthy volunteers treated with GSK1322322, a novel antibiotic targeting bacterial peptide deformylase/Experiment 1/Signature 2 |
|
|
|
| Microbiome changes in healthy volunteers treated with GSK1322322, a novel antibiotic targeting bacterial peptide deformylase/Experiment 2 |
|
|
|
| Microbiome changes in healthy volunteers treated with GSK1322322, a novel antibiotic targeting bacterial peptide deformylase/Experiment 2/Signature 1 |
|
|
|
| Microbiome changes in healthy volunteers treated with GSK1322322, a novel antibiotic targeting bacterial peptide deformylase/Experiment 2/Signature 2 |
|
|
|
| Microbiome of the lower genital tract in Chinese women with endometriosis by 16s-rRNA sequencing technique: a pilot study |
|
|
|
| Microbiome of the lower genital tract in Chinese women with endometriosis by 16s-rRNA sequencing technique: a pilot study/Experiment 1 |
|
|
|
| Microbiome of the lower genital tract in Chinese women with endometriosis by 16s-rRNA sequencing technique: a pilot study/Experiment 1/Signature 1 |
|
|
|
| Microbiome of the lower genital tract in Chinese women with endometriosis by 16s-rRNA sequencing technique: a pilot study/Experiment 2 |
|
|
|
| Microbiome of the lower genital tract in Chinese women with endometriosis by 16s-rRNA sequencing technique: a pilot study/Experiment 2/Signature 1 |
|
|
|
| Microbiome Profile of Deep Endometriosis Patients: Comparison of Vaginal Fluid, Endometrium and Lesion |
|
|
|
| Microbiome Profile of Deep Endometriosis Patients: Comparison of Vaginal Fluid, Endometrium and Lesion/Experiment 1 |
|
|
|
| Microbiome Profile of Deep Endometriosis Patients: Comparison of Vaginal Fluid, Endometrium and Lesion/Experiment 1/Signature 1 |
|
|
|
| Microbiome Profile of Deep Endometriosis Patients: Comparison of Vaginal Fluid, Endometrium and Lesion/Experiment 1/Signature 2 |
|
|
|
| Microbiome Profile of Deep Endometriosis Patients: Comparison of Vaginal Fluid, Endometrium and Lesion/Experiment 2 |
|
|
|
| Microbiome Profile of Deep Endometriosis Patients: Comparison of Vaginal Fluid, Endometrium and Lesion/Experiment 2/Signature 1 |
|
|
|
| Microbiome Profile of Deep Endometriosis Patients: Comparison of Vaginal Fluid, Endometrium and Lesion/Experiment 2/Signature 2 |
|
|
|
| Microbiome Profile of Deep Endometriosis Patients: Comparison of Vaginal Fluid, Endometrium and Lesion/Experiment 3 |
|
|
|
| Microbiome Profile of Deep Endometriosis Patients: Comparison of Vaginal Fluid, Endometrium and Lesion/Experiment 3/Signature 1 |
|
|
|
| Microbiome Profile of Deep Endometriosis Patients: Comparison of Vaginal Fluid, Endometrium and Lesion/Experiment 3/Signature 2 |
|
|
|
| Microbiome recovery in adult females with uncomplicated urinary tract infections in a randomised phase 2A trial of the novel antibiotic gepotidacin (GSK140944) |
|
|
|
| Microbiome Responses to an Uncontrolled Short-Term Diet Intervention in the Frame of the Citizen Science Project/Experiment 1 |
|
|
|
| Microbiome Responses to an Uncontrolled Short-Term Diet Intervention in the Frame of the Citizen Science Project/Experiment 1/Signature 1 |
|
|
|
| Microbiome Responses to an Uncontrolled Short-Term Diet Intervention in the Frame of the Citizen Science Project/Experiment 1/Signature 2 |
|
|
|
| Microbiomic differences at cancer-prone oral mucosa sites with marijuana usage |
|
|
|
| Microbiomic differences at cancer-prone oral mucosa sites with marijuana usage/Experiment 1 |
|
|
|
| Microbiomic differences at cancer-prone oral mucosa sites with marijuana usage/Experiment 1/Signature 1 |
|
|
|
| Microbiomic differences at cancer-prone oral mucosa sites with marijuana usage/Experiment 1/Signature 2 |
|
|
|
| Microbiomic differences at cancer-prone oral mucosa sites with marijuana usage/Experiment 2 |
|
|
|
| Microbiomic differences at cancer-prone oral mucosa sites with marijuana usage/Experiment 2/Signature 1 |
|
|
|
| Microbiomic differences at cancer-prone oral mucosa sites with marijuana usage/Experiment 2/Signature 2 |
|
|
|
| Microbiomic differences at cancer-prone oral mucosa sites with marijuana usage/Experiment 3 |
|
|
|
| Microbiomic differences at cancer-prone oral mucosa sites with marijuana usage/Experiment 3/Signature 1 |
|
|
|
| Microbiomic differences at cancer-prone oral mucosa sites with marijuana usage/Experiment 3/Signature 2 |
|
|
|
| Microbiota and Derived Parameters in Fecal Samples of Infants with Non-IgE Cow's Milk Protein Allergy under a Restricted Diet |
|
|
|
| Microbiota and Derived Parameters in Fecal Samples of Infants with Non-IgE Cow's Milk Protein Allergy under a Restricted Diet/Experiment 1 |
|
|
|
| Microbiota and Derived Parameters in Fecal Samples of Infants with Non-IgE Cow's Milk Protein Allergy under a Restricted Diet/Experiment 1/Signature 1 |
|
|
|
| Microbiota and Derived Parameters in Fecal Samples of Infants with Non-IgE Cow's Milk Protein Allergy under a Restricted Diet/Experiment 2 |
|
|
|
| Microbiota and Derived Parameters in Fecal Samples of Infants with Non-IgE Cow's Milk Protein Allergy under a Restricted Diet/Experiment 2/Signature 1 |
|
|
|
| Microbiota and Derived Parameters in Fecal Samples of Infants with Non-IgE Cow's Milk Protein Allergy under a Restricted Diet/Experiment 2/Signature 2 |
|
|
|
| Microbiota changes in a pediatric acute lymphocytic leukemia mouse model |
|
|
|
| Microbiota changes in a pediatric acute lymphocytic leukemia mouse model/Experiment 1 |
|
|
|
| Microbiota changes in a pediatric acute lymphocytic leukemia mouse model/Experiment 1/Signature 1 |
|
|
|
| Microbiota changes in a pediatric acute lymphocytic leukemia mouse model/Experiment 1/Signature 2 |
|
|
|
| Microbiota composition and distribution along the female reproductive tract of women with endometriosis |
|
|
|
| Microbiota composition and distribution along the female reproductive tract of women with endometriosis/Experiment 1 |
|
|
|
| Microbiota composition and distribution along the female reproductive tract of women with endometriosis/Experiment 1/Signature 1 |
|
|
|
| Microbiota composition and distribution along the female reproductive tract of women with endometriosis/Experiment 2 |
|
|
|
| Microbiota composition and distribution along the female reproductive tract of women with endometriosis/Experiment 2/Signature 1 |
|
|
|
| Microbiota composition and distribution along the female reproductive tract of women with endometriosis/Experiment 2/Signature 2 |
|
|
|
| Microbiota composition and distribution along the female reproductive tract of women with endometriosis/Experiment 3 |
|
|
|
| Microbiota composition and distribution along the female reproductive tract of women with endometriosis/Experiment 3/Signature 1 |
|
|
|
| Microbiota composition and distribution along the female reproductive tract of women with endometriosis/Experiment 3/Signature 2 |
|
|
|
| Microbiota composition and distribution along the female reproductive tract of women with endometriosis/Experiment 4 |
|
|
|
| Microbiota composition and distribution along the female reproductive tract of women with endometriosis/Experiment 4/Signature 1 |
|
|
|
| Microbiota composition and distribution along the female reproductive tract of women with endometriosis/Experiment 4/Signature 2 |
|
|
|
| Microbiota composition and distribution along the female reproductive tract of women with endometriosis/Experiment 5 |
|
|
|
| Microbiota composition and distribution along the female reproductive tract of women with endometriosis/Experiment 5/Signature 1 |
|
|
|
| Microbiota composition and distribution along the female reproductive tract of women with endometriosis/Experiment 5/Signature 2 |
|
|
|
| Minimal residual disease negativity in multiple myeloma is associated with intestinal microbiota composition |
|
|
|
| Minimal residual disease negativity in multiple myeloma is associated with intestinal microbiota composition/Experiment 1 |
|
|
|
| Minimal residual disease negativity in multiple myeloma is associated with intestinal microbiota composition/Experiment 1/Signature 1 |
|
|
|
| Minimal residual disease negativity in multiple myeloma is associated with intestinal microbiota composition/Experiment 1/Signature 2 |
|
|
|
| Minimal residual disease negativity in multiple myeloma is associated with intestinal microbiota composition/Experiment 2 |
|
|
|
| Minimal residual disease negativity in multiple myeloma is associated with intestinal microbiota composition/Experiment 2/Signature 1 |
|
|
|
| Minimal residual disease negativity in multiple myeloma is associated with intestinal microbiota composition/Experiment 2/Signature 2 |
|
|
|
| Minimal residual disease negativity in multiple myeloma is associated with intestinal microbiota composition/Experiment 3 |
|
|
|
| Minimal residual disease negativity in multiple myeloma is associated with intestinal microbiota composition/Experiment 3/Signature 1 |
|
|
|
| Minimal residual disease negativity in multiple myeloma is associated with intestinal microbiota composition/Experiment 4 |
|
|
|
| Minimal residual disease negativity in multiple myeloma is associated with intestinal microbiota composition/Experiment 4/Signature 1 |
|
|
|
| Minimal residual disease negativity in multiple myeloma is associated with intestinal microbiota composition/Experiment 5 |
|
|
|
| Minimal residual disease negativity in multiple myeloma is associated with intestinal microbiota composition/Experiment 5/Signature 1 |
|
|
|
| Minimal residual disease negativity in multiple myeloma is associated with intestinal microbiota composition/Experiment 6 |
|
|
|
| Minimal residual disease negativity in multiple myeloma is associated with intestinal microbiota composition/Experiment 6/Signature 1 |
|
|
|
| Molecular Alteration Analysis of Human Gut Microbial Composition in Graves' disease Patients |
|
|
|
| Molecular Alteration Analysis of Human Gut Microbial Composition in Graves' disease Patients/Experiment 1 |
|
|
|
| Molecular Alteration Analysis of Human Gut Microbial Composition in Graves' disease Patients/Experiment 1/Signature 1 |
|
|
|
| Molecular Alteration Analysis of Human Gut Microbial Composition in Graves' disease Patients/Experiment 1/Signature 2 |
|
|
|
| Molecular detection of intrauterine microbial colonization in women with endometriosis |
|
|
|
| Molecular detection of intrauterine microbial colonization in women with endometriosis/Experiment 1 |
|
|
|
| Molecular detection of intrauterine microbial colonization in women with endometriosis/Experiment 1/Signature 1 |
|
|
|
| Molecular detection of intrauterine microbial colonization in women with endometriosis/Experiment 2 |
|
|
|
| Molecular detection of intrauterine microbial colonization in women with endometriosis/Experiment 2/Signature 1 |
|
|
|
| Molecular detection of intrauterine microbial colonization in women with endometriosis/Experiment 2/Signature 2 |
|
|
|
| Molecular detection of intrauterine microbial colonization in women with endometriosis/Experiment 3 |
|
|
|
| Molecular detection of intrauterine microbial colonization in women with endometriosis/Experiment 3/Signature 1 |
|
|
|
| Molecular detection of microbial colonization in cervical mucus of women with and without endometriosis |
|
|
|
| Molecular detection of microbial colonization in cervical mucus of women with and without endometriosis/Experiment 1 |
|
|
|
| Molecular detection of microbial colonization in cervical mucus of women with and without endometriosis/Experiment 1/Signature 1 |
|
|
|
| Molecular estimation of alteration in intestinal microbial composition in Hashimoto's thyroiditis patients |
|
|
|
| Molecular estimation of alteration in intestinal microbial composition in Hashimoto's thyroiditis patients/Experiment 1 |
|
|
|
| Molecular estimation of alteration in intestinal microbial composition in Hashimoto's thyroiditis patients/Experiment 1/Signature 1 |
|
|
|
| Molecular estimation of alteration in intestinal microbial composition in Hashimoto's thyroiditis patients/Experiment 1/Signature 2 |
|
|
|
| Mucosa-Associated Microbiota in Gastric Cancer Tissues Compared With Non-cancer Tissues |
|
|
|
| Mucosa-Associated Microbiota in Gastric Cancer Tissues Compared With Non-cancer Tissues/Experiment 1 |
|
|
|
| Mucosa-Associated Microbiota in Gastric Cancer Tissues Compared With Non-cancer Tissues/Experiment 1/Signature 1 |
|
|
|
| Mucosa-Associated Microbiota in Gastric Cancer Tissues Compared With Non-cancer Tissues/Experiment 1/Signature 2 |
|
|
|
| Mucosal microbiome dysbiosis in gastric carcinogenesis |
|
|
|
| Mucosal microbiome dysbiosis in gastric carcinogenesis/Experiment 1 |
|
|
|
| Mucosal microbiome dysbiosis in gastric carcinogenesis/Experiment 1/Signature 1 |
|
|
|
| Mucosal microbiome dysbiosis in gastric carcinogenesis/Experiment 1/Signature 2 |
|
|
|
| Mucosal microbiome dysbiosis in gastric carcinogenesis/Experiment 2 |
|
|
|
| Mucosal microbiome dysbiosis in gastric carcinogenesis/Experiment 2/Signature 1 |
|
|
|
| Mucosal microbiome dysbiosis in gastric carcinogenesis/Experiment 2/Signature 2 |
|
|
|
| Mucosal microbiome dysbiosis in gastric carcinogenesis/Experiment 3 |
|
|
|
| Mucosal microbiome dysbiosis in gastric carcinogenesis/Experiment 3/Signature 1 |
|
|
|
| Mucosal microbiome dysbiosis in gastric carcinogenesis/Experiment 3/Signature 2 |
|
|
|
| Multiple sclerosis patients have a distinct gut microbiota compared to healthy controls |
|
|
|
| Multiple sclerosis patients have a distinct gut microbiota compared to healthy controls/Experiment 1 |
|
|
|
| Multiple sclerosis patients have a distinct gut microbiota compared to healthy controls/Experiment 1/Signature 1 |
|
|
|
| Multiple sclerosis patients have a distinct gut microbiota compared to healthy controls/Experiment 1/Signature 2 |
|
|
|
| Nasopharyngeal microbiome reveals the prevalence of opportunistic pathogens in SARS-CoV-2 infected individuals and their association with host types |
|
|
|
| Nasopharyngeal microbiome reveals the prevalence of opportunistic pathogens in SARS-CoV-2 infected individuals and their association with host types/Experiment 1 |
|
|
|
| Nasopharyngeal microbiome reveals the prevalence of opportunistic pathogens in SARS-CoV-2 infected individuals and their association with host types/Experiment 1/Signature 1 |
|
|
|
| Nasopharyngeal microbiome reveals the prevalence of opportunistic pathogens in SARS-CoV-2 infected individuals and their association with host types/Experiment 1/Signature 2 |
|
|
|
| Nasopharyngeal Microbiome Signature in COVID-19 Positive Patients: Can We Definitively Get a Role to Fusobacterium periodonticum? |
|
|
|
| Nasopharyngeal Microbiome Signature in COVID-19 Positive Patients: Can We Definitively Get a Role to Fusobacterium periodonticum?/Experiment 1 |
|
|
|
| Nasopharyngeal Microbiome Signature in COVID-19 Positive Patients: Can We Definitively Get a Role to Fusobacterium periodonticum?/Experiment 1/Signature 1 |
|
|
|
| Nasopharyngeal Microbiota Profiling of SARS-CoV-2 Infected Patients |
|
|
|
| Nasopharyngeal Microbiota Profiling of SARS-CoV-2 Infected Patients |
|
|
|
| Nasopharyngeal Microbiota Profiling of SARS-CoV-2 Infected Patients/Experiment 1 |
|
|
|
| Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer |
|
|
|
| Nonalcoholic fatty liver disease is associated with dysbiosis independent of body mass index and insulin resistance |
|
|
|
| Nonalcoholic fatty liver disease is associated with dysbiosis independent of body mass index and insulin resistance/Experiment 1 |
|
|
|
| Nonalcoholic fatty liver disease is associated with dysbiosis independent of body mass index and insulin resistance/Experiment 1/Signature 1 |
|
|
|
| Nonalcoholic fatty liver disease is associated with dysbiosis independent of body mass index and insulin resistance/Experiment 1/Signature 2 |
|
|
|
| Observational Cohort Study of Oral Mycobiome and Interkingdom Interactions over the Course of Induction Therapy for Leukemia |
|
|
|
| Observational Cohort Study of Oral Mycobiome and Interkingdom Interactions over the Course of Induction Therapy for Leukemia/Experiment 1 |
|
|
|
| Observational Cohort Study of Oral Mycobiome and Interkingdom Interactions over the Course of Induction Therapy for Leukemia/Experiment 1/Signature 1 |
|
|
|
| Observational Cohort Study of Oral Mycobiome and Interkingdom Interactions over the Course of Induction Therapy for Leukemia/Experiment 1/Signature 2 |
|
|
|
| Observational Cohort Study of Oral Mycobiome and Interkingdom Interactions over the Course of Induction Therapy for Leukemia/Experiment 2 |
|
|
|
| Observational Cohort Study of Oral Mycobiome and Interkingdom Interactions over the Course of Induction Therapy for Leukemia/Experiment 2/Signature 1 |
|
|
|
| Observational Cohort Study of Oral Mycobiome and Interkingdom Interactions over the Course of Induction Therapy for Leukemia/Experiment 2/Signature 2 |
|
|
|
| Observational Cohort Study of Oral Mycobiome and Interkingdom Interactions over the Course of Induction Therapy for Leukemia/Experiment 2/Signature 3 |
|
|
|
| Observational Cohort Study of Oral Mycobiome and Interkingdom Interactions over the Course of Induction Therapy for Leukemia/Experiment 2/Signature 4 |
|
|
|
| Oral and Gut Microbial Diversity and Immune Regulation in Patients with HIV on Antiretroviral Therapy/Experiment 1 |
|
|
|
| Oral and Gut Microbial Diversity and Immune Regulation in Patients with HIV on Antiretroviral Therapy/Experiment 1/Signature 1 |
|
|
|
| Oral and Gut Microbial Diversity and Immune Regulation in Patients with HIV on Antiretroviral Therapy/Experiment 1/Signature 2 |
|
|
|
| Oral and Gut Microbial Diversity and Immune Regulation in Patients with HIV on Antiretroviral Therapy/Experiment 1/Signature 3 |
|
|
|
| Oral and Gut Microbial Diversity and Immune Regulation in Patients with HIV on Antiretroviral Therapy/Experiment 1/Signature 4 |
|
|
|
| Oral and Gut Microbial Diversity and Immune Regulation in Patients with HIV on Antiretroviral Therapy/Experiment 1/Signature 5 |
|
|
|
| Oral and Gut Microbial Diversity and Immune Regulation in Patients with HIV on Antiretroviral Therapy/Experiment 1/Signature 6 |
|
|
|
| Oral bacterial community dynamics in paediatric patients with malignancies in relation to chemotherapy-related oral mucositis: a prospective study/Experiment 3/Signature 2 |
|
|
|
| Oral bacterial community dynamics in paediatric patients with malignancies in relation to chemotherapy-related oral mucositis: a prospective study/Experiment 5/Signature 1 |
|
|
|
| Oral bacterial community dynamics in paediatric patients with malignancies in relation to chemotherapy-related oral mucositis: a prospective study/Experiment 5/Signature 2 |
|
|
|
| Oral health and plaque microbial profile in juvenile idiopathic arthritis |
|
|
|
| Oral health and plaque microbial profile in juvenile idiopathic arthritis/Experiment 1 |
|
|
|
| Oral health and plaque microbial profile in juvenile idiopathic arthritis/Experiment 1/Signature 1 |
|
|
|
| Oral health and plaque microbial profile in juvenile idiopathic arthritis/Experiment 1/Signature 2 |
|
|
|
| Oral microbial dysbiosis linked to worsened periodontal condition in rheumatoid arthritis patients/Experiment 2 |
|
|
|
| Oral microbial dysbiosis linked to worsened periodontal condition in rheumatoid arthritis patients/Experiment 2/Signature 1 |
|
|
|
| Oral microbial dysbiosis linked to worsened periodontal condition in rheumatoid arthritis patients/Experiment 2/Signature 2 |
|
|
|
| Oral microbiome and history of smoking and colorectal cancer |
|
|
|
| Oral microbiome and history of smoking and colorectal cancer/Experiment 1 |
|
|
|
| Oral microbiome and history of smoking and colorectal cancer/Experiment 2 |
|
|
|
| Oral microbiome and history of smoking and colorectal cancer/Experiment 2/Signature 1 |
|
|
|
| Oral microbiome and history of smoking and colorectal cancer/Experiment 3 |
|
|
|
| Oral microbiome and history of smoking and colorectal cancer/Experiment 3/Signature 1 |
|
|
|
| Oral microbiome and history of smoking and colorectal cancer/Experiment 4 |
|
|
|
| Oral microbiome and history of smoking and colorectal cancer/Experiment 4/Signature 1 |
|
|
|
| Oral microbiome and history of smoking and colorectal cancer/Experiment 4/Signature 2 |
|
|
|
| Oral microbiome and obesity in a large study of low-income and African-American populations |
|
|
|
| Oral microbiome and obesity in a large study of low-income and African-American populations/Experiment 1 |
|
|
|
| Oral microbiome and obesity in a large study of low-income and African-American populations/Experiment 1/Signature 1 |
|
|
|
| Oral microbiome and obesity in a large study of low-income and African-American populations/Experiment 2 |
|
|
|
| Oral microbiome and obesity in a large study of low-income and African-American populations/Experiment 2/Signature 1 |
|
|
|
| Oral microbiome and obesity in a large study of low-income and African-American populations/Experiment 2/Signature 2 |
|
|
|
| Oral Microbiome in HIV-Infected Women: Shifts in the Abundance of Pathogenic and Beneficial Bacteria Are Associated with Aging, HIV Load, CD4 Count, and Antiretroviral Therapy |
|
|
|
| Oral Microbiome in HIV-Infected Women: Shifts in the Abundance of Pathogenic and Beneficial Bacteria Are Associated with Aging, HIV Load, CD4 Count, and Antiretroviral Therapy/Experiment 1 |
|
|
|
| Oral Microbiome in HIV-Infected Women: Shifts in the Abundance of Pathogenic and Beneficial Bacteria Are Associated with Aging, HIV Load, CD4 Count, and Antiretroviral Therapy/Experiment 1/Signature 1 |
|
|
|
| Oral Microbiome in HIV-Infected Women: Shifts in the Abundance of Pathogenic and Beneficial Bacteria Are Associated with Aging, HIV Load, CD4 Count, and Antiretroviral Therapy/Experiment 2 |
|
|
|
| Oral Microbiome in HIV-Infected Women: Shifts in the Abundance of Pathogenic and Beneficial Bacteria Are Associated with Aging, HIV Load, CD4 Count, and Antiretroviral Therapy/Experiment 2/Signature 1 |
|
|
|
| Oral Microbiome in HIV-Infected Women: Shifts in the Abundance of Pathogenic and Beneficial Bacteria Are Associated with Aging, HIV Load, CD4 Count, and Antiretroviral Therapy/Experiment 3 |
|
|
|
| Oral Microbiome in HIV-Infected Women: Shifts in the Abundance of Pathogenic and Beneficial Bacteria Are Associated with Aging, HIV Load, CD4 Count, and Antiretroviral Therapy/Experiment 3/Signature 1 |
|
|
|
| Oral Microbiome in Patients with Oesophageal Squamous Cell Carcinoma |
|
|
|
| Oral Microbiome in Patients with Oesophageal Squamous Cell Carcinoma/Experiment 1 |
|
|
|
| Oral Microbiome in Patients with Oesophageal Squamous Cell Carcinoma/Experiment 1/Signature 1 |
|
|
|
| Oral Microbiome in Patients with Oesophageal Squamous Cell Carcinoma/Experiment 1/Signature 2 |
|
|
|
| Oral Microbiome in Patients with Oesophageal Squamous Cell Carcinoma/Experiment 2 |
|
|
|
| Oral Microbiome in Patients with Oesophageal Squamous Cell Carcinoma/Experiment 2/Signature 1 |
|
|
|
| Oral Microbiome in Patients with Oesophageal Squamous Cell Carcinoma/Experiment 2/Signature 2 |
|
|
|
| Oral Microbiota and Risk for Esophageal Squamous Cell Carcinoma in a High-Risk Area of China |
|
|
|
| Oral Microbiota and Risk for Esophageal Squamous Cell Carcinoma in a High-Risk Area of China/Experiment 1 |
|
|
|
| Oral Microbiota and Risk for Esophageal Squamous Cell Carcinoma in a High-Risk Area of China/Experiment 1/Signature 1 |
|
|
|
| Oral Microbiota and Risk for Esophageal Squamous Cell Carcinoma in a High-Risk Area of China/Experiment 1/Signature 2 |
|
|
|
| Oral Microbiota and Risk for Esophageal Squamous Cell Carcinoma in a High-Risk Area of China/Experiment 2 |
|
|
|
| Oral Microbiota and Risk for Esophageal Squamous Cell Carcinoma in a High-Risk Area of China/Experiment 2/Signature 1 |
|
|
|
| Oral Microbiota and Risk for Esophageal Squamous Cell Carcinoma in a High-Risk Area of China/Experiment 2/Signature 2 |
|
|
|
| Oral Microbiota Community Dynamics Associated With Oral Squamous Cell Carcinoma Staging |
|
|
|
| Oral Microbiota Community Dynamics Associated With Oral Squamous Cell Carcinoma Staging/Experiment 1 |
|
|
|
| Oral Microbiota Community Dynamics Associated With Oral Squamous Cell Carcinoma Staging/Experiment 1/Signature 1 |
|
|
|
| Oral Microbiota Community Dynamics Associated With Oral Squamous Cell Carcinoma Staging/Experiment 1/Signature 2 |
|
|
|
| Oral Microbiota Community Dynamics Associated With Oral Squamous Cell Carcinoma Staging/Experiment 2 |
|
|
|
| Oral Microbiota Community Dynamics Associated With Oral Squamous Cell Carcinoma Staging/Experiment 2/Signature 1 |
|
|
|
| Oral Microbiota Community Dynamics Associated With Oral Squamous Cell Carcinoma Staging/Experiment 2/Signature 2 |
|
|
|
| Oral Microbiota Community Dynamics Associated With Oral Squamous Cell Carcinoma Staging/Experiment 3 |
|
|
|
| Oral Microbiota Community Dynamics Associated With Oral Squamous Cell Carcinoma Staging/Experiment 3/Signature 1 |
|
|
|
| Oral Microbiota Community Dynamics Associated With Oral Squamous Cell Carcinoma Staging/Experiment 3/Signature 2 |
|
|
|
| Oral microbiota dysbiosis and its association with Henoch-Schönlein Purpura in children |
|
|
|
| Oral microbiota dysbiosis and its association with Henoch-Schönlein Purpura in children/Experiment 1 |
|
|
|
| Oral microbiota dysbiosis and its association with Henoch-Schönlein Purpura in children/Experiment 1/Signature 1 |
|
|
|
| Oral microbiota dysbiosis and its association with Henoch-Schönlein Purpura in children/Experiment 1/Signature 2 |
|
|
|
| Oral Microbiota Identifies Patients in Early Onset Rheumatoid Arthritis |
|
|
|
| Oral Microbiota Identifies Patients in Early Onset Rheumatoid Arthritis/Experiment 1 |
|
|
|
| Oral Microbiota Identifies Patients in Early Onset Rheumatoid Arthritis/Experiment 1/Signature 1 |
|
|
|
| Oral Microbiota Identifies Patients in Early Onset Rheumatoid Arthritis/Experiment 1/Signature 2 |
|
|
|
| Oral Microbiota Perturbations Are Linked to High Risk for Rheumatoid Arthritis |
|
|
|
| Oral Microbiota Perturbations Are Linked to High Risk for Rheumatoid Arthritis/Experiment 1 |
|
|
|
| Oral Microbiota Perturbations Are Linked to High Risk for Rheumatoid Arthritis/Experiment 1/Signature 1 |
|
|
|
| Oral Microbiota Perturbations Are Linked to High Risk for Rheumatoid Arthritis/Experiment 1/Signature 2 |
|
|
|
| Oral status in patients with early rheumatoid arthritis: a prospective, case-control study |
|
|
|
| Oral status in patients with early rheumatoid arthritis: a prospective, case-control study/Experiment 1/Signature 2 |
|
|
|
| Overweight and Obesity in Children Are Associated with an Abundance of Firmicutes and Reduction of Bifidobacterium in Their Gastrointestinal Microbiota |
|
|
|
| Overweight and Obesity in Children Are Associated with an Abundance of Firmicutes and Reduction of Bifidobacterium in Their Gastrointestinal Microbiota/Experiment 1 |
|
|
|
| Overweight and Obesity in Children Are Associated with an Abundance of Firmicutes and Reduction of Bifidobacterium in Their Gastrointestinal Microbiota/Experiment 1/Signature 1 |
|
|
|
| Overweight and Obesity in Children Are Associated with an Abundance of Firmicutes and Reduction of Bifidobacterium in Their Gastrointestinal Microbiota/Experiment 1/Signature 2 |
|
|
|
| Parkinson's disease-associated alterations of the gut microbiome predict disease-relevant changes in metabolic functions |
|
|
|
| Parkinson's disease-associated alterations of the gut microbiome predict disease-relevant changes in metabolic functions/Experiment 1 |
|
|
|
| Parkinson's disease-associated alterations of the gut microbiome predict disease-relevant changes in metabolic functions/Experiment 1/Signature 1 |
|
|
|
| Parkinson's disease-associated alterations of the gut microbiome predict disease-relevant changes in metabolic functions/Experiment 1/Signature 2 |
|
|
|
| Parkinson's disease-associated alterations of the gut microbiome predict disease-relevant changes in metabolic functions/Experiment 2 |
|
|
|
| Parkinson's disease-associated alterations of the gut microbiome predict disease-relevant changes in metabolic functions/Experiment 2/Signature 1 |
|
|
|
| Parkinson's disease-associated alterations of the gut microbiome predict disease-relevant changes in metabolic functions/Experiment 2/Signature 2 |
|
|
|
| Parkinson's disease-associated alterations of the gut microbiome predict disease-relevant changes in metabolic functions/Experiment 3 |
|
|
|
| Parkinson's disease-associated alterations of the gut microbiome predict disease-relevant changes in metabolic functions/Experiment 3/Signature 1 |
|
|
|
| Patients With Reflux Esophagitis Possess a Possible Different Oral Microbiota Compared With Healthy Controls |
|
|
|
| Patients With Reflux Esophagitis Possess a Possible Different Oral Microbiota Compared With Healthy Controls/Experiment 1 |
|
|
|
| Patients With Reflux Esophagitis Possess a Possible Different Oral Microbiota Compared With Healthy Controls/Experiment 1/Signature 1 |
|
|
|
| Patients With Reflux Esophagitis Possess a Possible Different Oral Microbiota Compared With Healthy Controls/Experiment 1/Signature 2 |
|
|
|
| Penile Anaerobic Dysbiosis as a Risk Factor for HIV Infection/Experiment 1/Signature 2 |
|
|
|
| Periodontal disease and the oral microbiota in new-onset rheumatoid arthritis |
|
|
|
| Periodontal disease and the oral microbiota in new-onset rheumatoid arthritis/Experiment 1 |
|
|
|
| Periodontal disease and the oral microbiota in new-onset rheumatoid arthritis/Experiment 1/Signature 1 |
|
|
|
| Periodontal disease and the oral microbiota in new-onset rheumatoid arthritis/Experiment 1/Signature 2 |
|
|
|
| Perturbations of the Gut Microbiome and Metabolome in Children with Calcium Oxalate Kidney Stone Disease |
|
|
|
| Phenylketonuric diet negatively impacts on butyrate production |
|
|
|
| Phenylketonuric diet negatively impacts on butyrate production/Experiment 1 |
|
|
|
| Phenylketonuric diet negatively impacts on butyrate production/Experiment 1/Signature 1 |
|
|
|
| Pneumococcal Colonization and the Nasopharyngeal Microbiota of Children in Botswana |
|
|
|
| Pneumococcal Colonization and the Nasopharyngeal Microbiota of Children in Botswana/Experiment 1 |
|
|
|
| Pneumococcal Colonization and the Nasopharyngeal Microbiota of Children in Botswana/Experiment 1/Signature 1 |
|
|
|
| Pneumococcal Colonization and the Nasopharyngeal Microbiota of Children in Botswana/Experiment 1/Signature 2 |
|
|
|
| Possible association of Bifidobacterium and Lactobacillus in the gut microbiota of patients with major depressive disorder |
|
|
|
| Possible association of Bifidobacterium and Lactobacillus in the gut microbiota of patients with major depressive disorder/Experiment 1 |
|
|
|
| Possible association of Bifidobacterium and Lactobacillus in the gut microbiota of patients with major depressive disorder/Experiment 1/Signature 1 |
|
|
|
| Possible association of Firmicutes in the gut microbiota of patients with major depressive disorder |
|
|
|
| Possible association of Firmicutes in the gut microbiota of patients with major depressive disorder/Experiment 1 |
|
|
|
| Possible association of Firmicutes in the gut microbiota of patients with major depressive disorder/Experiment 1/Signature 1 |
|
|
|
| Possible association of Firmicutes in the gut microbiota of patients with major depressive disorder/Experiment 1/Signature 2 |
|
|
|
| Postmenopause as a key factor in the composition of the Endometrial Cancer Microbiome (ECbiome) |
|
|
|
| Postmenopause as a key factor in the composition of the Endometrial Cancer Microbiome (ECbiome)/Experiment 1 |
|
|
|
| Postmenopause as a key factor in the composition of the Endometrial Cancer Microbiome (ECbiome)/Experiment 1/Signature 1 |
|
|
|
| Postmenopause as a key factor in the composition of the Endometrial Cancer Microbiome (ECbiome)/Experiment 1/Signature 2 |
|
|
|
| Postmenopause as a key factor in the composition of the Endometrial Cancer Microbiome (ECbiome)/Experiment 2 |
|
|
|
| Postmenopause as a key factor in the composition of the Endometrial Cancer Microbiome (ECbiome)/Experiment 2/Signature 1 |
|
|
|
| Postmenopause as a key factor in the composition of the Endometrial Cancer Microbiome (ECbiome)/Experiment 2/Signature 2 |
|
|
|
| Potential Association between Vaginal Microbiota and Cervical Carcinogenesis in Korean Women: A Cohort Study |
|
|
|
| Potential Association between Vaginal Microbiota and Cervical Carcinogenesis in Korean Women: A Cohort Study/Experiment 1 |
|
|
|
| Potential Association between Vaginal Microbiota and Cervical Carcinogenesis in Korean Women: A Cohort Study/Experiment 1/Signature 1 |
|
|
|
| Potential Association between Vaginal Microbiota and Cervical Carcinogenesis in Korean Women: A Cohort Study/Experiment 1/Signature 2 |
|
|
|
| Potential Association between Vaginal Microbiota and Cervical Carcinogenesis in Korean Women: A Cohort Study/Experiment 2 |
|
|
|
| Potential Association between Vaginal Microbiota and Cervical Carcinogenesis in Korean Women: A Cohort Study/Experiment 2/Signature 1 |
|
|
|
| Potential Association between Vaginal Microbiota and Cervical Carcinogenesis in Korean Women: A Cohort Study/Experiment 2/Signature 2 |
|
|
|
| Potential of fecal microbiota for early-stage detection of colorectal cancer |
|
|
|
| Potential of fecal microbiota for early-stage detection of colorectal cancer/Experiment 1 |
|
|
|
| Potential of fecal microbiota for early-stage detection of colorectal cancer/Experiment 1/Signature 1 |
|
|
|
| Potential of fecal microbiota for early-stage detection of colorectal cancer/Experiment 1/Signature 3 |
|
|
|
| Pre-obese children's dysbiotic gut microbiome and unhealthy diets may predict the development of obesity |
|
|
|
| Pre-obese children's dysbiotic gut microbiome and unhealthy diets may predict the development of obesity/Experiment 1 |
|
|
|
| Pre-obese children's dysbiotic gut microbiome and unhealthy diets may predict the development of obesity/Experiment 1/Signature 1 |
|
|
|
| Pre-obese children's dysbiotic gut microbiome and unhealthy diets may predict the development of obesity/Experiment 1/Signature 2 |
|
|
|
| Pre-obese children's dysbiotic gut microbiome and unhealthy diets may predict the development of obesity/Experiment 2 |
|
|
|
| Pre-obese children's dysbiotic gut microbiome and unhealthy diets may predict the development of obesity/Experiment 2/Signature 1 |
|
|
|
| Pre-obese children's dysbiotic gut microbiome and unhealthy diets may predict the development of obesity/Experiment 2/Signature 2 |
|
|
|
| Predictability and persistence of prebiotic dietary supplementation in a healthy human cohort |
|
|
|
| Predictability and persistence of prebiotic dietary supplementation in a healthy human cohort/Experiment 1 |
|
|
|
| Predictability and persistence of prebiotic dietary supplementation in a healthy human cohort/Experiment 1/Signature 1 |
|
|
|
| Predictability and persistence of prebiotic dietary supplementation in a healthy human cohort/Experiment 2 |
|
|
|
| Predictability and persistence of prebiotic dietary supplementation in a healthy human cohort/Experiment 2/Signature 1 |
|
|
|
| Preliminary Comparison of Oral and Intestinal Human Microbiota in Patients with Colorectal Cancer: A Pilot Study/Experiment 1 |
|
|
|
| Preliminary Comparison of Oral and Intestinal Human Microbiota in Patients with Colorectal Cancer: A Pilot Study/Experiment 1/Signature 1 |
|
|
|
| Preliminary Comparison of Oral and Intestinal Human Microbiota in Patients with Colorectal Cancer: A Pilot Study/Experiment 2 |
|
|
|
| Preliminary Comparison of Oral and Intestinal Human Microbiota in Patients with Colorectal Cancer: A Pilot Study/Experiment 2/Signature 1 |
|
|
|
| Prenatal and Peripartum Exposure to Antibiotics and Cesarean Section Delivery Are Associated with Differences in Diversity and Composition of the Infant Meconium Microbiome |
|
|
|
| Prenatal and Peripartum Exposure to Antibiotics and Cesarean Section Delivery Are Associated with Differences in Diversity and Composition of the Infant Meconium Microbiome |
|
|
|
| Prenatal and Peripartum Exposure to Antibiotics and Cesarean Section Delivery Are Associated with Differences in Diversity and Composition of the Infant Meconium Microbiome/Experiment 1 |
|
|
|
| Prenatal and Peripartum Exposure to Antibiotics and Cesarean Section Delivery Are Associated with Differences in Diversity and Composition of the Infant Meconium Microbiome/Experiment 1 |
|
|
|
| Prenatal and Peripartum Exposure to Antibiotics and Cesarean Section Delivery Are Associated with Differences in Diversity and Composition of the Infant Meconium Microbiome/Experiment 1/Signature 1 |
|
|
|
| Prenatal and Peripartum Exposure to Antibiotics and Cesarean Section Delivery Are Associated with Differences in Diversity and Composition of the Infant Meconium Microbiome/Experiment 1/Signature 1 |
|
|
|
| Prenatal and Peripartum Exposure to Antibiotics and Cesarean Section Delivery Are Associated with Differences in Diversity and Composition of the Infant Meconium Microbiome/Experiment 1/Signature 2 |
|
|
|
| Prenatal and Peripartum Exposure to Antibiotics and Cesarean Section Delivery Are Associated with Differences in Diversity and Composition of the Infant Meconium Microbiome/Experiment 2 |
|
|
|
| Prenatal and Peripartum Exposure to Antibiotics and Cesarean Section Delivery Are Associated with Differences in Diversity and Composition of the Infant Meconium Microbiome/Experiment 2/Signature 1 |
|
|
|
| Prenatal and Peripartum Exposure to Antibiotics and Cesarean Section Delivery Are Associated with Differences in Diversity and Composition of the Infant Meconium Microbiome/Experiment 2/Signature 2 |
|
|
|
| Prenatal and postnatal antibiotic exposure influences the gut microbiota of preterm infants in neonatal intensive care units |
|
|
|
| Prenatal and postnatal antibiotic exposure influences the gut microbiota of preterm infants in neonatal intensive care units/Experiment 1 |
|
|
|
| Prenatal and postnatal antibiotic exposure influences the gut microbiota of preterm infants in neonatal intensive care units/Experiment 1/Signature 1 |
|
|
|
| Prenatal and postnatal antibiotic exposure influences the gut microbiota of preterm infants in neonatal intensive care units/Experiment 1/Signature 2 |
|
|
|
| Prenatal and postnatal antibiotic exposure influences the gut microbiota of preterm infants in neonatal intensive care units/Experiment 2 |
|
|
|
| Prenatal and postnatal antibiotic exposure influences the gut microbiota of preterm infants in neonatal intensive care units/Experiment 2/Signature 1 |
|
|
|
| Prenatal and postnatal antibiotic exposure influences the gut microbiota of preterm infants in neonatal intensive care units/Experiment 2/Signature 2 |
|
|
|
| Pretreatment gut microbiome predicts chemotherapy-related bloodstream infection |
|
|
|
| Pretreatment gut microbiome predicts chemotherapy-related bloodstream infection/Experiment 1 |
|
|
|
| Pretreatment gut microbiome predicts chemotherapy-related bloodstream infection/Experiment 1/Signature 1 |
|
|
|
| Pretreatment gut microbiome predicts chemotherapy-related bloodstream infection/Experiment 1/Signature 2 |
|
|
|
| Probiotics Ameliorate Colon Epithelial Injury Induced by Ambient Ultrafine Particles Exposure |
|
|
|
| Probiotics Ameliorate Colon Epithelial Injury Induced by Ambient Ultrafine Particles Exposure/Experiment 1 |
|
|
|
| Probiotics Ameliorate Colon Epithelial Injury Induced by Ambient Ultrafine Particles Exposure/Experiment 1/Signature 1 |
|
|
|
| Probiotics Ameliorate Colon Epithelial Injury Induced by Ambient Ultrafine Particles Exposure/Experiment 1/Signature 2 |
|
|
|
| Probiotics modify human intestinal mucosa-associated microbiota in patients with colorectal cancer |
|
|
|
| Probiotics modify human intestinal mucosa-associated microbiota in patients with colorectal cancer/Experiment 1 |
|
|
|
| Probiotics modify human intestinal mucosa-associated microbiota in patients with colorectal cancer/Experiment 1/Signature 1 |
|
|
|
| Probiotics modify human intestinal mucosa-associated microbiota in patients with colorectal cancer/Experiment 1/Signature 2 |
|
|
|
| Probiotics modify human intestinal mucosa-associated microbiota in patients with colorectal cancer/Experiment 2 |
|
|
|
| Probiotics modify human intestinal mucosa-associated microbiota in patients with colorectal cancer/Experiment 2/Signature 1 |
|
|
|
| Probiotics modify human intestinal mucosa-associated microbiota in patients with colorectal cancer/Experiment 2/Signature 2 |
|
|
|
| Probiotics modify human intestinal mucosa-associated microbiota in patients with colorectal cancer/Experiment 3 |
|
|
|
| Probiotics modify human intestinal mucosa-associated microbiota in patients with colorectal cancer/Experiment 3/Signature 1 |
|
|
|
| Probiotics modify human intestinal mucosa-associated microbiota in patients with colorectal cancer/Experiment 3/Signature 2 |
|
|
|
| Probiotics modify human intestinal mucosa-associated microbiota in patients with colorectal cancer/Experiment 4 |
|
|
|
| Probiotics modify human intestinal mucosa-associated microbiota in patients with colorectal cancer/Experiment 4/Signature 1 |
|
|
|
| Probiotics modify human intestinal mucosa-associated microbiota in patients with colorectal cancer/Experiment 4/Signature 2 |
|
|
|
| Probiotics modify human intestinal mucosa-associated microbiota in patients with colorectal cancer/Experiment 5 |
|
|
|
| Probiotics modify human intestinal mucosa-associated microbiota in patients with colorectal cancer/Experiment 5/Signature 1 |
|
|
|
| Probiotics modify human intestinal mucosa-associated microbiota in patients with colorectal cancer/Experiment 5/Signature 3 |
|
|
|
| Probiotics modify human intestinal mucosa-associated microbiota in patients with colorectal cancer/Experiment 6 |
|
|
|
| Probiotics modify human intestinal mucosa-associated microbiota in patients with colorectal cancer/Experiment 6/Signature 1 |
|
|
|
| Probiotics modify human intestinal mucosa-associated microbiota in patients with colorectal cancer/Experiment 6/Signature 2 |
|
|
|
| Prospective observational study of vaginal microbiota pre- and post-rescue cervical cerclage |
|
|
|
| Prospective observational study of vaginal microbiota pre- and post-rescue cervical cerclage/Experiment 1 |
|
|
|
| Prospective observational study of vaginal microbiota pre- and post-rescue cervical cerclage/Experiment 1/Signature 1 |
|
|
|
| Prospective observational study of vaginal microbiota pre- and post-rescue cervical cerclage/Experiment 1/Signature 2 |
|
|
|
| Protection of the Human Gut Microbiome From Antibiotics |
|
|
|
| Protection of the Human Gut Microbiome From Antibiotics/Experiment 1 |
|
|
|
| Protection of the Human Gut Microbiome From Antibiotics/Experiment 1/Signature 1 |
|
|
|
| Protection of the Human Gut Microbiome From Antibiotics/Experiment 1/Signature 2 |
|
|
|
| Protection of the Human Gut Microbiome From Antibiotics/Experiment 2 |
|
|
|
| Protection of the Human Gut Microbiome From Antibiotics/Experiment 2/Signature 1 |
|
|
|
| Protection of the Human Gut Microbiome From Antibiotics/Experiment 2/Signature 2 |
|
|
|
| Protection of the Human Gut Microbiome From Antibiotics/Experiment 3 |
|
|
|
| Protection of the Human Gut Microbiome From Antibiotics/Experiment 3/Signature 1 |
|
|
|
| Protection of the Human Gut Microbiome From Antibiotics/Experiment 3/Signature 2 |
|
|
|
| Psoriatic patients have a distinct structural and functional fecal microbiota compared with controls |
|
|
|
| Psoriatic patients have a distinct structural and functional fecal microbiota compared with controls/Experiment 1 |
|
|
|
| Psoriatic patients have a distinct structural and functional fecal microbiota compared with controls/Experiment 1/Signature 1 |
|
|
|
| Psoriatic patients have a distinct structural and functional fecal microbiota compared with controls/Experiment 1/Signature 2 |
|
|
|
| Quantitative differences in intestinal Faecalibacterium prausnitzii in obese Indian children |
|
|
|
| Quantitative differences in intestinal Faecalibacterium prausnitzii in obese Indian children/Experiment 1 |
|
|
|
| Quantitative differences in intestinal Faecalibacterium prausnitzii in obese Indian children/Experiment 1/Signature 1 |
|
|
|
| Racial Differences in the Oral Microbiome: Data from Low-Income Populations of African Ancestry and European Ancestry/Experiment 1 |
|
|
|
| Racial Differences in the Oral Microbiome: Data from Low-Income Populations of African Ancestry and European Ancestry/Experiment 1/Signature 1 |
|
|
|
| Racial Differences in the Oral Microbiome: Data from Low-Income Populations of African Ancestry and European Ancestry/Experiment 1/Signature 2 |
|
|
|
| Re-purposing 16S rRNA gene sequence data from within case paired tumor biopsy and tumor-adjacent biopsy or fecal samples to identify microbial markers for colorectal cancer |
|
|
|
| Rectal Microbiome Alterations Associated With Oral Human Immunodeficiency Virus Pre-Exposure Prophylaxis |
|
|
|
| Rectal Microbiome Alterations Associated With Oral Human Immunodeficiency Virus Pre-Exposure Prophylaxis/Experiment 1 |
|
|
|
| Rectal Microbiome Alterations Associated With Oral Human Immunodeficiency Virus Pre-Exposure Prophylaxis/Experiment 1/Signature 1 |
|
|
|
| Rectal Microbiome Alterations Associated With Oral Human Immunodeficiency Virus Pre-Exposure Prophylaxis/Experiment 1/Signature 2 |
|
|
|
| Rectal Microbiome Alterations Associated With Oral Human Immunodeficiency Virus Pre-Exposure Prophylaxis/Experiment 2 |
|
|
|
| Rectal Microbiome Alterations Associated With Oral Human Immunodeficiency Virus Pre-Exposure Prophylaxis/Experiment 2/Signature 1 |
|
|
|
| Rectal microbiota among HIV-uninfected, untreated HIV, and treated HIV-infected in Nigeria |
|
|
|
| Rectal microbiota among HIV-uninfected, untreated HIV, and treated HIV-infected in Nigeria/Experiment 1 |
|
|
|
| Rectal microbiota among HIV-uninfected, untreated HIV, and treated HIV-infected in Nigeria/Experiment 1/Signature 1 |
|
|
|
| Rectal microbiota among HIV-uninfected, untreated HIV, and treated HIV-infected in Nigeria/Experiment 1/Signature 2 |
|
|
|
| Rectal microbiota among HIV-uninfected, untreated HIV, and treated HIV-infected in Nigeria/Experiment 2 |
|
|
|
| Rectal microbiota among HIV-uninfected, untreated HIV, and treated HIV-infected in Nigeria/Experiment 2/Signature 1 |
|
|
|
| Reduced Levels of D-dimer and Changes in Gut Microbiota Composition After Probiotic Intervention in HIV-Infected Individuals on Stable ART |
|
|
|
| Reduced Levels of D-dimer and Changes in Gut Microbiota Composition After Probiotic Intervention in HIV-Infected Individuals on Stable ART/Experiment 1 |
|
|
|
| Reduced Levels of D-dimer and Changes in Gut Microbiota Composition After Probiotic Intervention in HIV-Infected Individuals on Stable ART/Experiment 1/Signature 1 |
|
|
|
| Reduced Levels of D-dimer and Changes in Gut Microbiota Composition After Probiotic Intervention in HIV-Infected Individuals on Stable ART/Experiment 1/Signature 2 |
|
|
|
| Reduced Levels of D-dimer and Changes in Gut Microbiota Composition After Probiotic Intervention in HIV-Infected Individuals on Stable ART/Experiment 2 |
|
|
|
| Reduced Levels of D-dimer and Changes in Gut Microbiota Composition After Probiotic Intervention in HIV-Infected Individuals on Stable ART/Experiment 2/Signature 1 |
|
|
|
| Reduced microbial diversity in adult survivors of childhood acute lymphoblastic leukemia and microbial associations with increased immune activation |
|
|
|
| Reduced microbial diversity in adult survivors of childhood acute lymphoblastic leukemia and microbial associations with increased immune activation/Experiment 1 |
|
|
|
| Reduced microbial diversity in adult survivors of childhood acute lymphoblastic leukemia and microbial associations with increased immune activation/Experiment 1/Signature 1 |
|
|
|
| Reduced microbial diversity in adult survivors of childhood acute lymphoblastic leukemia and microbial associations with increased immune activation/Experiment 1/Signature 2 |
|
|
|
| Reduced microbiome alpha diversity in young patients with ADHD |
|
|
|
| Reduced microbiome alpha diversity in young patients with ADHD/Experiment 1 |
|
|
|
| Reduced microbiome alpha diversity in young patients with ADHD/Experiment 1/Signature 1 |
|
|
|
| Reduced microbiome alpha diversity in young patients with ADHD/Experiment 1/Signature 2 |
|
|
|
| Regorafenib plus toripalimab in patients with metastatic colorectal cancer: a phase Ib/II clinical trial and gut microbiome analysis |
|
|
|
| Regorafenib plus toripalimab in patients with metastatic colorectal cancer: a phase Ib/II clinical trial and gut microbiome analysis/Experiment 1/Signature 1 |
|
|
|
| Regulatory T Cells and Plasmacytoid Dendritic Cells Within the Tumor Microenvironment in Gastric Cancer Are Correlated With Gastric Microbiota Dysbiosis: A Preliminary Study |
|
|
|
| Regulatory T Cells and Plasmacytoid Dendritic Cells Within the Tumor Microenvironment in Gastric Cancer Are Correlated With Gastric Microbiota Dysbiosis: A Preliminary Study/Experiment 1 |
|
|
|
| Regulatory T Cells and Plasmacytoid Dendritic Cells Within the Tumor Microenvironment in Gastric Cancer Are Correlated With Gastric Microbiota Dysbiosis: A Preliminary Study/Experiment 1/Signature 1 |
|
|
|
| Regulatory T Cells and Plasmacytoid Dendritic Cells Within the Tumor Microenvironment in Gastric Cancer Are Correlated With Gastric Microbiota Dysbiosis: A Preliminary Study/Experiment 1/Signature 2 |
|
|
|
| Regulatory T Cells and Plasmacytoid Dendritic Cells Within the Tumor Microenvironment in Gastric Cancer Are Correlated With Gastric Microbiota Dysbiosis: A Preliminary Study/Experiment 2 |
|
|
|
| Regulatory T Cells and Plasmacytoid Dendritic Cells Within the Tumor Microenvironment in Gastric Cancer Are Correlated With Gastric Microbiota Dysbiosis: A Preliminary Study/Experiment 2/Signature 1 |
|
|
|
| Regulatory T Cells and Plasmacytoid Dendritic Cells Within the Tumor Microenvironment in Gastric Cancer Are Correlated With Gastric Microbiota Dysbiosis: A Preliminary Study/Experiment 2/Signature 2 |
|
|
|
| Regulatory T Cells and Plasmacytoid Dendritic Cells Within the Tumor Microenvironment in Gastric Cancer Are Correlated With Gastric Microbiota Dysbiosis: A Preliminary Study/Experiment 3 |
|
|
|
| Regulatory T Cells and Plasmacytoid Dendritic Cells Within the Tumor Microenvironment in Gastric Cancer Are Correlated With Gastric Microbiota Dysbiosis: A Preliminary Study/Experiment 3/Signature 1 |
|
|
|
| Regulatory T Cells and Plasmacytoid Dendritic Cells Within the Tumor Microenvironment in Gastric Cancer Are Correlated With Gastric Microbiota Dysbiosis: A Preliminary Study/Experiment 3/Signature 2 |
|
|
|
| Relationship between acetaldehyde concentration in mouth air and characteristics of microbiota of tongue dorsum in Japanese healthy adults: a cross-sectional study |
|
|
|
| Relationship between acetaldehyde concentration in mouth air and characteristics of microbiota of tongue dorsum in Japanese healthy adults: a cross-sectional study/Experiment 1 |
|
|
|
| Relationship between acetaldehyde concentration in mouth air and characteristics of microbiota of tongue dorsum in Japanese healthy adults: a cross-sectional study/Experiment 1/Signature 1 |
|
|
|
| Relationship between acetaldehyde concentration in mouth air and characteristics of microbiota of tongue dorsum in Japanese healthy adults: a cross-sectional study/Experiment 1/Signature 2 |
|
|
|
| Respiratory Disease following Viral Lung Infection Alters the Murine Gut Microbiota |
|
|
|
| Respiratory Disease following Viral Lung Infection Alters the Murine Gut Microbiota/Experiment 1 |
|
|
|
| Respiratory Disease following Viral Lung Infection Alters the Murine Gut Microbiota/Experiment 1/Signature 1 |
|
|
|
| Respiratory Disease following Viral Lung Infection Alters the Murine Gut Microbiota/Experiment 1/Signature 2 |
|
|
|
| Respiratory Disease following Viral Lung Infection Alters the Murine Gut Microbiota/Experiment 2 |
|
|
|
| Respiratory Disease following Viral Lung Infection Alters the Murine Gut Microbiota/Experiment 2/Signature 1 |
|
|
|
| Respiratory Disease following Viral Lung Infection Alters the Murine Gut Microbiota/Experiment 2/Signature 2 |
|
|
|
| Respiratory Tract Dysbiosis Is Associated with Worse Outcomes in Mechanically Ventilated Patients |
|
|
|
| Reversion of Gut Microbiota during the Recovery Phase in Patients with Asymptomatic or Mild COVID-19: Longitudinal Study |
|
|
|
| Reversion of Gut Microbiota during the Recovery Phase in Patients with Asymptomatic or Mild COVID-19: Longitudinal Study/Experiment 1 |
|
|
|
| Reversion of Gut Microbiota during the Recovery Phase in Patients with Asymptomatic or Mild COVID-19: Longitudinal Study/Experiment 1/Signature 1 |
|
|
|
| Reversion of Gut Microbiota during the Recovery Phase in Patients with Asymptomatic or Mild COVID-19: Longitudinal Study/Experiment 1/Signature 2 |
|
|
|
| Reversion of Gut Microbiota during the Recovery Phase in Patients with Asymptomatic or Mild COVID-19: Longitudinal Study/Experiment 2 |
|
|
|
| Reversion of Gut Microbiota during the Recovery Phase in Patients with Asymptomatic or Mild COVID-19: Longitudinal Study/Experiment 2/Signature 1 |
|
|
|
| Reversion of Gut Microbiota during the Recovery Phase in Patients with Asymptomatic or Mild COVID-19: Longitudinal Study/Experiment 2/Signature 2 |
|
|
|
| Reversion of Gut Microbiota during the Recovery Phase in Patients with Asymptomatic or Mild COVID-19: Longitudinal Study/Experiment 3 |
|
|
|
| Reversion of Gut Microbiota during the Recovery Phase in Patients with Asymptomatic or Mild COVID-19: Longitudinal Study/Experiment 3/Signature 1 |
|
|
|
| Reversion of Gut Microbiota during the Recovery Phase in Patients with Asymptomatic or Mild COVID-19: Longitudinal Study/Experiment 3/Signature 2 |
|
|
|
| Salivary Microbial Dysbiosis is Associated with Systemic Inflammatory Markers and Predicted Oral Metabolites in Non-Small Cell Lung Cancer Patients |
|
|
|
| Salivary Microbial Dysbiosis is Associated with Systemic Inflammatory Markers and Predicted Oral Metabolites in Non-Small Cell Lung Cancer Patients/Experiment 1 |
|
|
|
| Salivary Microbial Dysbiosis is Associated with Systemic Inflammatory Markers and Predicted Oral Metabolites in Non-Small Cell Lung Cancer Patients/Experiment 1/Signature 1 |
|
|
|
| Salivary Microbial Dysbiosis is Associated with Systemic Inflammatory Markers and Predicted Oral Metabolites in Non-Small Cell Lung Cancer Patients/Experiment 1/Signature 2 |
|
|
|
| Salivary Microbial Dysbiosis is Associated with Systemic Inflammatory Markers and Predicted Oral Metabolites in Non-Small Cell Lung Cancer Patients/Experiment 2 |
|
|
|
| Salivary Microbial Dysbiosis is Associated with Systemic Inflammatory Markers and Predicted Oral Metabolites in Non-Small Cell Lung Cancer Patients/Experiment 2/Signature 1 |
|
|
|
| Salivary Microbial Dysbiosis is Associated with Systemic Inflammatory Markers and Predicted Oral Metabolites in Non-Small Cell Lung Cancer Patients/Experiment 2/Signature 2 |
|
|
|
| Salivary microbiota and inflammation-related proteins in patients with psoriasis |
|
|
|
| Salivary microbiota and inflammation-related proteins in patients with psoriasis |
|
|
|
| Salivary Oral Microbiome of Children With Juvenile Idiopathic Arthritis: A Norwegian Cross-Sectional Study |
|
|
|
| Salivary Oral Microbiome of Children With Juvenile Idiopathic Arthritis: A Norwegian Cross-Sectional Study/Experiment 1 |
|
|
|
| Salivary Oral Microbiome of Children With Juvenile Idiopathic Arthritis: A Norwegian Cross-Sectional Study/Experiment 1/Signature 1 |
|
|
|
| Salivary Oral Microbiome of Children With Juvenile Idiopathic Arthritis: A Norwegian Cross-Sectional Study/Experiment 1/Signature 2 |
|
|
|
| Salivary Oral Microbiome of Children With Juvenile Idiopathic Arthritis: A Norwegian Cross-Sectional Study/Experiment 2 |
|
|
|
| Salivary Oral Microbiome of Children With Juvenile Idiopathic Arthritis: A Norwegian Cross-Sectional Study/Experiment 2/Signature 1 |
|
|
|
| Salivary Oral Microbiome of Children With Juvenile Idiopathic Arthritis: A Norwegian Cross-Sectional Study/Experiment 2/Signature 2 |
|
|
|
| SARS-CoV-2 does not have a strong effect on the nasopharyngeal microbial composition |
|
|
|
| SARS-CoV-2 does not have a strong effect on the nasopharyngeal microbial composition/Experiment 1 |
|
|
|
| SARS-CoV-2 infection and viral load are associated with the upper respiratory tract microbiome |
|
|
|
| SARS-CoV-2 infection and viral load are associated with the upper respiratory tract microbiome/Experiment 1 |
|
|
|
| SARS-CoV-2 infection and viral load are associated with the upper respiratory tract microbiome/Experiment 1/Signature 1 |
|
|
|
| SARS-CoV-2 infection and viral load are associated with the upper respiratory tract microbiome/Experiment 1/Signature 2 |
|
|
|
| SARS-CoV-2 infection and viral load are associated with the upper respiratory tract microbiome/Experiment 2 |
|
|
|
| SARS-CoV-2 infection and viral load are associated with the upper respiratory tract microbiome/Experiment 2/Signature 1 |
|
|
|
| SARS-CoV-2 infection and viral load are associated with the upper respiratory tract microbiome/Experiment 2/Signature 2 |
|
|
|
| Self-Balance of Intestinal Flora in Spouses of Patients With Rheumatoid Arthritis |
|
|
|
| Self-Balance of Intestinal Flora in Spouses of Patients With Rheumatoid Arthritis/Experiment 1 |
|
|
|
| Self-Balance of Intestinal Flora in Spouses of Patients With Rheumatoid Arthritis/Experiment 1/Signature 5 |
|
|
|
| Self-Balance of Intestinal Flora in Spouses of Patients With Rheumatoid Arthritis/Experiment 1/Signature 8 |
|
|
|
| Sex-specific effects of PM2.5 maternal exposure on offspring's serum lipoproteins and gut microbiota |
|
|
|
| Sex-specific effects of PM2.5 maternal exposure on offspring's serum lipoproteins and gut microbiota/Experiment 1 |
|
|
|
| Sex-specific effects of PM2.5 maternal exposure on offspring's serum lipoproteins and gut microbiota/Experiment 1/Signature 1 |
|
|
|
| Sex-specific effects of PM2.5 maternal exposure on offspring's serum lipoproteins and gut microbiota/Experiment 1/Signature 2 |
|
|
|
| Sex-specific effects of PM2.5 maternal exposure on offspring's serum lipoproteins and gut microbiota/Experiment 2 |
|
|
|
| Sex-specific effects of PM2.5 maternal exposure on offspring's serum lipoproteins and gut microbiota/Experiment 2/Signature 1 |
|
|
|
| Sex-specific effects of PM2.5 maternal exposure on offspring's serum lipoproteins and gut microbiota/Experiment 3 |
|
|
|
| Sex-specific effects of PM2.5 maternal exposure on offspring's serum lipoproteins and gut microbiota/Experiment 3/Signature 1 |
|
|
|
| Sex-specific effects of PM2.5 maternal exposure on offspring's serum lipoproteins and gut microbiota/Experiment 3/Signature 2 |
|
|
|
| Sex-specific effects of PM2.5 maternal exposure on offspring's serum lipoproteins and gut microbiota/Experiment 4 |
|
|
|
| Sex-specific effects of PM2.5 maternal exposure on offspring's serum lipoproteins and gut microbiota/Experiment 4/Signature 1 |
|
|
|
| Sex-specific effects of PM2.5 maternal exposure on offspring's serum lipoproteins and gut microbiota/Experiment 5 |
|
|
|
| Sex-specific effects of PM2.5 maternal exposure on offspring's serum lipoproteins and gut microbiota/Experiment 5/Signature 1 |
|
|
|
| Sex-specific effects of PM2.5 maternal exposure on offspring's serum lipoproteins and gut microbiota/Experiment 5/Signature 2 |
|
|
|
| Sex-specific effects of PM2.5 maternal exposure on offspring's serum lipoproteins and gut microbiota/Experiment 6 |
|
|
|
| Sex-specific effects of PM2.5 maternal exposure on offspring's serum lipoproteins and gut microbiota/Experiment 6/Signature 1 |
|
|
|
| Sex-specific effects of PM2.5 maternal exposure on offspring's serum lipoproteins and gut microbiota/Experiment 6/Signature 2 |
|
|
|
| Sex-specific effects of PM2.5 maternal exposure on offspring's serum lipoproteins and gut microbiota/Experiment 7 |
|
|
|
| Sex-specific effects of PM2.5 maternal exposure on offspring's serum lipoproteins and gut microbiota/Experiment 7/Signature 1 |
|
|
|
| Sex-specific effects of PM2.5 maternal exposure on offspring's serum lipoproteins and gut microbiota/Experiment 7/Signature 2 |
|
|
|
| Sex-specific impact of asthma during pregnancy on infant gut microbiota |
|
|
|
| Sex-specific impact of asthma during pregnancy on infant gut microbiota/Experiment 1 |
|
|
|
| Sex-specific impact of asthma during pregnancy on infant gut microbiota/Experiment 1/Signature 1 |
|
|
|
| Sex-specific impact of asthma during pregnancy on infant gut microbiota/Experiment 1/Signature 2 |
|
|
|
| Sex-specific impact of asthma during pregnancy on infant gut microbiota/Experiment 2 |
|
|
|
| Sex-specific impact of asthma during pregnancy on infant gut microbiota/Experiment 2/Signature 1 |
|
|
|
| Sex-specific impact of asthma during pregnancy on infant gut microbiota/Experiment 2/Signature 2 |
|
|
|
| Sex-specific impact of asthma during pregnancy on infant gut microbiota/Experiment 3 |
|
|
|
| Sex-specific impact of asthma during pregnancy on infant gut microbiota/Experiment 3/Signature 1 |
|
|
|
| Sex-specific impact of asthma during pregnancy on infant gut microbiota/Experiment 4 |
|
|
|
| Sex-specific impact of asthma during pregnancy on infant gut microbiota/Experiment 4/Signature 1 |
|
|
|
| Sex-specific impact of asthma during pregnancy on infant gut microbiota/Experiment 5 |
|
|
|
| Sex-specific impact of asthma during pregnancy on infant gut microbiota/Experiment 5/Signature 1 |
|
|
|
| Sex-specific impact of asthma during pregnancy on infant gut microbiota/Experiment 5/Signature 2 |
|
|
|
| Sex-specific impact of asthma during pregnancy on infant gut microbiota/Experiment 6 |
|
|
|
| Sex-specific impact of asthma during pregnancy on infant gut microbiota/Experiment 6/Signature 1 |
|
|
|
| Sex-specific impact of asthma during pregnancy on infant gut microbiota/Experiment 7 |
|
|
|
| Sex-specific impact of asthma during pregnancy on infant gut microbiota/Experiment 7/Signature 1 |
|
|
|
| Sex-specific impact of asthma during pregnancy on infant gut microbiota/Experiment 7/Signature 2 |
|
|
|
| Shift in skin microbiota of Western European women across aging |
|
|
|
| Shift in skin microbiota of Western European women across aging/Experiment 1 |
|
|
|
| Shift in skin microbiota of Western European women across aging/Experiment 1/Signature 1 |
|
|
|
| Shift in skin microbiota of Western European women across aging/Experiment 1/Signature 2 |
|
|
|
| Shifts in Lachnospira and Clostridium sp. in the 3-month stool microbiome are associated with preschool age asthma |
|
|
|
| Shifts in Lachnospira and Clostridium sp. in the 3-month stool microbiome are associated with preschool age asthma/Experiment 1 |
|
|
|
| Shifts in Lachnospira and Clostridium sp. in the 3-month stool microbiome are associated with preschool age asthma/Experiment 1/Signature 1 |
|
|
|
| Shifts in Lachnospira and Clostridium sp. in the 3-month stool microbiome are associated with preschool age asthma/Experiment 1/Signature 2 |
|
|
|
| Shifts in Lachnospira and Clostridium sp. in the 3-month stool microbiome are associated with preschool age asthma/Experiment 2 |
|
|
|
| Shifts in Lachnospira and Clostridium sp. in the 3-month stool microbiome are associated with preschool age asthma/Experiment 2/Signature 1 |
|
|
|
| Shifts in the Fecal Microbiota Associated with Adenomatous Polyps |
|
|
|
| Shifts in the Fecal Microbiota Associated with Adenomatous Polyps/Experiment 1 |
|
|
|
| Shifts in the Fecal Microbiota Associated with Adenomatous Polyps/Experiment 1/Signature 1 |
|
|
|
| Shifts in the Fecal Microbiota Associated with Adenomatous Polyps/Experiment 1/Signature 2 |
|
|
|
| Short- and long-term impacts of azithromycin treatment on the gut microbiota in children: A double-blind, randomized, placebo-controlled trial |
|
|
|
| Short- and long-term impacts of azithromycin treatment on the gut microbiota in children: A double-blind, randomized, placebo-controlled trial/Experiment 1 |
|
|
|
| Short- and long-term impacts of azithromycin treatment on the gut microbiota in children: A double-blind, randomized, placebo-controlled trial/Experiment 1/Signature 1 |
|
|
|
| Short- and long-term impacts of azithromycin treatment on the gut microbiota in children: A double-blind, randomized, placebo-controlled trial/Experiment 1/Signature 2 |
|
|
|
| Short-term effect of antibiotics on human gut microbiota |
|
|
|
| Short-term effect of antibiotics on human gut microbiota/Experiment 1 |
|
|
|
| Short-term effect of antibiotics on human gut microbiota/Experiment 1/Signature 1 |
|
|
|
| Short-term effect of antibiotics on human gut microbiota/Experiment 1/Signature 2 |
|
|
|
| Short-term effect of antibiotics on human gut microbiota/Experiment 2 |
|
|
|
| Short-term effect of antibiotics on human gut microbiota/Experiment 2/Signature 1 |
|
|
|
| Short-term effect of antibiotics on human gut microbiota/Experiment 2/Signature 2 |
|
|
|
| Short-term effect of antibiotics on human gut microbiota/Experiment 3 |
|
|
|
| Short-term effect of antibiotics on human gut microbiota/Experiment 3/Signature 1 |
|
|
|
| Short-term effect of antibiotics on human gut microbiota/Experiment 3/Signature 2 |
|
|
|
| Short-term effect of antibiotics on human gut microbiota/Experiment 4 |
|
|
|
| Short-term effect of antibiotics on human gut microbiota/Experiment 4/Signature 1 |
|
|
|
| Short-term effect of antibiotics on human gut microbiota/Experiment 4/Signature 2 |
|
|
|
| Short-term effect of antibiotics on human gut microbiota/Experiment 5 |
|
|
|
| Short-term effect of antibiotics on human gut microbiota/Experiment 5/Signature 1 |
|
|
|
| Short-term effect of antibiotics on human gut microbiota/Experiment 5/Signature 2 |
|
|
|
| Signatures in the gut microbiota of Japanese infants who developed food allergies in early childhood |
|
|
|
| Signatures in the gut microbiota of Japanese infants who developed food allergies in early childhood/Experiment 1 |
|
|
|
| Signatures in the gut microbiota of Japanese infants who developed food allergies in early childhood/Experiment 1/Signature 1 |
|
|
|
| Signatures in the gut microbiota of Japanese infants who developed food allergies in early childhood/Experiment 1/Signature 2 |
|
|
|
| Signatures of COVID-19 severity and immune response in the respiratory tract microbiome |
|
|
|
| Signatures of Mucosal Microbiome in Oral Squamous Cell Carcinoma Identified Using a Random Forest Model |
|
|
|
| Signatures of Mucosal Microbiome in Oral Squamous Cell Carcinoma Identified Using a Random Forest Model/Experiment 1 |
|
|
|
| Signatures of Mucosal Microbiome in Oral Squamous Cell Carcinoma Identified Using a Random Forest Model/Experiment 1/Signature 1 |
|
|
|
| Signatures of Mucosal Microbiome in Oral Squamous Cell Carcinoma Identified Using a Random Forest Model/Experiment 1/Signature 2 |
|
|
|
| Similarly in depression, nuances of gut microbiota: Evidences from a shotgun metagenomics sequencing study on major depressive disorder versus bipolar disorder with current major depressive episode patients |
|
|
|
| Similarly in depression, nuances of gut microbiota: Evidences from a shotgun metagenomics sequencing study on major depressive disorder versus bipolar disorder with current major depressive episode patients/Experiment 1 |
|
|
|
| Similarly in depression, nuances of gut microbiota: Evidences from a shotgun metagenomics sequencing study on major depressive disorder versus bipolar disorder with current major depressive episode patients/Experiment 1/Signature 1 |
|
|
|
| Similarly in depression, nuances of gut microbiota: Evidences from a shotgun metagenomics sequencing study on major depressive disorder versus bipolar disorder with current major depressive episode patients/Experiment 1/Signature 2 |
|
|
|
| Similarly in depression, nuances of gut microbiota: Evidences from a shotgun metagenomics sequencing study on major depressive disorder versus bipolar disorder with current major depressive episode patients/Experiment 2 |
|
|
|
| Similarly in depression, nuances of gut microbiota: Evidences from a shotgun metagenomics sequencing study on major depressive disorder versus bipolar disorder with current major depressive episode patients/Experiment 2/Signature 1 |
|
|
|
| Six-month follow-up of gut microbiota richness in patients with COVID-19 |
|
|
|
| Six-month follow-up of gut microbiota richness in patients with COVID-19/Experiment 1 |
|
|
|
| Six-month follow-up of gut microbiota richness in patients with COVID-19/Experiment 2 |
|
|
|
| Skin microbiome before development of atopic dermatitis: Early colonization with commensal staphylococci at 2 months is associated with a lower risk of atopic dermatitis at 1 year |
|
|
|
| Skin microbiome before development of atopic dermatitis: Early colonization with commensal staphylococci at 2 months is associated with a lower risk of atopic dermatitis at 1 year/Experiment 1 |
|
|
|
| Skin microbiome before development of atopic dermatitis: Early colonization with commensal staphylococci at 2 months is associated with a lower risk of atopic dermatitis at 1 year/Experiment 1/Signature 1 |
|
|
|
| Socioeconomic Status and the Gut Microbiome: A TwinsUK Cohort Study |
|
|
|
| Socioeconomic Status and the Gut Microbiome: A TwinsUK Cohort Study/Experiment 1 |
|
|
|
| Socioeconomic Status and the Gut Microbiome: A TwinsUK Cohort Study/Experiment 1/Signature 1 |
|
|
|
| Socioeconomic Status and the Gut Microbiome: A TwinsUK Cohort Study/Experiment 1/Signature 2 |
|
|
|
| Specific class of intrapartum antibiotics relates to maturation of the infant gut microbiota: a prospective cohort study |
|
|
|
| Specific class of intrapartum antibiotics relates to maturation of the infant gut microbiota: a prospective cohort study/Experiment 1 |
|
|
|
| Specific class of intrapartum antibiotics relates to maturation of the infant gut microbiota: a prospective cohort study/Experiment 1/Signature 1 |
|
|
|
| Specific class of intrapartum antibiotics relates to maturation of the infant gut microbiota: a prospective cohort study/Experiment 1/Signature 2 |
|
|
|
| Specific class of intrapartum antibiotics relates to maturation of the infant gut microbiota: a prospective cohort study/Experiment 2 |
|
|
|
| Specific class of intrapartum antibiotics relates to maturation of the infant gut microbiota: a prospective cohort study/Experiment 2/Signature 1 |
|
|
|
| Specific class of intrapartum antibiotics relates to maturation of the infant gut microbiota: a prospective cohort study/Experiment 2/Signature 2 |
|
|
|
| Specific class of intrapartum antibiotics relates to maturation of the infant gut microbiota: a prospective cohort study/Experiment 3 |
|
|
|
| Specific class of intrapartum antibiotics relates to maturation of the infant gut microbiota: a prospective cohort study/Experiment 3/Signature 1 |
|
|
|
| Specific class of intrapartum antibiotics relates to maturation of the infant gut microbiota: a prospective cohort study/Experiment 4 |
|
|
|
| Specific class of intrapartum antibiotics relates to maturation of the infant gut microbiota: a prospective cohort study/Experiment 4/Signature 1 |
|
|
|
| Specific class of intrapartum antibiotics relates to maturation of the infant gut microbiota: a prospective cohort study/Experiment 4/Signature 2 |
|
|
|
| Specific class of intrapartum antibiotics relates to maturation of the infant gut microbiota: a prospective cohort study/Experiment 5 |
|
|
|
| Specific class of intrapartum antibiotics relates to maturation of the infant gut microbiota: a prospective cohort study/Experiment 5/Signature 1 |
|
|
|
| Stool microbiome and metabolome differences between colorectal cancer patients and healthy adults |
|
|
|
| Stool microbiome and metabolome differences between colorectal cancer patients and healthy adults/Experiment 1 |
|
|
|
| Stool microbiome and metabolome differences between colorectal cancer patients and healthy adults/Experiment 1/Signature 1 |
|
|
|
| Stool microbiome and metabolome differences between colorectal cancer patients and healthy adults/Experiment 1/Signature 2 |
|
|
|
| Structural and functional profiles of the gut microbial community in polycystic ovary syndrome with insulin resistance (IR-PCOS): a pilot study |
|
|
|
| Structural and functional profiles of the gut microbial community in polycystic ovary syndrome with insulin resistance (IR-PCOS): a pilot study/Experiment 1 |
|
|
|
| Structural and functional profiles of the gut microbial community in polycystic ovary syndrome with insulin resistance (IR-PCOS): a pilot study/Experiment 1/Signature 1 |
|
|
|
| Structural and functional profiles of the gut microbial community in polycystic ovary syndrome with insulin resistance (IR-PCOS): a pilot study/Experiment 1/Signature 2 |
|
|
|
| Structural and functional profiles of the gut microbial community in polycystic ovary syndrome with insulin resistance (IR-PCOS): a pilot study/Experiment 2 |
|
|
|
| Structural and functional profiles of the gut microbial community in polycystic ovary syndrome with insulin resistance (IR-PCOS): a pilot study/Experiment 2/Signature 1 |
|
|
|
| Structural and functional profiles of the gut microbial community in polycystic ovary syndrome with insulin resistance (IR-PCOS): a pilot study/Experiment 2/Signature 2 |
|
|
|
| Structural and functional profiles of the gut microbial community in polycystic ovary syndrome with insulin resistance (IR-PCOS): a pilot study/Experiment 3 |
|
|
|
| Structural and functional profiles of the gut microbial community in polycystic ovary syndrome with insulin resistance (IR-PCOS): a pilot study/Experiment 3/Signature 1 |
|
|
|
| Structural and functional profiles of the gut microbial community in polycystic ovary syndrome with insulin resistance (IR-PCOS): a pilot study/Experiment 3/Signature 2 |
|
|
|
| Study 449 |
|
|
|
| Study 449/Experiment 1 |
|
|
|
| Study 449/Experiment 1/Signature 1 |
|
|
|
| Study 449/Experiment 1/Signature 2 |
|
|
|
| Study 501 |
|
|
|
| Study 501/Experiment 1 |
|
|
|
| Study 501/Experiment 1/Signature 1 |
|
|
|
| Study 513 |
|
|
|
| Study 513/Experiment 1 |
|
|
|
| Study 513/Experiment 1/Signature 1 |
|
|
|
| Study 513/Experiment 2 |
|
|
|
| Study 513/Experiment 2/Signature 1 |
|
|
|
| Study 562/Experiment 1/Signature 3 |
|
|
|
| Study 562/Experiment 4/Signature 2 |
|
|
|
| Study 562/Experiment 5/Signature 1 |
|
|
|
| Study 562/Experiment 5/Signature 2 |
|
|
|
| Study 562/Experiment 7/Signature 1 |
|
|
|
| Study 562/Experiment 8/Signature 1 |
|
|
|
| Study 562/Experiment 8/Signature 2 |
|
|
|
| Study 668 |
|
|
|
| Study of the diversity and short-chain fatty acids production by the bacterial community in overweight and obese Mexican children |
|
|
|
| Study of the diversity and short-chain fatty acids production by the bacterial community in overweight and obese Mexican children/Experiment 1 |
|
|
|
| Study of the diversity and short-chain fatty acids production by the bacterial community in overweight and obese Mexican children/Experiment 1/Signature 1 |
|
|
|
| Study of the diversity and short-chain fatty acids production by the bacterial community in overweight and obese Mexican children/Experiment 1/Signature 2 |
|
|
|
| Study of the diversity and short-chain fatty acids production by the bacterial community in overweight and obese Mexican children/Experiment 2 |
|
|
|
| Study of the diversity and short-chain fatty acids production by the bacterial community in overweight and obese Mexican children/Experiment 2/Signature 1 |
|
|
|
| Study of the diversity and short-chain fatty acids production by the bacterial community in overweight and obese Mexican children/Experiment 2/Signature 2 |
|
|
|
| Subgingival Microbial Changes During the First 3 Months of Fixed Appliance Treatment in Female Adult Patients |
|
|
|
| Subgingival Microbial Changes During the First 3 Months of Fixed Appliance Treatment in Female Adult Patients/Experiment 1 |
|
|
|
| Subgingival Microbial Changes During the First 3 Months of Fixed Appliance Treatment in Female Adult Patients/Experiment 1/Signature 1 |
|
|
|
| Subgingival Microbial Changes During the First 3 Months of Fixed Appliance Treatment in Female Adult Patients/Experiment 2 |
|
|
|
| Subgingival Microbial Changes During the First 3 Months of Fixed Appliance Treatment in Female Adult Patients/Experiment 2/Signature 1 |
|
|
|
| Subgingival Microbial Changes During the First 3 Months of Fixed Appliance Treatment in Female Adult Patients/Experiment 2/Signature 2 |
|
|
|
| Subgingival Microbiome in Rheumatoid Arthritis Patients with Periodontitis |
|
|
|
| Subgingival Microbiome in Rheumatoid Arthritis Patients with Periodontitis/Experiment 1 |
|
|
|
| Subgingival Microbiome in Rheumatoid Arthritis Patients with Periodontitis/Experiment 1/Signature 1 |
|
|
|
| Subgingival Microbiome in Rheumatoid Arthritis Patients with Periodontitis/Experiment 1/Signature 2 |
|
|
|
| Subgingival microbiome of deep and shallow periodontal sites in patients with rheumatoid arthritis: a pilot study |
|
|
|
| Subgingival microbiome of deep and shallow periodontal sites in patients with rheumatoid arthritis: a pilot study/Experiment 1 |
|
|
|
| Subgingival microbiome of deep and shallow periodontal sites in patients with rheumatoid arthritis: a pilot study/Experiment 1/Signature 1 |
|
|
|
| Subgingival microbiome of deep and shallow periodontal sites in patients with rheumatoid arthritis: a pilot study/Experiment 1/Signature 2 |
|
|
|
| Subgingival microbiome of rheumatoid arthritis patients in relation to their disease status and periodontal health |
|
|
|
| Subgingival microbiome of rheumatoid arthritis patients in relation to their disease status and periodontal health/Experiment 1 |
|
|
|
| Subgingival microbiome of rheumatoid arthritis patients in relation to their disease status and periodontal health/Experiment 1/Signature 1 |
|
|
|
| Subgingival microbiome of rheumatoid arthritis patients in relation to their disease status and periodontal health/Experiment 1/Signature 2 |
|
|
|
| Subgingival Microbiota during Healthy Pregnancy and Pregnancy Gingivitis/Experiment 3 |
|
|
|
| Subgingival Microbiota during Healthy Pregnancy and Pregnancy Gingivitis/Experiment 3/Signature 1 |
|
|
|
| Subgingival Microbiota during Healthy Pregnancy and Pregnancy Gingivitis/Experiment 3/Signature 2 |
|
|
|
| Subgingival Microbiota during Healthy Pregnancy and Pregnancy Gingivitis/Experiment 4 |
|
|
|
| Subgingival Microbiota during Healthy Pregnancy and Pregnancy Gingivitis/Experiment 4/Signature 1 |
|
|
|
| Subgingival Microbiota during Healthy Pregnancy and Pregnancy Gingivitis/Experiment 4/Signature 2 |
|
|
|
| Suppression of the gut microbiome ameliorates age-related arterial dysfunction and oxidative stress in mice |
|
|
|
| Taxonomic and Functional Differences in Cervical Microbiome Associated with Cervical Cancer Development |
|
|
|
| Taxonomic and Functional Differences in Cervical Microbiome Associated with Cervical Cancer Development/Experiment 1 |
|
|
|
| Taxonomic and Functional Differences in Cervical Microbiome Associated with Cervical Cancer Development/Experiment 1/Signature 1 |
|
|
|
| Temporal association between human upper respiratory and gut bacterial microbiomes during the course of COVID-19 in adults |
|
|
|
| Temporal association between human upper respiratory and gut bacterial microbiomes during the course of COVID-19 in adults/Experiment 1 |
|
|
|
| Temporal association between human upper respiratory and gut bacterial microbiomes during the course of COVID-19 in adults/Experiment 2 |
|
|
|
| Temporal association between human upper respiratory and gut bacterial microbiomes during the course of COVID-19 in adults/Experiment 3 |
|
|
|
| Temporal association between human upper respiratory and gut bacterial microbiomes during the course of COVID-19 in adults/Experiment 4 |
|
|
|
| Temporal association between human upper respiratory and gut bacterial microbiomes during the course of COVID-19 in adults/Experiment 5 |
|
|
|
| Temporal association between human upper respiratory and gut bacterial microbiomes during the course of COVID-19 in adults/Experiment 6 |
|
|
|
| Temporal association between human upper respiratory and gut bacterial microbiomes during the course of COVID-19 in adults/Experiment 7 |
|
|
|
| Temporal changes in gut microbiota profile in children with acute lymphoblastic leukemia prior to commencement-, during-, and post-cessation of chemotherapy |
|
|
|
| Temporal changes in gut microbiota profile in children with acute lymphoblastic leukemia prior to commencement-, during-, and post-cessation of chemotherapy/Experiment 1 |
|
|
|
| Temporal changes in gut microbiota profile in children with acute lymphoblastic leukemia prior to commencement-, during-, and post-cessation of chemotherapy/Experiment 1/Signature 1 |
|
|
|
| Temporal changes in gut microbiota profile in children with acute lymphoblastic leukemia prior to commencement-, during-, and post-cessation of chemotherapy/Experiment 1/Signature 2 |
|
|
|
| Temporal changes in gut microbiota profile in children with acute lymphoblastic leukemia prior to commencement-, during-, and post-cessation of chemotherapy/Experiment 1/Signature 3 |
|
|
|
| Temporal changes in gut microbiota profile in children with acute lymphoblastic leukemia prior to commencement-, during-, and post-cessation of chemotherapy/Experiment 1/Signature 4 |
|
|
|
| The Alteration in Composition and Function of Gut Microbiome in Patients with Type 2 Diabetes |
|
|
|
| The Alteration in Composition and Function of Gut Microbiome in Patients with Type 2 Diabetes/Experiment 1 |
|
|
|
| The Alteration in Composition and Function of Gut Microbiome in Patients with Type 2 Diabetes/Experiment 1/Signature 1 |
|
|
|
| The Alteration in Composition and Function of Gut Microbiome in Patients with Type 2 Diabetes/Experiment 1/Signature 2 |
|
|
|
| The alteration of gut microbiome and metabolism in amyotrophic lateral sclerosis patients |
|
|
|
| The alteration of gut microbiome and metabolism in amyotrophic lateral sclerosis patients/Experiment 1 |
|
|
|
| The alteration of gut microbiome and metabolism in amyotrophic lateral sclerosis patients/Experiment 1/Signature 1 |
|
|
|
| The alteration of gut microbiome and metabolism in amyotrophic lateral sclerosis patients/Experiment 1/Signature 2 |
|
|
|
| The Alterations of Vaginal Microbiome in HPV16 Infection as Identified by Shotgun Metagenomic Sequencing |
|
|
|
| The Alterations of Vaginal Microbiome in HPV16 Infection as Identified by Shotgun Metagenomic Sequencing/Experiment 1 |
|
|
|
| The Alterations of Vaginal Microbiome in HPV16 Infection as Identified by Shotgun Metagenomic Sequencing/Experiment 1/Signature 1 |
|
|
|
| The Association Between Gestational Diabetes and Microbiota in Placenta and Cord Blood |
|
|
|
| The Association Between Gestational Diabetes and Microbiota in Placenta and Cord Blood/Experiment 1 |
|
|
|
| The Association Between Gestational Diabetes and Microbiota in Placenta and Cord Blood/Experiment 1/Signature 1 |
|
|
|
| The Association Between Gestational Diabetes and Microbiota in Placenta and Cord Blood/Experiment 1/Signature 2 |
|
|
|
| The Association Between Smoking and Gut Microbiome in Bangladesh |
|
|
|
| The Association Between Smoking and Gut Microbiome in Bangladesh/Experiment 1 |
|
|
|
| The Association Between Smoking and Gut Microbiome in Bangladesh/Experiment 1/Signature 1 |
|
|
|
| The Association Between Smoking and Gut Microbiome in Bangladesh/Experiment 1/Signature 2 |
|
|
|
| The Association Between Smoking and Gut Microbiome in Bangladesh/Experiment 1/Signature 3 |
|
|
|
| The Associations between Diet and Socioeconomic Disparities and the Intestinal Microbiome in Preadolescence |
|
|
|
| The Associations between Diet and Socioeconomic Disparities and the Intestinal Microbiome in Preadolescence/Experiment 1 |
|
|
|
| The Associations between Diet and Socioeconomic Disparities and the Intestinal Microbiome in Preadolescence/Experiment 1/Signature 1 |
|
|
|
| The Associations between Diet and Socioeconomic Disparities and the Intestinal Microbiome in Preadolescence/Experiment 1/Signature 2 |
|
|
|
| The Bacterial Gut Microbiota of Schoolchildren from High and Low Socioeconomic Status: A Study in an Urban Area of Makassar, Indonesia |
|
|
|
| The Bacterial Gut Microbiota of Schoolchildren from High and Low Socioeconomic Status: A Study in an Urban Area of Makassar, Indonesia/Experiment 1 |
|
|
|
| The Bacterial Gut Microbiota of Schoolchildren from High and Low Socioeconomic Status: A Study in an Urban Area of Makassar, Indonesia/Experiment 1/Signature 1 |
|
|
|
| The Bacterial Gut Microbiota of Schoolchildren from High and Low Socioeconomic Status: A Study in an Urban Area of Makassar, Indonesia/Experiment 1/Signature 2 |
|
|
|
| The biodiversity Composition of Microbiome in Ovarian Carcinoma Patients |
|
|
|
| The biodiversity Composition of Microbiome in Ovarian Carcinoma Patients/Experiment 1 |
|
|
|
| The biodiversity Composition of Microbiome in Ovarian Carcinoma Patients/Experiment 1/Signature 1 |
|
|
|
| The biodiversity Composition of Microbiome in Ovarian Carcinoma Patients/Experiment 1/Signature 2 |
|
|
|
| The circulating microbiome signature and inferred functional metagenomics in alcoholic hepatitis |
|
|
|
| The circulating microbiome signature and inferred functional metagenomics in alcoholic hepatitis/Experiment 1 |
|
|
|
| The circulating microbiome signature and inferred functional metagenomics in alcoholic hepatitis/Experiment 1/Signature 1 |
|
|
|
| The circulating microbiome signature and inferred functional metagenomics in alcoholic hepatitis/Experiment 1/Signature 2 |
|
|
|
| The circulating microbiome signature and inferred functional metagenomics in alcoholic hepatitis/Experiment 2 |
|
|
|
| The circulating microbiome signature and inferred functional metagenomics in alcoholic hepatitis/Experiment 2/Signature 1 |
|
|
|
| The circulating microbiome signature and inferred functional metagenomics in alcoholic hepatitis/Experiment 2/Signature 2 |
|
|
|
| The circulating microbiome signature and inferred functional metagenomics in alcoholic hepatitis/Experiment 3 |
|
|
|
| The circulating microbiome signature and inferred functional metagenomics in alcoholic hepatitis/Experiment 3/Signature 1 |
|
|
|
| The circulating microbiome signature and inferred functional metagenomics in alcoholic hepatitis/Experiment 3/Signature 2 |
|
|
|
| The circulating microbiome signature and inferred functional metagenomics in alcoholic hepatitis/Experiment 4 |
|
|
|
| The circulating microbiome signature and inferred functional metagenomics in alcoholic hepatitis/Experiment 4/Signature 1 |
|
|
|
| The circulating microbiome signature and inferred functional metagenomics in alcoholic hepatitis/Experiment 4/Signature 2 |
|
|
|
| The clinical outcomes of medical therapies in chronic rhinosinusitis are independent of microbiomic outcomes: a double-blinded, randomised placebo-controlled trial |
|
|
|
| The clinical outcomes of medical therapies in chronic rhinosinusitis are independent of microbiomic outcomes: a double-blinded, randomised placebo-controlled trial |
|
|
|
| The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients/Experiment 3/Signature 1 |
|
|
|
| The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients/Experiment 3/Signature 2 |
|
|
|
| The differential distribution of bacteria between cancerous and noncancerous ovarian tissues in situ |
|
|
|
| The differential distribution of bacteria between cancerous and noncancerous ovarian tissues in situ/Experiment 1 |
|
|
|
| The Diversity of Gut Microbiome is Associated With Favorable Responses to Anti-Programmed Death 1 Immunotherapy in Chinese Patients With NSCLC/Experiment 1/Signature 1 |
|
|
|
| The East Asian gut microbiome is distinct from colocalized White subjects and connected to metabolic health |
|
|
|
| The East Asian gut microbiome is distinct from colocalized White subjects and connected to metabolic health/Experiment 1 |
|
|
|
| The East Asian gut microbiome is distinct from colocalized White subjects and connected to metabolic health/Experiment 1/Signature 1 |
|
|
|
| The East Asian gut microbiome is distinct from colocalized White subjects and connected to metabolic health/Experiment 1/Signature 2 |
|
|
|
| The Endobiota Study: Comparison of Vaginal, Cervical and Gut Microbiota Between Women with Stage 3/4 Endometriosis and Healthy Controls |
|
|
|
| The Endobiota Study: Comparison of Vaginal, Cervical and Gut Microbiota Between Women with Stage 3/4 Endometriosis and Healthy Controls/Experiment 1 |
|
|
|
| The Endobiota Study: Comparison of Vaginal, Cervical and Gut Microbiota Between Women with Stage 3/4 Endometriosis and Healthy Controls/Experiment 1/Signature 1 |
|
|
|
| The Endobiota Study: Comparison of Vaginal, Cervical and Gut Microbiota Between Women with Stage 3/4 Endometriosis and Healthy Controls/Experiment 2 |
|
|
|
| The Endobiota Study: Comparison of Vaginal, Cervical and Gut Microbiota Between Women with Stage 3/4 Endometriosis and Healthy Controls/Experiment 2/Signature 1 |
|
|
|
| The Endobiota Study: Comparison of Vaginal, Cervical and Gut Microbiota Between Women with Stage 3/4 Endometriosis and Healthy Controls/Experiment 2/Signature 2 |
|
|
|
| The Endobiota Study: Comparison of Vaginal, Cervical and Gut Microbiota Between Women with Stage 3/4 Endometriosis and Healthy Controls/Experiment 3 |
|
|
|
| The Endobiota Study: Comparison of Vaginal, Cervical and Gut Microbiota Between Women with Stage 3/4 Endometriosis and Healthy Controls/Experiment 3/Signature 1 |
|
|
|
| The Endobiota Study: Comparison of Vaginal, Cervical and Gut Microbiota Between Women with Stage 3/4 Endometriosis and Healthy Controls/Experiment 4 |
|
|
|
| The Endobiota Study: Comparison of Vaginal, Cervical and Gut Microbiota Between Women with Stage 3/4 Endometriosis and Healthy Controls/Experiment 4/Signature 1 |
|
|
|
| The Endobiota Study: Comparison of Vaginal, Cervical and Gut Microbiota Between Women with Stage 3/4 Endometriosis and Healthy Controls/Experiment 5 |
|
|
|
| The Endobiota Study: Comparison of Vaginal, Cervical and Gut Microbiota Between Women with Stage 3/4 Endometriosis and Healthy Controls/Experiment 5/Signature 1 |
|
|
|
| The Endobiota Study: Comparison of Vaginal, Cervical and Gut Microbiota Between Women with Stage 3/4 Endometriosis and Healthy Controls/Experiment 5/Signature 2 |
|
|
|
| The Gastric Microbiome Is Perturbed in Advanced Gastric Adenocarcinoma Identified Through Shotgun Metagenomics |
|
|
|
| The Gastric Microbiome Is Perturbed in Advanced Gastric Adenocarcinoma Identified Through Shotgun Metagenomics/Experiment 1 |
|
|
|
| The Gastric Microbiome Is Perturbed in Advanced Gastric Adenocarcinoma Identified Through Shotgun Metagenomics/Experiment 1/Signature 1 |
|
|
|
| The Gastric Microbiome Is Perturbed in Advanced Gastric Adenocarcinoma Identified Through Shotgun Metagenomics/Experiment 1/Signature 2 |
|
|
|
| The gut microbiome and inflammation in obsessive-compulsive disorder patients compared to age- and sex-matched controls: a pilot study |
|
|
|
| The gut microbiome composition associates with bipolar disorder and illness severity |
|
|
|
| The gut microbiome composition associates with bipolar disorder and illness severity/Experiment 1 |
|
|
|
| The gut microbiome composition associates with bipolar disorder and illness severity/Experiment 1/Signature 1 |
|
|
|
| The gut microbiome of Mexican children affected by obesity |
|
|
|
| The gut microbiome of Mexican children affected by obesity |
|
|
|
| The gut microbiome of Mexican children affected by obesity/Experiment 1 |
|
|
|
| The gut microbiome of Mexican children affected by obesity/Experiment 1 |
|
|
|
| The gut microbiome of Mexican children affected by obesity/Experiment 1/Signature 1 |
|
|
|
| The gut microbiome of Mexican children affected by obesity/Experiment 1/Signature 1 |
|
|
|
| The gut microbiome of Mexican children affected by obesity/Experiment 1/Signature 2 |
|
|
|
| The gut microbiome of Mexican children affected by obesity/Experiment 1/Signature 2 |
|
|
|
| The Gut Microbiome Signatures Discriminate Healthy From Pulmonary Tuberculosis Patients |
|
|
|
| The Gut Microbiome Signatures Discriminate Healthy From Pulmonary Tuberculosis Patients/Experiment 1 |
|
|
|
| The Gut Microbiome Signatures Discriminate Healthy From Pulmonary Tuberculosis Patients/Experiment 1/Signature 1 |
|
|
|
| The Gut Microbiome Signatures Discriminate Healthy From Pulmonary Tuberculosis Patients/Experiment 1/Signature 2 |
|
|
|
| The gut microbiota is associated with psychiatric symptom severity and treatment outcome among individuals with serious mental illness |
|
|
|
| The gut microbiota is associated with psychiatric symptom severity and treatment outcome among individuals with serious mental illness/Experiment 1 |
|
|
|
| The gut microbiota is associated with psychiatric symptom severity and treatment outcome among individuals with serious mental illness/Experiment 1/Signature 1 |
|
|
|
| The gut microbiota is associated with psychiatric symptom severity and treatment outcome among individuals with serious mental illness/Experiment 1/Signature 2 |
|
|
|
| The gut microbiota is associated with psychiatric symptom severity and treatment outcome among individuals with serious mental illness/Experiment 2 |
|
|
|
| The gut microbiota is associated with psychiatric symptom severity and treatment outcome among individuals with serious mental illness/Experiment 2/Signature 1 |
|
|
|
| The gut microbiota is associated with psychiatric symptom severity and treatment outcome among individuals with serious mental illness/Experiment 3 |
|
|
|
| The gut microbiota is associated with psychiatric symptom severity and treatment outcome among individuals with serious mental illness/Experiment 3/Signature 1 |
|
|
|
| The gut microbiota is associated with psychiatric symptom severity and treatment outcome among individuals with serious mental illness/Experiment 3/Signature 2 |
|
|
|
| The gut microbiota is associated with psychiatric symptom severity and treatment outcome among individuals with serious mental illness/Experiment 4 |
|
|
|
| The gut microbiota is associated with psychiatric symptom severity and treatment outcome among individuals with serious mental illness/Experiment 4/Signature 1 |
|
|
|
| The gut microbiota of Colombians differs from that of Americans, Europeans and Asians |
|
|
|
| The gut microbiota of Colombians differs from that of Americans, Europeans and Asians/Experiment 1 |
|
|
|
| The gut microbiota of Colombians differs from that of Americans, Europeans and Asians/Experiment 1/Signature 1 |
|
|
|
| The gut microbiota of Colombians differs from that of Americans, Europeans and Asians/Experiment 1/Signature 2 |
|
|
|
| The gut microbiota of Colombians differs from that of Americans, Europeans and Asians/Experiment 2 |
|
|
|
| The gut microbiota of Colombians differs from that of Americans, Europeans and Asians/Experiment 2/Signature 1 |
|
|
|
| The gut microbiota of Colombians differs from that of Americans, Europeans and Asians/Experiment 2/Signature 2 |
|
|
|
| The gut microbiota of Colombians differs from that of Americans, Europeans and Asians/Experiment 3 |
|
|
|
| The gut microbiota of Colombians differs from that of Americans, Europeans and Asians/Experiment 3/Signature 1 |
|
|
|
| The gut microbiota of Colombians differs from that of Americans, Europeans and Asians/Experiment 3/Signature 2 |
|
|
|
| The gut microbiota of Colombians differs from that of Americans, Europeans and Asians/Experiment 4 |
|
|
|
| The gut microbiota of Colombians differs from that of Americans, Europeans and Asians/Experiment 4/Signature 1 |
|
|
|
| The gut microbiota of Colombians differs from that of Americans, Europeans and Asians/Experiment 4/Signature 2 |
|
|
|
| The human gut microbiome as a screening tool for colorectal cancer |
|
|
|
| The human gut microbiome as a screening tool for colorectal cancer/Experiment 1 |
|
|
|
| The human gut microbiome as a screening tool for colorectal cancer/Experiment 1/Signature 1 |
|
|
|
| The human gut microbiome as a screening tool for colorectal cancer/Experiment 1/Signature 2 |
|
|
|
| The imbalance of gut microbiota and its correlation with plasma inflammatory cytokines in pemphigus vulgaris patients |
|
|
|
| The impact of NBUVB on microbial community profiling in the lesional skin of vitiligo subjects |
|
|
|
| The impact of NBUVB on microbial community profiling in the lesional skin of vitiligo subjects/Experiment 1 |
|
|
|
| The impact of NBUVB on microbial community profiling in the lesional skin of vitiligo subjects/Experiment 2 |
|
|
|
| The impact of NBUVB on microbial community profiling in the lesional skin of vitiligo subjects/Experiment 3 |
|
|
|
| The impact of postnatal antibiotics on the preterm intestinal microbiome |
|
|
|
| The impact of postnatal antibiotics on the preterm intestinal microbiome/Experiment 1 |
|
|
|
| The impact of postnatal antibiotics on the preterm intestinal microbiome/Experiment 1/Signature 1 |
|
|
|
| The influence of in vitro pectin fermentation on the human fecal microbiome |
|
|
|
| The influence of in vitro pectin fermentation on the human fecal microbiome/Experiment 1 |
|
|
|
| The influence of in vitro pectin fermentation on the human fecal microbiome/Experiment 1/Signature 1 |
|
|
|
| The influence of in vitro pectin fermentation on the human fecal microbiome/Experiment 1/Signature 2 |
|
|
|
| The Intestinal Microbiota in Acute Anorexia Nervosa and During Renourishment: Relationship to Depression, Anxiety, and Eating Disorder Psychopathology |
|
|
|
| The Intestinal Microbiota in Acute Anorexia Nervosa and During Renourishment: Relationship to Depression, Anxiety, and Eating Disorder Psychopathology/Experiment 1 |
|
|
|
| The Intestinal Microbiota in Acute Anorexia Nervosa and During Renourishment: Relationship to Depression, Anxiety, and Eating Disorder Psychopathology/Experiment 1/Signature 1 |
|
|
|
| The Intestinal Microbiota in Acute Anorexia Nervosa and During Renourishment: Relationship to Depression, Anxiety, and Eating Disorder Psychopathology/Experiment 1/Signature 2 |
|
|
|
| The Intestinal Microbiota in Acute Anorexia Nervosa and During Renourishment: Relationship to Depression, Anxiety, and Eating Disorder Psychopathology/Experiment 2 |
|
|
|
| The Intestinal Microbiota in Acute Anorexia Nervosa and During Renourishment: Relationship to Depression, Anxiety, and Eating Disorder Psychopathology/Experiment 2/Signature 1 |
|
|
|
| The intestinal microflora in allergic Estonian and Swedish 2-year-old children |
|
|
|
| The intestinal microflora in allergic Estonian and Swedish 2-year-old children/Experiment 1 |
|
|
|
| The intestinal microflora in allergic Estonian and Swedish 2-year-old children/Experiment 1/Signature 1 |
|
|
|
| The intestinal microflora in allergic Estonian and Swedish 2-year-old children/Experiment 1/Signature 2 |
|
|
|
| The ketogenic diet influences taxonomic and functional composition of the gut microbiota in children with severe epilepsy |
|
|
|
| The ketogenic diet influences taxonomic and functional composition of the gut microbiota in children with severe epilepsy/Experiment 1 |
|
|
|
| The ketogenic diet influences taxonomic and functional composition of the gut microbiota in children with severe epilepsy/Experiment 1/Signature 1 |
|
|
|
| The ketogenic diet influences taxonomic and functional composition of the gut microbiota in children with severe epilepsy/Experiment 1/Signature 2 |
|
|
|
| The lower respiratory tract microbiome of critically ill patients with COVID-19 |
|
|
|
| The lower respiratory tract microbiome of critically ill patients with COVID-19/Experiment 1 |
|
|
|
| The lower respiratory tract microbiome of critically ill patients with COVID-19/Experiment 1/Signature 1 |
|
|
|
| The lower respiratory tract microbiome of critically ill patients with COVID-19/Experiment 1/Signature 2 |
|
|
|
| The Microbiome of Prostate Fluid Is Associated With Prostate Cancer |
|
|
|
| The Microbiome of Prostate Fluid Is Associated With Prostate Cancer |
|
|
|
| The Microbiome of Prostate Fluid Is Associated With Prostate Cancer/Experiment 1 |
|
|
|
| The Microbiome of Prostate Fluid Is Associated With Prostate Cancer/Experiment 1 |
|
|
|
| The Microbiome of Prostate Fluid Is Associated With Prostate Cancer/Experiment 1/Signature 1 |
|
|
|
| The Microbiome of Prostate Fluid Is Associated With Prostate Cancer/Experiment 1/Signature 1 |
|
|
|
| The Microbiome of Prostate Fluid Is Associated With Prostate Cancer/Experiment 1/Signature 2 |
|
|
|
| The Microbiome of Prostate Fluid Is Associated With Prostate Cancer/Experiment 1/Signature 2 |
|
|
|
| The microbiota of the gut in preschool children with normal and excessive body weight |
|
|
|
| The microbiota of the gut in preschool children with normal and excessive body weight/Experiment 1 |
|
|
|
| The microbiota of the gut in preschool children with normal and excessive body weight/Experiment 1/Signature 1 |
|
|
|
| The microbiota of the gut in preschool children with normal and excessive body weight/Experiment 1/Signature 2 |
|
|
|
| The nasal microbiome in asthma/Experiment 1 |
|
|
|
| The nasal microbiome in asthma/Experiment 1/Signature 1 |
|
|
|
| The nasal microbiome in asthma/Experiment 2 |
|
|
|
| The nasal microbiome in asthma/Experiment 2/Signature 1 |
|
|
|
| The nasal microbiome in asthma/Experiment 4 |
|
|
|
| The nasal microbiome in asthma/Experiment 4/Signature 1 |
|
|
|
| The oral microbiome of early stage Parkinson's disease and its relationship with functional measures of motor and non-motor function/Experiment 1/Signature 1 |
|
|
|
| The oral microbiome of early stage Parkinson's disease and its relationship with functional measures of motor and non-motor function/Experiment 1/Signature 2 |
|
|
|
| The oral microbiome of patients undergoing treatment for severe aplastic anemia: a pilot study |
|
|
|
| The oral microbiome of patients undergoing treatment for severe aplastic anemia: a pilot study/Experiment 1 |
|
|
|
| The oral microbiome of patients undergoing treatment for severe aplastic anemia: a pilot study/Experiment 1/Signature 1 |
|
|
|
| The oral microbiome of patients undergoing treatment for severe aplastic anemia: a pilot study/Experiment 2 |
|
|
|
| The oral microbiome of patients undergoing treatment for severe aplastic anemia: a pilot study/Experiment 2/Signature 1 |
|
|
|
| The oral microbiome of patients undergoing treatment for severe aplastic anemia: a pilot study/Experiment 3 |
|
|
|
| The oral microbiome of patients undergoing treatment for severe aplastic anemia: a pilot study/Experiment 3/Signature 1 |
|
|
|
| The oral microbiome of patients undergoing treatment for severe aplastic anemia: a pilot study/Experiment 4 |
|
|
|
| The oral microbiome of patients undergoing treatment for severe aplastic anemia: a pilot study/Experiment 4/Signature 1 |
|
|
|
| The oral microbiota in colorectal cancer is distinctive and predictive |
|
|
|
| The oral microbiota in colorectal cancer is distinctive and predictive/Experiment 1 |
|
|
|
| The oral microbiota in colorectal cancer is distinctive and predictive/Experiment 1/Signature 1 |
|
|
|
| The oral microbiota in colorectal cancer is distinctive and predictive/Experiment 1/Signature 2 |
|
|
|
| The oropharyngeal microbiome is altered in individuals with schizophrenia and mania |
|
|
|
| The oropharyngeal microbiome is altered in individuals with schizophrenia and mania/Experiment 1 |
|
|
|
| The oropharyngeal microbiome is altered in individuals with schizophrenia and mania/Experiment 1/Signature 1 |
|
|
|
| The oropharyngeal microbiome is altered in individuals with schizophrenia and mania/Experiment 1/Signature 2 |
|
|
|
| The oropharyngeal microbiome is altered in individuals with schizophrenia and mania/Experiment 2 |
|
|
|
| The oropharyngeal microbiome is altered in individuals with schizophrenia and mania/Experiment 2/Signature 1 |
|
|
|
| The oropharyngeal microbiome is altered in individuals with schizophrenia and mania/Experiment 2/Signature 2 |
|
|
|
| The Performance of an Oral Microbiome Biomarker Panel in Predicting Oral Cavity and Oropharyngeal Cancers |
|
|
|
| The Performance of an Oral Microbiome Biomarker Panel in Predicting Oral Cavity and Oropharyngeal Cancers/Experiment 1 |
|
|
|
| The Performance of an Oral Microbiome Biomarker Panel in Predicting Oral Cavity and Oropharyngeal Cancers/Experiment 1/Signature 1 |
|
|
|
| The Performance of an Oral Microbiome Biomarker Panel in Predicting Oral Cavity and Oropharyngeal Cancers/Experiment 2 |
|
|
|
| The Performance of an Oral Microbiome Biomarker Panel in Predicting Oral Cavity and Oropharyngeal Cancers/Experiment 2/Signature 1 |
|
|
|
| The Performance of an Oral Microbiome Biomarker Panel in Predicting Oral Cavity and Oropharyngeal Cancers/Experiment 2/Signature 2 |
|
|
|
| The potential of fecal microbiota and amino acids to detect and monitor patients with adenoma |
|
|
|
| The potential of fecal microbiota and amino acids to detect and monitor patients with adenoma/Experiment 1 |
|
|
|
| The potential of fecal microbiota and amino acids to detect and monitor patients with adenoma/Experiment 1/Signature 1 |
|
|
|
| The potential of fecal microbiota and amino acids to detect and monitor patients with adenoma/Experiment 1/Signature 2 |
|
|
|
| The potential of fecal microbiota and amino acids to detect and monitor patients with adenoma/Experiment 2 |
|
|
|
| The potential of fecal microbiota and amino acids to detect and monitor patients with adenoma/Experiment 3 |
|
|
|
| The potential of fecal microbiota and amino acids to detect and monitor patients with adenoma/Experiment 3/Signature 1 |
|
|
|
| The potential of fecal microbiota and amino acids to detect and monitor patients with adenoma/Experiment 3/Signature 2 |
|
|
|
| The potential of fecal microbiota and amino acids to detect and monitor patients with adenoma/Experiment 4 |
|
|
|
| The potential of fecal microbiota and amino acids to detect and monitor patients with adenoma/Experiment 4/Signature 1 |
|
|
|
| The potential of fecal microbiota and amino acids to detect and monitor patients with adenoma/Experiment 4/Signature 2 |
|
|
|
| The potential of fecal microbiota and amino acids to detect and monitor patients with adenoma/Experiment 5 |
|
|
|
| The potential of fecal microbiota and amino acids to detect and monitor patients with adenoma/Experiment 5/Signature 1 |
|
|
|
| The potential of fecal microbiota and amino acids to detect and monitor patients with adenoma/Experiment 5/Signature 2 |
|
|
|
| The potential of fecal microbiota and amino acids to detect and monitor patients with adenoma/Experiment 5/Signature 3 |
|
|
|
| The relationship between cigarette smoking and the tongue microbiome in an East Asian population |
|
|
|
| The relationship between cigarette smoking and the tongue microbiome in an East Asian population/Experiment 1 |
|
|
|
| The relationship between cigarette smoking and the tongue microbiome in an East Asian population/Experiment 1/Signature 1 |
|
|
|
| The relationship between cigarette smoking and the tongue microbiome in an East Asian population/Experiment 1/Signature 2 |
|
|
|
| The role of the gut microbiome on the efficacy of immune checkpoint inhibitors in Japanese responder patients with advanced non-small cell lung cancer/Experiment 1/Signature 1 |
|
|
|
| The role of the gut microbiome on the efficacy of immune checkpoint inhibitors in Japanese responder patients with advanced non-small cell lung cancer/Experiment 1/Signature 2 |
|
|
|
| The role of the vaginal microbiome in distinguishing female chronic pelvic pain caused by endometriosis/adenomyosis |
|
|
|
| The role of the vaginal microbiome in distinguishing female chronic pelvic pain caused by endometriosis/adenomyosis/Experiment 1 |
|
|
|
| The role of the vaginal microbiome in distinguishing female chronic pelvic pain caused by endometriosis/adenomyosis/Experiment 1/Signature 1 |
|
|
|
| The role of the vaginal microbiome in distinguishing female chronic pelvic pain caused by endometriosis/adenomyosis/Experiment 1/Signature 2 |
|
|
|
| The role of the vaginal microbiome in distinguishing female chronic pelvic pain caused by endometriosis/adenomyosis/Experiment 2 |
|
|
|
| The role of the vaginal microbiome in distinguishing female chronic pelvic pain caused by endometriosis/adenomyosis/Experiment 2/Signature 1 |
|
|
|
| The role of the vaginal microbiome in distinguishing female chronic pelvic pain caused by endometriosis/adenomyosis/Experiment 2/Signature 2 |
|
|
|
| The salivary microbiome as an indicator of carcinogenesis in patients with oropharyngeal squamous cell carcinoma: A pilot study |
|
|
|
| The salivary microbiome as an indicator of carcinogenesis in patients with oropharyngeal squamous cell carcinoma: A pilot study/Experiment 1 |
|
|
|
| The salivary microbiome as an indicator of carcinogenesis in patients with oropharyngeal squamous cell carcinoma: A pilot study/Experiment 1/Signature 1 |
|
|
|
| The salivary microbiome as an indicator of carcinogenesis in patients with oropharyngeal squamous cell carcinoma: A pilot study/Experiment 1/Signature 2 |
|
|
|
| The salivary microbiome as an indicator of carcinogenesis in patients with oropharyngeal squamous cell carcinoma: A pilot study/Experiment 2 |
|
|
|
| The salivary microbiome as an indicator of carcinogenesis in patients with oropharyngeal squamous cell carcinoma: A pilot study/Experiment 2/Signature 1 |
|
|
|
| The salivary microbiome as an indicator of carcinogenesis in patients with oropharyngeal squamous cell carcinoma: A pilot study/Experiment 2/Signature 2 |
|
|
|
| The semen microbiome and its relationship with local immunology and viral load in HIV infection/Experiment 1/Signature 1 |
|
|
|
| The skin microbiome is different in pediatric versus adult atopic dermatitis |
|
|
|
| The skin microbiome is different in pediatric versus adult atopic dermatitis/Experiment 1 |
|
|
|
| The skin microbiome is different in pediatric versus adult atopic dermatitis/Experiment 1/Signature 1 |
|
|
|
| The skin microbiome is different in pediatric versus adult atopic dermatitis/Experiment 1/Signature 2 |
|
|
|
| The skin microbiome is different in pediatric versus adult atopic dermatitis/Experiment 1/Signature 3 |
|
|
|
| The skin microbiome is different in pediatric versus adult atopic dermatitis/Experiment 1/Signature 4 |
|
|
|
| The skin microbiome is different in pediatric versus adult atopic dermatitis/Experiment 2 |
|
|
|
| The skin microbiome is different in pediatric versus adult atopic dermatitis/Experiment 2/Signature 1 |
|
|
|
| The skin microbiome is different in pediatric versus adult atopic dermatitis/Experiment 2/Signature 2 |
|
|
|
| The skin microbiome is different in pediatric versus adult atopic dermatitis/Experiment 3 |
|
|
|
| The skin microbiome is different in pediatric versus adult atopic dermatitis/Experiment 3/Signature 1 |
|
|
|
| The skin microbiome is different in pediatric versus adult atopic dermatitis/Experiment 3/Signature 2 |
|
|
|
| The skin microbiome is different in pediatric versus adult atopic dermatitis/Experiment 3/Signature 3 |
|
|
|
| The skin microbiome is different in pediatric versus adult atopic dermatitis/Experiment 3/Signature 4 |
|
|
|
| The skin microbiome is different in pediatric versus adult atopic dermatitis/Experiment 4 |
|
|
|
| The skin microbiome is different in pediatric versus adult atopic dermatitis/Experiment 4/Signature 1 |
|
|
|
| The skin microbiome is different in pediatric versus adult atopic dermatitis/Experiment 5 |
|
|
|
| The skin microbiome is different in pediatric versus adult atopic dermatitis/Experiment 5/Signature 1 |
|
|
|
| The skin microbiome is different in pediatric versus adult atopic dermatitis/Experiment 6 |
|
|
|
| The skin microbiome is different in pediatric versus adult atopic dermatitis/Experiment 6/Signature 1 |
|
|
|
| The skin microbiome is different in pediatric versus adult atopic dermatitis/Experiment 7 |
|
|
|
| The skin microbiome is different in pediatric versus adult atopic dermatitis/Experiment 7/Signature 1 |
|
|
|
| The skin microbiome is different in pediatric versus adult atopic dermatitis/Experiment 7/Signature 2 |
|
|
|
| The skin microbiome is different in pediatric versus adult atopic dermatitis/Experiment 7/Signature 3 |
|
|
|
| The skin microbiome is different in pediatric versus adult atopic dermatitis/Experiment 7/Signature 4 |
|
|
|
| The subgingival microbiome in patients with established rheumatoid arthritis |
|
|
|
| The subgingival microbiome in patients with established rheumatoid arthritis/Experiment 1 |
|
|
|
| The subgingival microbiome in patients with established rheumatoid arthritis/Experiment 1/Signature 1 |
|
|
|
| The Vaginal Microbiome as a Tool to Predict rASRM Stage of Disease in Endometriosis: a Pilot Study |
|
|
|
| The Vaginal Microbiome as a Tool to Predict rASRM Stage of Disease in Endometriosis: a Pilot Study/Experiment 1 |
|
|
|
| The Vaginal Microbiome as a Tool to Predict rASRM Stage of Disease in Endometriosis: a Pilot Study/Experiment 1/Signature 1 |
|
|
|
| Tongue microbiome of smokeless tobacco users |
|
|
|
| Tongue microbiome of smokeless tobacco users/Experiment 1 |
|
|
|
| Tongue microbiome of smokeless tobacco users/Experiment 1/Signature 1 |
|
|
|
| Tongue microbiome of smokeless tobacco users/Experiment 1/Signature 2 |
|
|
|
| Tumour-associated and non-tumour-associated microbiota in colorectal cancer |
|
|
|
| Tumour-associated and non-tumour-associated microbiota in colorectal cancer/Experiment 1 |
|
|
|
| Twice-daily application of HIV microbicides alter the vaginal microbiota |
|
|
|
| Twice-daily application of HIV microbicides alter the vaginal microbiota/Experiment 1 |
|
|
|
| Twice-daily application of HIV microbicides alter the vaginal microbiota/Experiment 1/Signature 1 |
|
|
|
| Unique Gut Microbiome in HIV Patients on Antiretroviral Therapy (ART) Suggests Association with Chronic Inflammation/Experiment 1/Signature 1 |
|
|
|
| Unraveling gut microbiota in Parkinson's disease and atypical parkinsonism/Experiment 1/Signature 1 |
|
|
|
| Unraveling gut microbiota in Parkinson's disease and atypical parkinsonism/Experiment 1/Signature 2 |
|
|
|
| Unraveling gut microbiota in Parkinson's disease and atypical parkinsonism/Experiment 2 |
|
|
|
| Unraveling gut microbiota in Parkinson's disease and atypical parkinsonism/Experiment 2/Signature 1 |
|
|
|
| Unraveling gut microbiota in Parkinson's disease and atypical parkinsonism/Experiment 2/Signature 2 |
|
|
|
| Unraveling gut microbiota in Parkinson's disease and atypical parkinsonism/Experiment 3 |
|
|
|
| Unraveling gut microbiota in Parkinson's disease and atypical parkinsonism/Experiment 3/Signature 1 |
|
|
|
| Unraveling gut microbiota in Parkinson's disease and atypical parkinsonism/Experiment 3/Signature 2 |
|
|
|
| Unraveling gut microbiota in Parkinson's disease and atypical parkinsonism/Experiment 4 |
|
|
|
| Unraveling gut microbiota in Parkinson's disease and atypical parkinsonism/Experiment 4/Signature 1 |
|
|
|
| Unraveling gut microbiota in Parkinson's disease and atypical parkinsonism/Experiment 4/Signature 2 |
|
|
|
| Unraveling gut microbiota in Parkinson's disease and atypical parkinsonism/Experiment 5 |
|
|
|
| Unraveling gut microbiota in Parkinson's disease and atypical parkinsonism/Experiment 5/Signature 1 |
|
|
|
| Unraveling gut microbiota in Parkinson's disease and atypical parkinsonism/Experiment 6 |
|
|
|
| Unraveling gut microbiota in Parkinson's disease and atypical parkinsonism/Experiment 6/Signature 1 |
|
|
|
| Unraveling gut microbiota in Parkinson's disease and atypical parkinsonism/Experiment 6/Signature 2 |
|
|
|
| Unraveling gut microbiota in Parkinson's disease and atypical parkinsonism/Experiment 7 |
|
|
|
| Unraveling gut microbiota in Parkinson's disease and atypical parkinsonism/Experiment 7/Signature 1 |
|
|
|
| Unraveling gut microbiota in Parkinson's disease and atypical parkinsonism/Experiment 7/Signature 2 |
|
|
|
| Unraveling gut microbiota in Parkinson's disease and atypical parkinsonism/Experiment 8 |
|
|
|
| Unraveling gut microbiota in Parkinson's disease and atypical parkinsonism/Experiment 8/Signature 1 |
|
|
|
| Unraveling gut microbiota in Parkinson's disease and atypical parkinsonism/Experiment 8/Signature 2 |
|
|
|
| Vaginal microbiome in early pregnancy and subsequent risk of spontaneous preterm birth: a case-control study |
|
|
|
| Vaginal microbiome in early pregnancy and subsequent risk of spontaneous preterm birth: a case-control study/Experiment 1 |
|
|
|
| Vaginal microbiome in early pregnancy and subsequent risk of spontaneous preterm birth: a case-control study/Experiment 1/Signature 1 |
|
|
|
| Variation of Gut Mucosal Microbiome With Anti-Saccharomyces cerevisiae Antibody Status in Pediatric Crohn Disease |
|
|
|
| Variation of Gut Mucosal Microbiome With Anti-Saccharomyces cerevisiae Antibody Status in Pediatric Crohn Disease/Experiment 1 |
|
|
|
| Variation of Gut Mucosal Microbiome With Anti-Saccharomyces cerevisiae Antibody Status in Pediatric Crohn Disease/Experiment 1/Signature 1 |
|
|
|
| Variation of Gut Mucosal Microbiome With Anti-Saccharomyces cerevisiae Antibody Status in Pediatric Crohn Disease/Experiment 1/Signature 2 |
|
|
|
| Variations of Tongue Coating Microbiota in Patients with Gastric Cancer |
|
|
|
| Variations of Tongue Coating Microbiota in Patients with Gastric Cancer/Experiment 1 |
|
|
|
| Variations of Tongue Coating Microbiota in Patients with Gastric Cancer/Experiment 1/Signature 1 |
|
|
|
| Variations of Tongue Coating Microbiota in Patients with Gastric Cancer/Experiment 1/Signature 2 |
|
|
|
